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As  a  major  component  of  the  adaptive  immune  system,  CD4+  T  cells  play  a  vital  
role  in  host  defense  and  immune  tolerance.  The  potency  and  accuracy  of  CD4+  T  cell-­‐‑
mediated  protection  lie  in  their  ability  to  differentiate  into  distinct  subsets  that  could  
carry  out  unique  duties.  In  this  dissertation,  we  dissected  the  roles  and  interplays  
between  two  emerging  mechanisms,  miRNAs  and  epigenetic  processes,  in  regulating  
CD4+  T  cell-­‐‑mediated  responses.  Using  both  gain-­‐‑  and  loss-­‐‑of-­‐‑function  genetic  tools,  we  
demonstrated  that  a  miRNA  cluster,  miR-­‐‑17-­‐‑92,  is  critical  to  promote  Th1  responses  and  
suppress  inducible  Treg  differentiation.  Mechanistically,  we  found  that  through  
targeting  Pten,  miR-­‐‑17-­‐‑92  promotes  PI3K  activation.  Strong  TCR-­‐‑PI3K  activation  leads  to  
the  accumulation  of  DNMT1,  elevated  CpG  methylation  in  the  foxp3  promoter,  and  
suppression  of  foxp3  transcription.  Furthermore,  we  demonstrated  that  an  epigenetic  
regulator,  methyl  CpG  binding  protein  2  (MeCP2),  is  critical  to  sustain  Foxp3  expression  
in  Tregs,  and  to  support  Th1  and  Th17  differentiation  in  conventional  CD4+  T  cells  
(Tcons).  In  Tregs,  MeCP2  directly  binds  to  the  CNS2  region  of  foxp3  locus  to  promote  its  
local  histone  H3  acetylation;  while  in  Tcons,  MeCP2  enhances  the  locus  accessibility  and  
transcription  of  miR-­‐‑124,  which  negatively  controls  SOCS5  translation  to  support  STAT1,  
STAT3  activation  and  Th1,  Th17  differentiation.  Overall,  miRNAs  and  epigenetic  
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1. Introduction  
1.1 Overview of T cell-mediated immune responses 
T  cell-­‐‑mediated  cellular  immunity  makes  up  an  important  component  of  the  
immune  system  and  is  critical  to  protect  the  host  from  infections  and  malignancies.  To  
initiate  a  T  cell  response,  foreign  or  altered  self-­‐‑antigens  from  pathogens  and  tumors  are  
first  taken,  processed  and  displayed  on  the  surfaces  of  antigen-­‐‑presenting  cells  (APCs)  in  
the  form  of  a  peptide-­‐‑major  histocompatibility  complex  (pMHC),  which  was  then  
recognized  by  an  antigen-­‐‑specific  T  cell  receptor  (TCR)  on  the  T  cells.  Antigen  
recognition  initiates  massive  downstream  signaling  cascades,  causing  naïve  T  cells  to  
undergo  extensive  expansion  and  functional  differentiation  for  pathogen  clearance.  
Upon  resolution  of  primary  responses,  the  majority  of  T  cells  undergo  contraction  via  
programmed  cell  death;  however,  a  small  population  of  antigen-­‐‑specific  T  cells  is  
maintained  as  a  memory  pool  and  is  poised  to  respond  rapidly  upon  secondary  
exposure  to  the  same  antigens1.  Understanding  the  molecular  mechanisms  of  how  T  cell  
responses  are  regulated  is  essential  for  the  development  of  novel  therapeutic  strategies  
to  treat  infections,  cancers,  and  autoimmunity.  In  this  dissertation,  I  dissected  the  role  of  
two  regulatory  machineries  controlling  CD4+  T  cell  differentiation  and  function:  




1.2 T helper cell differentiation and maintenance 
In  general,  mature  T  cells  can  be  divided  into  two  groups:  CD4+  helper  T  cells  
and  CD8+  cytotoxic  T  cells.  One  interesting  characteristic  that  separates  helper  T  cells  
from  cytotoxic  T  cells  is  their  ability  to  differentiate  into  functional  diverse  sub-­‐‑lineages  
that  are  capable  of  carrying  out  unique  immune  functions  under  different  
immunological  settings4.  Among  these,  Th1  cells  are  responsible  for  the  clearance  of  
intracellular  infection  and  are  implicated  as  the  effectors  in  various  malignancies  and  
inflammations;  Th2  cells  control  extracellular  microbe  infection  as  well  as  mediate  
chronic  inflammation  and  allergic  responses;  Th17  cells  contributes  to  host  defense  
against  extracellular  bacterial  and  fungi  and  have  also  been  linked  to  a  growing  list  of  
autoimmune  disorders;  in  addition,  peripheral  naïve  CD4+  T  cells  can  convert  to  Foxp3+  
regulatory  T  cells  (Tregs)  that  play  an  important  role  to  maintain  immune  tolerance  
particularly  in  the  mucosal  barrier5.  During  malignancy,  they  can  also  be  exploited  by  
tumors  to  promote  immune  evasion6.  In  addition  to  the  peripheral  derived  inducible  
Tregs  (iTregs),  Tregs  can  also  develop  from  the  thymus  (called  “tTreg  or  nTreg”).  
Because  tTregs  undergo  a  relatively  distinct  developmental  process  and  possess  several  
unique  features7,  I  will  briefly  introduce  them  in  this  section  and  discuss  them  in  further  
detail  in  section  1.3.    
1.2.1 T helper cell differentiation 
1.2.1.1 Role of TCR signaling in T helper cell differentiation 
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The  four  T  helper  subsets  mentioned  above  share  a  common  feature:  TCR  
signaling  is  an  absolute  requirement  for  their  differentiation8.  TCR-­‐‑pMHC  engagement  
and  co-­‐‑stimulation  activate  various  downstream  signaling  pathways  that  eventually  
lead  to  the  activation  of  several  important  transcription  factors  such  as  nuclear  factor  of  
activated  T-­‐‑cells  (NFAT),  activator  protein  1  (AP-­‐‑1),  and  nuclear  factor  kappa-­‐‑light-­‐‑
chain-­‐‑enhancer  of  activated  B  cells  (NF-­‐‑κB).  Through  direct  binding  to  the  promoters  or  
enhancers  of  signature  cytokine  genes  or  by  regulating  the  master  regulators  of  each  T  
helper  subset,  these  transcription  factors  promote  Th  differentiation.  However,  since  
these  factors  are  commonly  employed  during  differentiation  of  all  four  Th  lineages8,  
how,  then,  do  CD4+  T  cells  determine  to  which  fate  they  should  commit?  One  way  to  
achieve  this  is  through  sensing  the  specific  cytokine  milieu  that  is  shaped  by  distinct  
inflammatory  or  tolerogenic  conditions.  This  mechanism  will  be  discussed  in  detail  in  
section  1.2.1.2.  Besides,  accumulating  evidence  suggested  that  the  density  of  antigens  as  
well  as  the  strength/duration  of  TCR  signaling  also  dictate  the  fate  determination  of  
naïve  CD4+  T  cells  during  Th  differentiation9.  This  was  first  demonstrated  in  Th1/Th2  
polarization  by  Bottomly  and  colleagues10,11  and  further  confirmed  by  Paul’s  group12.  By  
using  natural  and  synthetic  variants  of  the  moth  cytochrome  C  (88-­‐‑103)  peptide  in  the  
context  of  the  MHC  II  molecule  I-­‐‑Ek,  they  showed  that  in  general,  weak  signalling  leads  
to  Th2  differentiation  while  strong  signalling  favours  Th1  commitment.  This  inhibition  
of  Th2  differentiation  by  strong  TCR  stimulation  was  partially  explained  by  the  strong  
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and  prolonged  ERK  activation  that  suppressed  early  GATA3  expression  and  IL-­‐‑2R-­‐‑
mediated  STAT5  activation,  both  of  which  are  critical  for  Th2  differentiation12.  Besides  
Th2  cells,  it  was  recently  reported  that  Th17  and  iTregs  also  favour  low-­‐‑strength  TCR  
stimulation  for  optimal  differentiation13-­‐‑15.  The  PI3K-­‐‑Akt-­‐‑mTOR  axis  downstream  of  
TCR  activation  has  been  suggested  to  be  critical  for  the  inhibition  of  iTreg  differentiation  
by  strong  TCR  stimulation14.  However,  the  underlying  molecular  mechanism  and  
whether  other  pathways  downstream  of  TCR  signaling  are  also  involved  in  this  process  
are  not  fully  understood.  In  Chapter  4,  we  attacked  this  question  with  a  TCR  transgenic  
system  and  showed  that  this  is  regulated  through  epigenetic  mechanisms  (See  Chapter  4  
for  details).  
1.2.1.2 Role of cytokine environment in T helper cell differentiation 
As  mentioned  above,  the  cytokine  milieu  provides  another  layer  of  guidance  for  
the  unique  lineage  choice  of  naïve  CD4+  T  cells  during  their  fate  specification8.  In  
general,  in  response  to  infections  or  malignancy,  innate  immune  cells  become  activated  
rapidly  and  secrete  cytokines  to  quickly  shape  the  microenvironment  for  Th  
differentiation.  The  unique  set  of  cytokines  generated  under  each  condition  then  bind  to  
their  receptors  on  CD4+  T  cells  and  initiate  the  differentiation  process  by  activating  a  
distinct  signal  transducer  and  activator  of  transcription  (STAT).  These  STAT  proteins  are  
central  to  shape  a  unique  active  enhancer  landscape  for  individual  Th  lineage16.  In  
addition,  they  could  also  drive  the  expression  of  master  transcription  factors,  which  in  
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turn  take  advantage  of  the  enhancer  landscape  to  specify  and  reinforce  lineage  fate  
determination.  
Th1  differentiation  is  initiated  by  STAT1,  which  is  activated  by  IL-­‐‑27  produced  
from  APCs  and  IFN-­‐‑γ  from  NK  cells.  STAT1  induces  the  expression  of  T-­‐‑bet,  the  master  
transcription  factor  for  Th1  cells17.  T-­‐‑bet  then  directly  drives  IFN-­‐‑γ  production  and  
opposes  the  inhibitory  effect  of  GATA3  on  Th1  differentiation18.  At  the  same  time,  
expression  of  IL-­‐‑12Rβ2  was  induced  by  T-­‐‑bet  to  allow  activation  of  STAT4  by  IL-­‐‑12  
produced  from  APCs19.  STAT4  then  further  promotes  IFN-­‐‑γ  expression,  which  in  turn  
boosts  STAT1  activation  through  a  positive-­‐‑feedback  loop  to  reinforce  Th1  commitment.    
Th2  differentiation  is  initiated  by  the  induction  of  its  master  transcription  factor  
GATA320.  GATA3  could  be  induced  either  through  IL-­‐‑4  mediated  STAT6  activation20,  or  
through  Notch-­‐‑mediated,  IL-­‐‑4-­‐‑independent  pathway21.  During  this  process,  TCR  
stimulation  also  drives  the  production  of  IL-­‐‑2  and  upregulation  of  the  IL-­‐‑2R  complex,  
which  lead  to  STAT5  activation.  Activated  STAT5  then  binds  to  il4ra  locus  and  
upregulate  IL-­‐‑4Rα  expression  to  boost  the  IL-­‐‑4R-­‐‑STAT6  axis,  and,  in  conjugation  with  
GATA3,  directly  binds  to  il4  locus  to  promote  IL-­‐‑4  expression.  IL-­‐‑4  then  reinforces  Th2  
commitment  through  this  autocrine  feedback  loop20.  
Both  Th17  and  iTreg  differentiation  require  TGF-­‐‑β,  which  promotes  their  lineage  
choice  through  at  least  two  mechanisms:  TGF-­‐‑β  may  indirectly  promote  Th17  and  iTreg  
commitment  through  inhibiting  Th1  and  Th2  differentiation;  or,  TGF-­‐‑β  could  directly  
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drive  the  expression  of  the  lineage  specific  transcription  factors  of  Th17  and  iTreg  cells,  
RORγt  and  Foxp3,  respectively22.  RORγt  and  Foxp3  antagonize  each  other’s  function  
through  direct  and  indirect  mechanisms23.  The  divergence  of  these  two  lineages  depends  
heavily  on  the  distinct  STATs  that  are  activated  during  this  process.  In  the  presence  of  
IL-­‐‑6,  STAT3  is  activated  and  it  directly  upregulates  RORγt  and  IL-­‐‑17  expression  through  
binding  to  their  genomic  loci.  Activated  STAT3  also  suppresses  iTreg  differentiation  by  
inhibiting  the  expression  of  Foxp3  and  its  interactions  with  RORγt.  On  the  other  hand,  
when  IL-­‐‑2  is  present,  it  leads  to  the  activation  of  STAT5,  which  potentiates  iTreg  
differentiation  through  directly  binding  to  foxp3  locus  and  promoting  Foxp3  expression3.  
Activated  STAT5  also  suppresses  the  Th17  lineage  by  competing  with  STAT3  for  
binding  to  the  il17  locus24.    
1.2.2 Maintenance and plasticity of T helper cell  
Although  different  T  helper  subsets  have  been  initially  widely  recognized  as  
stable  and  “terminally  differentiated”  lineages,  accumulating  evidences  have  now  
favored  that  there  are  actually  significant  phenotypic  flexibility  and  plasticity  in  these  
cells25.  By  definition,  each  distinct  T  helper  subset  was  originally  characterized  by  the  
expression  of  a  unique  cytokine  signature.  However,  it  was  now  clear  that,  under  certain  
polarizing  condition,  a  specified  T  helper  subset  could  be  induced  to  produce  the  
signature  cytokines  from  opposing  subsets.  For  example,  Th17  cells  often  co-­‐‑express  
IFN-­‐‑γ  and  IL-­‐‑17  in  a  variety  of  autoimmune  settings,  and  in  some  cases,  they  may  even  
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completely  convert  to  IFN-­‐‑γ  single  producers26;  also,  during  LCMV  infection,  in  vitro-­‐‑
differentiated  IL-­‐‑4-­‐‑producing  Th2  cells  could  produce  IFN-­‐‑γ  following  adoptive  
transfer27;  and  although  there  are  still  some  debates,  Tregs  (especially  iTregs)  could  lose  
Foxp3  expression  and  produce  inflammatory  cytokines28.  What  adds  up  to  the  
complexity  of  this  issue  is  that  T  helper  cells  can  also  express  more  than  one  master  
regulator29.  For  instance,  during  myelin  oligodendrocyte  glycoprotein  (MOG)-­‐‑  induced  
experimental  autoimmune  encephalomyelitis  (EAE),  a  substantial  portion  of  T  cells  that  
infiltrate  into  the  central  nervous  system  are  T-­‐‑bet+RORγt+,  and  these  cells  are  highly  
pathogenic.  In  addition,  besides  Foxp3,  Tregs  can  co-­‐‑express  T-­‐‑bet,  GATA3,  or  RORγt,  
all  of  which  have  functional  relevance.  During  type  I  inflammation,  Foxp3+Tregs  
upregulate  T-­‐‑bet,  which  drives  the  expression  of  CXCR3  to  guide  Tregs  to  traffic  to  the  
site  of  inflammation.  In  barrier  sites  such  as  the  GI  tract  and  skin,  Tregs  express  GATA3,  
and  it  is  critical  for  the  maintenance  of  Foxp3  expression  during  inflammation.  In  human  
peripheral  blood  and  lymphoid  tissues,  a  substantial  portion  of  Tregs  co-­‐‑express  Foxp3  
and  RORγt.  These  cells  also  express  CCR6  and  could  strongly  inhibit  effector  T  cell  
proliferation.  The  remarkable  plasticity  in  T  helper  cells  may  have  some  evolutionary  
benefit.  For  example,  this  would  allow  them  to  adapt  to  the  new  microenvironment  
when  facing  new  threats  and  challenges,  which  will  be  extremely  beneficial  for  the  host  
defense25.    
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1.3 Treg differentiation and maintenance 
A  hallmark  of  adaptive  immunity  is  the  ability  to  distinguish  “self”  and  “non-­‐‑
self”.  T  cells  must  quickly  respond  to  invasions  from  foreign  pathogens  but  at  the  same  
time  refrain  or  tolerate  from  the  detrimental  responses  against  self  and  food  antigens.  
Majority  of  this  tolerance  is  thought  to  be  achieved  through  negative  selection  in  the  
thymus,  in  which  most  of  the  self-­‐‑reactive  T  cells  are  deleted,  and  through  anergy,  in  
which  lymphocytes  become  functionally  inactivated  in  response  to  antigens  when  there  
is  lack  of  co-­‐‑stimulation.  However,  having  these  two  tolerogenic  mechanisms  seem  to  be  
insufficient  to  provide  full  protection  against  immune-­‐‑mediated  pathology.  Indeed,  a  
specialized  subset  of  T  cells  was  required  to  act  “in  trans”  to  suppress  pathogenic  
inflammation30.  These  cells  are  called  regulatory  T  cells  (Tregs).  Tregs  express  the  surface  
marker  CD25  and  the  master  transcription  factor  Foxp331.  Foxp3  is  not  only  essential  for  
the  development  of  Tregs  but  also  crucial  for  the  maintenance  of  their  lineage  identity  
and  suppressive  function5.  Consequently,  mutation  of  Foxp3  in  humans  causes  IPEX  
(immunodysregulation  polyendocrinopathy  enteropathy  X-­‐‑linked)  syndrome,  a  fatal  
lymphoproliferative  immune-­‐‑mediated  disorder,  and  targeted  deletion  of  Foxp3  in  mice  
led  to  similar  lethal  autoimmune  syndrome5.  In  addition  to  restraining  the  deleterious  
response  against  self-­‐‑antigens,  Tregs  were  also  crucial  to  limit  excessive  inflammatory  
responses  against  commensal  microbiota,  infections,  and  tumors.  Therefore,  
understanding  how  Tregs  are  differentiated  and  maintained  has  a  tremendous  
    
9  
therapeutic  potential  for  various  immune-­‐‑mediated  diseases.  As  mentioned  earlier,  
Tregs  can  differentiate  from  both  the  thymus  (tTreg  or  nTreg)  and  periphery  (iTreg).  
Since  the  differentiation  process  of  iTreg  has  been  discussed  in  section  1.2,  I  will  mainly  
focus  on  nTregs  in  this  following  section.      
1.3.1 Treg differentiation 
1.3.1.1 Role of TCR signaling in Treg differentiation 
Similar  to  the  differentiation  of  most  T  cell  subsets,  Treg  development  in  the  
thymus  also  requires  TCR  signaling  and  CD28  mediated  co-­‐‑stimulation.  TCR/CD28  
signaling  activates  many  transcription  factors  such  as  NFAT,  NF-­‐‑κB  (C-­‐‑Rel),  AP-­‐‑1,  
CREB1,  which  directly  bind  to  foxp3  locus  and  induce  its  expression5.  Perturbation  of  
these  signaling  pathways  with  genetic  manipulations  leads  to  significant  reduction  of  
Treg  frequency  and  Foxp3  expression,  demonstrating  a  crucial  role  of  TCR/CD28  
signaling  in  orchestrating  nTreg  development.  In  addition,  nTreg  differentiation  also  
depends  heavily  on  the  strength  of  TCR  signals  that  they  receive5.  The  early  
observations  that  nTregs  express  higher  level  of  CD25,  CD5  and  CTLA4,  all  induced  by  
stronger  TCR  stimulation,  suggested  that  nTregs  are  selected  by  TCR  signals  with  
increased  strength.  Analysis  of  TCR  transgenic  mice  in  the  RAG-­‐‑deficient  background  
further  supported  this  idea:  Tregs  bearing  a  transgene-­‐‑encoded  TCR  that  recognize  a  
self-­‐‑peptide  can  only  develop  when  a  high-­‐‑affinity  cognate  ligand,  but  not  a  low-­‐‑affinity  
ligand  is  co-­‐‑introduced  in  the  thymus  by  another  transgene32.  TCR  repertoires  studies  
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later  suggested  that  Tregs  are  likely  to  be  selected  by  TCR  signals  with  strength  range  
between  those  that  mediate  positive  selection  of  conventional  CD4+  T  cells  and  those  that  
mediate  negative  selection  of  high-­‐‑affinity  self-­‐‑reactive  T  cells33.    
1.3.1.2 Role of cytokine signaling in Treg differentiation 
Although  it  is  now  commonly  accepted  that  TCR  signal  plays  an  instructive  
function  for  Treg  differentiation,  it  by  itself  is  not  sufficient  to  specify  the  Treg  lineage  in  
the  thymus.  Signals  from  the  common  gamma-­‐‑chain  (γc)  cytokines  (IL-­‐‑2,  and  to  a  less  
extent,  IL-­‐‑7  and  IL-­‐‑15)  and  TGF-­‐‑β  are  also  required  for  nTreg  differentiation.  IL-­‐‑2  or  IL-­‐‑
2Rα  deficient  mice  have  a  50%  reduction  of  the  frequency  and  absolute  number  of  Tregs  
in  the  thymus34,  and  additional  ablation  of  IL-­‐‑7  and  IL-­‐‑15  signaling  completely  abrogate  
nTreg  development35.  IL-­‐‑2  signaling  leads  to  activation  of  transcription  factor  STAT5.  
Since  STAT5  binds  to  foxp3  promoter  and  CNS2  region,  IL-­‐‑2  signals  may  directly  
facilitate  Foxp3  induction  through  STAT5  activation.  Consistently,  T  cell  specific  
deletion  of  STAT5  leads  to  a  significant  reduction  of  Foxp3+  Tregs  in  the  thymus36.  
However,  IL-­‐‑2-­‐‑STAT5  pathway  may  also  facilitate  nTreg  differentiation  through  other  
mechanisms,  such  as  promoting  the  proliferation  or  survival  of  nTregs  or  their  
precursors.  In  agreement  with  this  idea,  forced  expression  of  prosurvival  molecules  such  
as  Bcl-­‐‑2  in  STAT5-­‐‑deficient  cells  sufficiently  rescued  the  defect  of  nTreg  differentiation37.  
In  addition  to  IL-­‐‑2,  TGF-­‐‑β  is  another  cytokine  that  was  critical  for  nTreg  differentiation.  
In  neonatal  mice  with  specific  TGF-­‐‑βRI  deficiency  in  T  cells,  there  is  a  substantial  
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impairment  of  nTregs  development  in  the  thymus38.  It  was  then  found  that  TGF-­‐‑β  
signaling  leads  to  the  activation  of  Smads,  which  bind  to  the  CNS1  region  of  foxp3  locus  
and  directly  induces  its  expression39.  However,  there  could  also  be  other  explanations.  
For  example,  it  was  recently  found  that  TGFβRII  deficient  Tregs  in  the  thymus  express  
high  level  of  proapoptotic  proteins  Bim  and  undergo  extensive  apoptosis  during  agonist  
antigen-­‐‑mediated  selection40.  So  TGF-­‐‑β  may  also  facilitate  nTreg  differentiation  
indirectly  through  promoting  their  survival  during  negative  selection.  
1.3.2 Treg stability and maintenance 
It  was  recently  reported  that  various  T  helper  subsets  have  unexpected  plasticity  
and  could  be  induced  to  produce  signature  cytokines  of  other  T  helper  subsets.  This  
raises  the  question  that  whether  the  previously  thought  “stable”  and  “distinct”  Foxp3+  
Treg  lineage  could  also  be  “reprogrammed”  into  effector  T  cells  in  response  to  certain  
environmental  cues.  Recent  studies  have  brought  up  a  very  complicated  and  
controversial  picture.    
The  first  suggestions  that  Tregs  are  unstable  came  from  studies  using  in  vitro  
culture  of  sorted  Foxp3+  Tregs  from  several  different  Foxp3  reporter  mice.  When  sorted  
Foxp3+  Tregs  were  cultured  with  TCR  stimulation  and  various  T  helper  polarizing  
cytokines  (such  as  IL-­‐‑6,  IL-­‐‑4,  TNF),  a  small  fraction  of  them  lose  Foxp3  expression,  and  
these  “ex-­‐‑Tregs”  acquire  ability  to  produce  inflammatory  cytokines  such  as  IFN-­‐‑γ,  IL-­‐‑2  
and  IL-­‐‑1741,42.  This  was  further  confirmed  later  by  in  vivo  experiments  with  adoptive  
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transfer  of  these  sorted  Foxp3+  Tregs  into  lymphopenic  recipients.  Since  these  
approaches  all  involve  cell  sorting,  the  potential  outgrowth  of  few  contaminating  Foxp3-­‐‑  
cells  may  contribute  to  the  outcome  of  these  experiments.  However,  this  is  less  likely  
because  Foxp3-­‐‑  cells  spiked  into  Foxp3+  cells  fail  to  grow  out  in  lymphopenic  hosts,  and  
even  double  sorted  (>99.99%  purity)  Foxp3+  cells  will  generate  ex-­‐‑Tregs  in  these  
settings43.  Recently,  genetic  fate  mapping  approaches  have  been  utilized  to  study  the  
stability  of  Foxp3  expression  in  Tregs  without  involving  cell  sorting  and  adoptive  
transfers.  Bluestone  and  colleagues  generated  a  mouse  model  to  label  these  ex-­‐‑Tregs  in  
vivo  by  crossing  the  BAC  transgenic  mice  expressing  GFP-­‐‑Cre  fusion  protein  under  the  
control  of  the  foxp3  promoter  with  ROSA26-­‐‑STOP-­‐‑YFP  reporter  mice44.  In  these  mice,  
cells  that  have  a  history  of  Foxp3  expression  will  be  labelled  with  YFP  and  cells  that  are  
currently  expressing  Foxp3  will  be  GFP  positive.  Strikingly,  in  naïve  mice,  they  found  
that  around  10-­‐‑15%  of  YFP+  cells  are  Foxp3  and  GFP  negative,  and  this  number  increases  
significantly  in  mice  under  strong  inflammation  (such  as  in  diabetic  NOD  mice).  
Collectively,  these  suggest  that  at  least  a  small  proportion  of  Tregs  become  unstable,  
particularly  during  inflammation.      
Despite  the  above  evidences  for  inflammation-­‐‑induced  Treg  destabilization  and  
reprogramming,  this  notion  has  evoked  great  controversy.  First,  the  pivotal  job  of  Tregs  
is  to  maintain  immune  tolerance.  If  Tregs  could  easily  lose  Foxp3  and  convert  to  
effectors,  how  can  they  suppress  inflammation  so  effectively?  From  the  immunotherapy  
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angle,  given  that  many  Foxp3+  Tregs  have  self-­‐‑reactive  TCRs,  it  could  be  a  catastrophe  if  
these  unstable  Tregs  are  used  to  treat  autoimmune  disorders43.  Against  this  “plasticity”  
model,  Tregs  have  shown  significant  potency  to  treat  various  immune-­‐‑mediated  
inflammatory  diseases  in  both  mouse  and  pre-­‐‑clinial  models  (eg:  IBD,  RA).  In  addition,  
some  recent  studies  have  provided  counter  evidence  against  the  “plasticity”  model.  
Particularly,  Rudensky  and  colleagues  have  used  a  different  genetic  lineage-­‐‑tracing  
model  to  demonstrate  that  there  is  little  or  no  conversion  of  Tregs  into  effectors  during  
physiological  and  various  inflammatory  conditions45.  In  this  model,  DNA  encoding  a  
GFP-­‐‑Cre-­‐‑ERT2  fusion  protein  was  knocked  into  the  3’  UTR  of  endogenous  foxp3  gene  
and  these  mice  were  then  crossed  with  ROSA26-­‐‑STOP-­‐‑YFP  reporter  mice.  This  allows  an  
inducible  but  heritable  labelling  of  cells  that  are  express  Foxp3  during  the  tamoxifen  
treatment  with  YFP.  When  these  mice  were  examined  2  weeks  or  5  months  after  
tamoxifen  induced  labelling,  they  found  that  very  few  (<5%)  YFP+  cells  are  negative  for  
Foxp3  expression.  Furthermore,  this  number  is  not  increased  under  various  
inflammatory  conditions  such  as  sublethal  irradiation  and  infection  with  listeria  
monocytogenes.  Therefore,  it  was  concluded  that  Tregs  exhibit  tremendous  stability  under  
both  physiological  and  pathological  conditions.    
There  could  be  at  least  several  explanations  for  the  discrepant  data  observed  
from  these  studies43.  First,  the  different  inflammatory  conditions  used  (T  helper  
polarizing  conditions,  adoptive  transfer  into  lymphopenic  recipients  vs.  infection  and  
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irradiation  model)  may  contribute  to  the  different  outcome.  Also,  the  two  lineage  tracing  
models  have  different  time  window  of  labelling.  Foxp3-­‐‑GFP-­‐‑Cre  BAC  transgenic  model  
labels  ex-­‐‑Tregs  that  are  accumulated  from  ontogeny  till  adulthood,  while  the  Foxp3-­‐‑
GFP-­‐‑Cre-­‐‑ERT2  model  only  start  to  label  these  cells  upon  tamoxifen  treatment.  Although  
this  controversy  is  far  from  reconciliation  at  this  time,  one  common  observation  from  
these  studies  is  that  there  seem  to  be  certain  heterogeneity  within  the  Treg  lineage:  even  
in  the  “plasticity”  models,  only  a  relatively  small  proportion  of  Tregs  (10%  to  15%)  may  
lose  Foxp3  expression,  while  majority  of  mature  Tregs  seem  to  be  highly  committed  and  
exhibit  stable  Foxp3  expression.  This  observed  stability  in  most  of  Tregs  implies  the  
existence  of  dedicated  machinery  governing  the  maintenance  of  Foxp3  expression.  
Several  transcription  factors  and  epigenetic  mechanisms  have  been  implicated  to  be  
involved  in  this  machinery.  We  will  discuss  these  aspects  in  further  detail  in  section  
1.5.3.    
  
1.4 The role of miRNAs in T cell activation and differentiation 
While  the  signaling  pathways  and  transcription  factors  controlling  T  cell  
activation  and  differentiation  have  been  studied  extensively  over  the  past  two  decades,  
recent  studies  clearly  pointed  out  an  emerging  role  of  a  group  of  small  non-­‐‑coding  
RNAs  in  the  regulatory  networks  governing  this  process.  miRNAs  are  small  (around  21-­‐‑
24  nucleotide  long)  endogenously  expressed  non-­‐‑coding  RNAs  that  regulate  gene  
    
15  
expression  post-­‐‑transcriptionally46.  They  are  first  transcribed  into  a  longer  primary  
miRNAs  (pri-­‐‑miRNAs)  and  further  processed  by  RNase  III  enzymes  Drosha  and  Dicer  
into  the  mature  form.  These  mature  miRNAs  are  then  loaded  to  the  miRNA-­‐‑induced  
silencing  complex  (miRISC)  and  guide  it  to  specific  target  mRNAs  through  
complementary  base  pairing.  miRISC  induces  degradation  of  target  mRNAs  and/or  
inhibits  their  translation.  The  2-­‐‑8  nucleotides  from  the  5’  end  of  miRNA  (seed  sequence)  
are  the  major  determinants  of  the  specificity  of  target  recognition  and  are  thus  used  
widely  in  target  prediction.  The  miRNA-­‐‑mediated  regulatory  network  is  highly  
complex.  Each  miRNA  may  have  multiple  mRNA  targets;  conversely,  each  mRNA  may  
be  targeted  by  multiple  different  miRNAs47.  Adding  to  this  complexity,  the  miRNA-­‐‑
mediated  targeting  is  also  context-­‐‑dependent  and  the  dominant  functional  target  of  a  
single  miRNA  may  vary  between  different  cell  types  and/or  during  different  biological  
processes.      
Recent  studies  suggest  that  miRNA-­‐‑mediated  gene  regulation  represents  a  
fundamental  layer  of  posttranscriptional  genetic  programs  in  immune  cells  and  has  
broad  effects  on  their  development,  activation,  differentiation,  and  effector  function48.  
An  intact  miRNA-­‐‑mediated  regulatory  network  is  required  for  the  maintenance  of  
immune  homeostasis  and  induction  of  immune  activation  against  pathogens;  and  
perturbation  of  this  machinery  may  contribute  to  immunopathology  during  
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autoimmunity  and  cancer.  Thus,  understanding  how  the  miRNA-­‐‑mediated  network  
regulates  immunity  has  great  therapeutic  potential.    
1.4.1 Regulation of T cell activation by miRNAs 
Early  evidence  of  the  involvement  of  miRNAs  in  T  cell  activation  came  from  
analysis  of  T  cells  lacking  certain  essential  factors  in  the  miRNA  biogenesis  pathway.  
These  studies  showed  that  global  disruption  of  the  miRNA  machinery  leads  to  
incompetence  of  T  cell  proliferation  and  survival,  as  well  as  aberrant  Th  effector  
differentiation  and  cytokine  production49.  While  these  studies  clearly  indicated  a  critical  
role  of  miRNA-­‐‑mediated  regulation  of  T  cell  activation  in  general,  it  failed  to  provide  a  
comprehensive  picture  of  the  miRNA  regulatory  network,  because  the  phenotype  
observed  in  these  T  cells  with  global  miRNA  disruption  might  result  from  an  integration  
of  both  the  negative  and  positive  effects  of  individual  miRNAs  regulating  these  
processes.  Therefore,  it  is  important  to  dissect  the  role  of  individual  miRNAs  in  T  cell  
activation.    
To  screen  for  individual  miRNAs  that  regulate  T  cell  activation,  Mark  Ansel  and  
colleagues  took  a  systemic  approach  to  transfect  T  cells  that  lack  global  miRNA  
expression  with  individual  synthetic  miRNA  oligonucleotides,  and  screened  for  the  
miRNAs  that  could  sufficiently  rescue  the  proliferative  defect  in  these  cells50.  Among  the  
miRNAs  that  could  promote  proliferation,  they  found  two  miRNA  seed  families  (miR-­‐‑17  
family  and  miR-­‐‑92  family)  that  were  significantly  enriched.  We  also  independently  
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identified  that  miRNAs  from  the  miR-­‐‑17-­‐‑92  cluster  were  significantly  increased  upon  T  
cell  activation  and  were  crucial  to  promote  T  cell  proliferation  and  survival  during  T  cell  
activation51.  While  this  miRNA  “add-­‐‑back”  approach  is  informative  in  determining  the  
dominant  miRNAs  that  contribute  to  the  defects  in  T  cells  with  global  miRNA  
disruption,  it  also  has  its  drawbacks.  As  mentioned  above,  because  the  hypoprolferation  
of  T  cells  with  global  miRNA  disruption  could  result  from  an  “add  up”  of  the  loss  of  
both  pro-­‐‑proliferative  miRNAs  and  anti-­‐‑proliferative  miRNAs,  many  important  
miRNAs  that  regulate  T  cell  responses  might  be  overlooked  by  this  approach.  In  this  
regard,  expression  profiling  for  miRNAs  that  are  dynamically  regulated  during  T  cell  
development  and  activation  is  very  informative  and  has  led  to  the  identification  of  many  
important  miRNAs  that  regulate  these  processes.    
miR-­‐‑181a  is  one  such  regulator  of  T  cell  activation52.  Expression  analysis  showed  
that  expression  of  miR-­‐‑181a  is  highly  dynamically  regulated  during  T  cell  maturation  
and  activation.  In  the  thymus,  miR-­‐‑181a  expressed  highly  in  the  DP  stage,  but  was  
reduced  significantly  as  T  cells  matured  to  the  CD4  and  CD8  SP  stages.  Its  level  was  
further  reduced  to  merely  ~10  copies/cell  when  peripheral  naïve  CD4+  T  cells  were  
activated  by  TCR  stimulation.  This  sequential  reduction  of  miR-­‐‑181a  level  correlates  well  
with  the  decreased  sensitivity  of  T  cells  during  these  developmental  and  activation  
processes  and  suggested  that  it  may  play  an  important  role  in  regulating  TCR  signaling  
strength.  Indeed,  further  gain  and  loss-­‐‑of-­‐‑function  studies  showed  that  through  
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targeting  multiple  phosphatases  that  blunt  TCR  signals,  miR-­‐‑181a  significantly  
augments  TCR  signaling  strength  and  promotes  T  cell  activation.  In  addition,  the  
reduction  of  miR-­‐‑181a  upon  TCR  activation  was  proposed  to  be  a  negative  feedback  
mechanism  to  fine-­‐‑tune  the  TCR  signaling  strength  against  antigens53.    
Besides  miR-­‐‑181a,  several  other  miRNAs  have  been  suggested  to  regulate  T  cell  
activation  by  targeting  key  components  of  the  pathways  downstream  of  TCR  
engagement.  We  and  others  found  that  by  targeting  PTEN,  miR-­‐‑17-­‐‑92  critically  supports  
the  activation  of  PI3K-­‐‑Akt  axis  and  T  cell  proliferation/survival54;  NFAT  and  NF-­‐‑κB  
activation  induce  the  expression  of  miR-­‐‑155,  which  targets  Ship1  and  Socs1  to  promote  T  
cell  activation  and  expansion55;  miR-­‐‑146a  is  also  upregulated  by  NF-­‐‑κB  activation  and  it  
inhibits  T  cell  activation  through  a  negative  feedback  loop  that  involves  its  targets  Traf6  
and  Irak156.  
1.4.2 Regulation of T helper cell differentiation by miRNAs 
As  introduced  earlier,  T  helper  cell  differentiation  is  a  highly  regulated  process  
when  a  T  cell  senses  and  interprets  signals  from  antigens  (TCR  signal  strength)  and  
environmental  cues  (cytokine  signaling).  Therefore,  it  is  not  surprising  that  many  of  the  
key  miRNAs  that  regulate  T  cell  activation  also  influence  T  helper  differentiation.    
We  identified  miR-­‐‑17-­‐‑92  as  a  potent  driver  for  Th1  mediated  responses54.  Naive  T  
cells  with  genetic  deletions  of  miR-­‐‑17-­‐‑92  showed  a  significant  reduction  in  IFN-­‐‑γ  
production  under  Th1  polarizing  conditions  in  vitro.  Conversely,  Overexpression  of  
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miR-­‐‑17-­‐‑92  in  T  cells  with  a  transgene  or  a  retrovirus  encoding  the  miR-­‐‑17-­‐‑92  gene  
promotes  Th1  differentiation.  In  addition,  miR-­‐‑17-­‐‑92-­‐‑deficient  T  cells  are  more  prone  to  
differentiate  into  Foxp3+  iTregs  when  exposed  to  TGF-­‐‑β  in  vitro.  Because  of  its  vigorous  
control  over  the  Th1  cell  iTreg  balance,  the  loss  of  miR-­‐‑17-­‐‑92  in  CD4+  T  cells  results  in  
tumor  evasion  in  an  allograft  model  of  B16  melanoma.  Recently,  we  found  that  miR-­‐‑17-­‐‑
92  is  also  required  for  optimal  Th17  responses  during  EAE.  Reconstitution  of  T  cells  that  
lack  miR-­‐‑17-­‐‑92  with  individual  miRNAs  identified  miR-­‐‑17  and  miR-­‐‑19b  as  the  
functional  representative  of  the  whole  cluster  in  regulating  these  processes.  
Mechanistically,  the  aberrant  Th1,  Th17  and  iTreg  differentiation  with  miR-­‐‑17-­‐‑92  
deficiency  could  at  least  be  in  part  explained  by  the  accumulation  of  its  bona-­‐‑fide  target  
PTEN  and  the  subsequent  blunted  PI3K-­‐‑Akt  activation.    
miR-­‐‑155  is  another  miRNA  that  influences  multiple  aspects  of  T  helper  
differentiation47.  miR-­‐‑155-­‐‑deficient  mice  are  highly  resistant  to  EAE  and  had  
significantly  reduced  footpad  inflammation  during  delayed-­‐‑type  hypersensitivity  (DTH)  
response.  Further  in  vitro  and  in  vivo  analysis  showed  that  miR-­‐‑155-­‐‑deficient  CD4+  T  cells  
have  defective  Th1  and  Th17  differentiation,  but  showed  a  moderate  bias  toward  Th2  
differentiation  and  IL-­‐‑4  production.  In  addition,  some  of  the  aged  miR-­‐‑155  mice  
developed  spontaneous  lung  inflammation  that  showed  characteristics  of  enhanced  Th2  
mediated  immune  pathology.  Among  the  many  identified  miR-­‐‑155  targets,  Socs1,  Ship1  
    
20  
could  be  responsible  for  its  regulation  on  Th1  and  Th17  differentiation,  while  cMaf  
contributes  to  the  aberrant  Th2  responses.    
In  addition  to  the  aforementioned  miRNAs  that  have  broad  effects  on  T  helper  
cell  activation  and  differentiation,  several  miRNAs  were  shown  to  specifically  affect  the  
differentiation  of  unique  Th  lineages.  miR-­‐‑29a  and  miR-­‐‑29b  were  potent  inhibitors  of  
Th1  differentiation.  Transfection  of  miR-­‐‑29a  and  miR-­‐‑29b  into  CD4+  T  cells  that  lack  all  
mature  miRNAs  sufficiently  reduced  the  aberrant  elevated  IFN-­‐‑γ  production  from  these  
cells50.  Transgenic  mice  with  a  “miRNA  sponge”  that  competes  with  endogenous  miR-­‐‑29  
targets  showed  enhanced  Th1  responses  and  greater  resistance  to  infections  with  Listeria  
monocytogenes  or  Mycobacterium  tuberculosis57.  Further  biochemical  analysis  revealed  that  
Tbx21(T-­‐‑bet),  Eomes,  and  Ifng  are  functional  relevant  targets  of  miR-­‐‑29  in  its  regulation  
of  Th1  differentiation.  miR-­‐‑326  is  an  important  regulator  of  Th17  differentiation58.  
Expression  profiling  experiments  showed  that  the  level  of  miR-­‐‑326  is  significantly  
elevated  in  patients  with  multiple  sclerosis  and  in  mice  with  aggressive  EAE  symptoms.  
CD4+  T  cells  that  overexpress  miR-­‐‑326  had  enhanced  Th17  differentiation  while  
introduction  of  a  miR-­‐‑326  sponge  reduced  Th17  differentiation.  The  effects  of  miR-­‐‑326  




1.4.3 Regulation of Tregs by miRNAs 
Early  implications  for  miRNA’s  role  in  Tregs  came  from  analysis  of  mice  with  T  
cell  specific  Dicer  deficiency.  It  was  shown  that  these  mice  lacking  miRNAs  in  T  cells  
had  a  significant  block  of  Treg  development  in  the  thymus,  as  well  as  reduced  iTreg  
differentiation  in  vitro.  Consequently,  many  of  these  mice  developed  spontaneous  
inflammation  and  immunopathology  as  they  aged59.  In  addition,  restricted  deletion  of  
Dicer  or  Drosha  in  Foxp3+  Tregs  led  to  unstable  Foxp3  expression  in  Tregs  and  early  
onset  of  spontaneous  autoimmunity60,61.  These  studies  suggested  that  miRNAs  are  not  
only  important  for  Treg  differentiation  but  also  crucial  for  their  maintenance  and  
suppressive  function.    
Expression  profiling  experiments  have  identified  several  miRNAs  that  are  
differentially  expressed  between  conventional  CD4+  T  cells  and  Tregs,  which  play  
important  roles  in  Treg  differentiation  and  maintenance.  Among  these,  miR-­‐‑155  was  
shown  to  be  a  direct  target  of  Foxp3  and  was  highly  expressed  in  Tregs.  miR-­‐‑155  
deficient  mice  had  reduced  percentages  and  numbers  of  Treg  in  the  thymus  and  spleen.  
Mechanistically,  miR-­‐‑155  was  shown  to  target  Socs1  directly,  which  is  a  negative  
regulator  of  the  IL-­‐‑2-­‐‑STAT5  signaling  pathway.  Therefore,  miR-­‐‑155  is  critical  for  the  
competitive  fitness  of  Tregs62.  In  addition,  miR-­‐‑146a  was  shown  to  play  a  critical  role  in  
regulating  Treg  suppressive  function.  miR-­‐‑146a-­‐‑deficient  Tregs  have  elevated  expression  




1.5 The role of epigenetic mechanisms in CD4+ T cell 
differentiation, plasticity, and maintenance 
Activation  of  transcription  factors  downstream  of  receptor-­‐‑mediated  signaling  is  
crucial  to  dictate  the  fate  determination  of  CD4+  T  cell  during  differentiation.  However,  
the  ability  of  these  factors  to  modulate  gene  transcription  also  depends  on  the  state  of  
chromatin  and  its  underlying  DNA,  which  is  governed  by  epigenetic  mechanisms3.  
Epigenetic  processes  are  modifications  that  affect  potentially  heritable  phenotypes  and  
gene  expression  without  altering  the  DNA  sequences.  In  mammals,  these  epigenetic  
processes  include,  but  are  not  limited  to,  DNA  methylation,  histone  modifications,  and  
higher-­‐‑order  chromatin  structure.    Through  epigenetic  processes,  gene  transcription  
programs  in  differentiating  or  differentiated  cells  can  be  faithfully  inherited  by  progeny  
cells,  but  at  the  same  time  preserve  the  potential  to  be  modified  in  response  to  altered  
environmental  signals.  Here  in  this  section,  we  will  discuss  some  of  the  major  
components  of  the  epigenetic  machinery  and  how  they  control  the  differentiation  and  
maintenance  of  CD4+  T  cells.    
1.5.1 Key components of the epigenetic machinery in CD4+ T cells 
1.5.1.1 DNA methylation 
DNA  methylation  is  a  process  that  involves  the  addition  of  a  methyl  group  to  the  
cytosine  nucleotide.  In  mammals,  methylation  mostly  occurs  in  the  cytosines  in  CpG  
dinucleotides.  These  CpG  dinucleotides  may  form  clusters  that  are  typically  300-­‐‑3000  
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base  pairs  long,  termed  CpG  islands.  Methylation  of  the  CpG  islands  in  the  promoter  
and  some  important  distal  cis-­‐‑  regulatory  elements  can  inhibit  gene  transcription  in  two  
major  ways.  DNA  methylation  could  directly  physically  block  the  binding  of  
transcription  factors  to  the  gene  promoters  or  distal  elements;  or  it  may  also  provide  
docking  sites  for  methyl-­‐‑CpG-­‐‑binding  domain  proteins  (MBDs)  that  recruit  other  
chromatin  remodeling  proteins  to  form  a  compact  and  inactive  heterochromatin,  thereby  
inhibiting  transcription3.  In  mammalian  cells,  there  are  mainly  two  classes  of  DNA  
methyltransferases  (DNMT)  that  catalyze  DNA  methylation:  DNMT1,  and  DNMT3  
(includes  DNMT3a  and  DNMT3b).  DNMT1  is  mainly  responsible  for  the  maintenance  of  
DNA  methylation  during  DNA  replication  but  it  is  suggested  to  also  have  de  novo  
methyltransferase  activity,  while  DNMT3  could  methylate  unmethylated  DNA  at  a  
relatively  high  rate  and  it  was  shown  to  mainly  function  as  de  novo  methyltransferase.  
Because  of  its  fundamental  regulation  of  gene  induction,  silencing,  and  maintenance,  
DNA  methylation  is  involved  in  many  biological  processes,  such  as  development,  
differentiation,  and  proliferation.  Not  surprisingly,  aberrant  DNA  methylation  and  
mutations  in  the  DNA  methylation  machinery  have  been  implicated  in  the  pathogenesis  
of  many  diseases  including  cancer  and  autoimmunity.    
1.5.1.2 Histone modifications 
Besides  DNA  methylation,  histone  modifications  are  another  type  of  epigenetic  
process  that  controls  the  accessibility  of  chromatins.  The  basic  unit  of  chromatin  is  the  
    
24  
nucleosome,  which  consists  of  a  piece  of  146-­‐‑base-­‐‑pair  DNA  wrapping  around  an  
octamer  of  histone  protein  cores.  The  histone  octamer  contains  two  copies  of  each  of  the  
histones  H2A,  H2B,  H3  and  H4.  In  addition,  the  N-­‐‑terminal  tails  of  histone  proteins  can  
be  modified  posttranslationally  through  acetylation,  methylation,  phosphorylation,  and  
ubiquitination64.  These  modifications  may  affect  chromosome  function  either  by  (i)  
altering  the  electrostatic  charge  of  the  histone,  thus  leading  to  a  structural  change  in  
chromatin  accessibility,  or  (ii)  by  creating  or  removing  certain  binding  sites  for  proteins  
that  could  regulate  transcription.  The  association  of  various  histone  modifications  with  
transcriptional  activity  has  led  to  the  “histone  code”  hypothesis65,  which  states  that  
histone  modifications  create  a  code  that  is  recognized  by  regulatory  proteins  that  contain  
certain  protein  domains,  and  this  may  dictate  the  potential  of  active  transcription  or  
silencing  of  genes.  Recent  genome-­‐‑wide  studies  have  identified  several  core  histone  
modifications  that  are  associated  with  and  could  faithfully  predict  genes  and  regulatory  
elements  that  are  active,  silenced,  or  inactive  but  poised66.  For  example,  cis-­‐‑elements  of  
genes  that  are  accessible  or  are  actively  transcribing  can  be  characterized  by  the  
acetylation  of  various  residues  of  histone  H3  and  H4,  as  well  as  by  the  mono-­‐‑,  di-­‐‑,  or  tri-­‐‑
methylation  of  H3  lysine  4  (H3K4).  In  contrast,  regulatory  regions  of  genes  that  are  
silenced  usually  lack  these  active  modifications,  but  are  instead  marked  with  di-­‐‑  or  tri-­‐‑
methylation  of  H3K27  and  H3K9.  Finally,  promoters  and  enhancers  of  genes  that  are  
poised  for  activation  or  silencing  either  lack  both  of  these  two  types  of  modifications,  or  
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have  both  permissive  and  repressive  modifications.  This  poised  state  allows  these  genes  
to  quickly  “turn  on”  or  “turn  off”  when  the  cells  sense  signals  from  altered  
environmental  cues.  In  addition,  it  is  worth  emphasizing  that  although  these  histone  
marks  were  originally  identified  by  their  association  with  different  transcription  states,  
accumulating  data  confirmed  that  they  do  not  merely  mark  “past  events”  but  indeed  
have  direct  effect  on  the  transcriptional  competence  of  genes.  For  instance,  treatment  of  
cells  with  various  inhibitors  that  block  certain  histone  acetylations  or  DNA  methylation  
could  significantly  alter  gene  expressions  and  cell  phenotypes67,68.    
1.5.2 Role of epigenetic mechanisms in T helper cell differentiation 
and plasticity 
1.5.2.1 Epigenetic regulation of T helper cell differentiation 
Early  indications  of  epigenetic  regulation  of  T  helper  cell  differentiation  came  
from  studies  that  identified  multiple  key  cis-­‐‑regulatory  elements  controlling  the  
transcription  of  the  genes  encoding  signature  cytokines  of  each  Th  subset.  Based  on  the  
sequence  conservation  among  species  and  the  presence  of  hallmark  epigenetic  
modifications,  multiple  conserved  non-­‐‑coding  sequences  (CNS)  were  identified  in  the  
ifng,  il4,  and  il17  loci  and  were  confirmed  to  have  enhancer  activity  both  in  vitro  and  in  
vivo.  These  studies  further  showed  that  these  cis-­‐‑elements  within  the  signature  cytokine  
loci  are  associated  with  active  epigenetic  marks  in  featured  lineages  while  exhibit  
repressive  marks  in  the  other  lineages3.  For  example,  in  Th1  cells,  the  ifng  locus  exhibits  
high  levels  of  permissive  H3K4  dimethylation  and  H3  acetylation,  and  CpG  islands  in  
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the  promoter  and  most  CNS  regions  are  completely  unmethylated;  in  contrast,  the  il4  
locus  is  enriched  with  repressive  H3K27  trimethylation  and  significant  CpG  methylation.  
On  the  other  hand,  in  Th2  cells,  the  il4  locus  is  permissive  while  the  ifng  locus  is  silenced.  
Importantly,  disruption  of  the  machinery  of  these  modifications  with  small  inhibitors  or  
genetic  tools  has  a  tremendous  effect  on  T  helper  cell  differentiation,  suggesting  that  
there  is  a  causal  relationship  between  epigenetic  mechanisms  and  cell  phenotypes.  
Although  it  is  now  clear  that  epigenetic  modifications  of  the  signature  gene  loci  play  a  
critical  role  in  T  helper  cell  differentiation,  how  these  chromatin  modifications  are  
regulated  and  their  interplay  with  upstream  signaling  pathways  are  much  less  known.  
Recent  global  epigenome  studies  suggested  that  cytokine  receptor  signaling  is  central  in  
shaping  the  chromatin  landscape  of  T  helper  cells  through  activation  of  different  
STATs16.  Particularly,  a  substantial  proportion  of  the  global  active  histone  modifications  
in  Th1  cells  are  dependent  on  STAT4  and  STAT1,  while  STAT6  has  a  major  role  in  
generating  the  active  enhancer  landscape  in  Th2  cells.  Importantly,  expression  of  the  
lineage  specific  master  regulators  failed  to  fully  re-­‐‑establish  the  STAT-­‐‑dependent  
enhancer  landscape.  These  studies  provide  a  potential  mechanism  by  which  
differentiating  CD4+  T  cells  could  sense  environmental  cues  and  translate  them  into  
modifications  of  the  enhancer  architecture.  However,  several  important  questions  still  
remain.  First,  since  these  studies  mainly  focused  on  histone  modifications,  how  DNA  
methylation  is  regulated  in  differentiating  T  helper  cells  is  much  less  clear.  Second,  as  
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TCR  signaling  strength  also  plays  an  important  role  in  determining  the  fate  of  T  helper  
cells,  whether  and  how  it  may  influence  the  epigenetic  modifications  need  to  be  
addressed.  Lastly,  the  previous  studies  focused  on  transcription  factors  that  could  
recruit  enzymes  that  directly  catalyze  the  histone  modification  or  DNA  methylation  
reaction,  but  whether  the  availability  of  these  enzymes  is  dynamically  regulated  during  
differentiation  has  been  overlooked.  For  these  purposes,  we  have  examined  the  level  of  
various  DNMTs  in  CD4+  T  cells  that  received  TCR  signals  with  different  strength  and  
duration69  (See  Chapter  4).  We  found  that  the  abundance  of  DNMT1  and  DNMT3  
proteins  are  positively  regulated  by  high-­‐‑affinity  and  prolonged  TCR  signals.  This  
elevated  abundance  then  leads  to  increased  enrichment  of  DNMTs  to  the  promoter  of  
foxp3  gene,  and  consequently  causes  enhanced  CpG  methylation  and  suppression  of  
iTreg  differentiation.  This  suggests  that  epigenetic  regulation  of  CD4+  T  cell  
differentiation  could  also  be  enforced  by  TCR  signaling,  which  calls  for  a  further  
comprehensive  investigation  in  the  future.  
1.5.2.2 Epigenetic regulation of T helper cell plasticity 
In  the  absence  of  environmental  perturbations,  the  unique  epigenetic  
characteristics  in  the  cytokine  gene  loci  for  different  T  helper  subsets  are  in  accordance  
with  their  relatively  stable  cytokine  production.  How,  then,  could  we  explain  the  
substantial  plasticity  of  T  helper  cells,  especially  when  they  are  exposed  to  altered  
environmental  cues?  Several  recent  studies  showed  that  in  contrast  to  the  cytokine  genes,  
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the  epigenetic  features  of  the  master  transcription  factors  are  less  entrenched  and  may  be  
more  accessible  to  for  chromatin  remodeling70.  For  example,  in  Th1  cells,  the  il4  gene  is  
completely  methylated  and  exhibits  very  little  permissive  H3K4  trimethylation  but  high  
levels  of  repressive  H3K27  trimethylation,  which  is  suggestive  of  gene  silencing.  
However,  looking  at  master  transcription  factors,  in  Th1  cells,  the  gata3  (the  Th2-­‐‑
specifying  transcription  factor)  locus  not  only  remains  partially  methylated,  but  is  also  
associated  with  bivalent  histone  modifications  that  maintain  accessibility.  Such  a  
strategy  keeps  the  locus  in  a  “poised”  state,  thereby  preserving  a  certain  degree  of  
lineage  plasticity.  For  further  investigation,  it  will  be  critical  to  identify  the  pioneer  
factors  that  are  able  to  bind  to  these  bivalent  features  to  initiate  chromatin  remodeling  
for  “re-­‐‑differentiation”.  
1.5.3 Role of epigenetic mechanisms in Treg differentiation and 
stability 
Unlike  the  conventional  T  helper  cells  whose  functions  are  mainly  characterized  
by  their  ability  to  make  one  or  two  signature  cytokines,  the  identity  of  Tregs  is  not  only  
featured  by  the  production  of  various  immune-­‐‑suppressive  cytokines  (eg:  TGFβ,  IL-­‐‑10,  
IL-­‐‑35),  but  also  defined  by  the  constitutive  expression  of  many  surface  molecules  (eg:  
CTLA-­‐‑4,  GITR,  CD39)  that  could  inhibit  target  cell  proliferation  or  function.  Expression  
of  these  Treg  signature  genes  is  mainly,  if  not  all,  controlled  by  the  master  transcription  
factor  of  Tregs,  Foxp371.  Therefore,  although  several  recent  studies  have  started  to  assess  
the  epigenetic  aspects  of  these  Foxp3-­‐‑regulated  genes,  the  majority  of  studies  have  
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focused  on  dissecting  the  epigenetic  mechanisms  that  regulate  expression  of  the  foxp3  
gene.  Sequence  conservation  and  specific  epigenetic  modification  patterns  have  
identified  several  important  conserved  non-­‐‑coding  regions,  all  of  which  were  shown  to  
be  involved  in  the  regulation  of  foxp3  expression.      
The  foxp3  promoter  is  a  classic  TATA  and  CAAT  box-­‐‑containing  promoter  that  is  
located  around  6kb  upstream  of  the  translational  start  site  of  foxp3  gene.  It  contains  a  
CpG  island,  which  is  completely  demethylated  in  Tregs  and  heavily  methylated  in  
opposing  lineages  such  as  Th1  cells72.  Interestingly,  in  resting  conventional  CD4+  T  cells,  
this  region  is  still  largely  demethylated,  suggesting  that  naïve  CD4+  T  cells  are  poised  for  
Foxp3  induction.  The  foxp3  promoter  contains  six  binding  sites  for  NFAT  and  AP-­‐‑1,  
which  promote  the  transcription  of  foxp3  in  response  to  TCR  signaling73.  This  agrees  
with  the  absolute  requirement  of  TCR  stimulation  for  both  nTreg  and  iTreg  
differentiation.  However,  it  was  also  very  clear  that  TCR  signaling  with  enhanced  
strength  actually  inhibits  Foxp3  induction  during  iTreg  differentiation.  This  suggests  
that  strong  TCR  stimulation  must  also  negatively  control  Foxp3  expression  through  a  
more  dominant  pathway.  Indeed,  we  found  that  extensive  TCR  activation  could  limit  
the  chromatin  accessibility  of  foxp3  locus  through  enhancing  the  CpG  methylation  of  
foxp3  promoter,  thereby  preventing  the  binding  of  transcription  factors  such  as  NFAT  
and  AP-­‐‑1  and  blocking  foxp3  transcription69  (See  Chapter  4  for  further  details).  
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The  second  important  conserved  region  controlling  foxp3  expression  is  a  TGF-­‐‑β  
sensitive  region  (CNS1)  that  contains  binding  sites  for  SMADs.  The  chromatin  region  of  
CNS1  is  also  more  accessible  in  Tregs  than  other  T  helper  subsets  and  naïve  
conventional  CD4+  T  cells,  as  indicated  by  increased  histone  acetylation74.  Moreover,  
mice  with  genetic  deletion  of  CNS1  contain  a  normal  nTreg  compartment,  but  exhibit  a  
50%  reduction  in  TGF-­‐‑β-­‐‑dependent  iTreg  differentiation75.  This  partial  reduction  clearly  
shows  that  SMADs-­‐‑mediated  chromatin  remodeling  of  CNS1  upon  TGF-­‐‑β  treatment  is  
required  for  Foxp3  induction  from  conventional  CD4+  T  cells;  nevertheless,  since  
neutralization  of  TGF-­‐‑β  could  completely  abolish  iTreg  differentiation76,  it  also  indicates  
that  other  pathways  downstream  of  TGF-­‐‑β  signaling  may  also  be  involved.  We  recently  
found  that  through  activation  of  the  p38  pathway,  TGF-­‐‑β  could  decrease  the  abundance  
of  DNMT1  and  subsequently  reduce  CpG  methylation  of  the  foxp3  promoter69,  thereby  
providing  a  SMADs-­‐‑independent  mechanism  for  TGF-­‐‑β-­‐‑induced  Foxp3  expression.    
CNS2  is  the  third  highly  conserved  non-­‐‑coding  region  that  regulates  Foxp3  
expression.  It  contains  a  CpG  island,  which  is  completely  demethylated  in  nTregs  but  is  
fully  methylated  in  conventional  CD4+  T  cells72.  The  enhancer  activity  of  CNS2  depends  
highly  on  its  demethylation  state,  as  methylation  of  CNS2  significantly  inhibits  the  
binding  of  transcription  factors  to  this  region77.  Interestingly,  as  opposed  to  CNS1,  CNS2  
seems  to  be  irrelevant  for  the  induction  of  Foxp3  but  instead  is  important  for  the  
maintenance  of  Foxp3:  mice  with  a  specific  deletion  of  CNS2  have  normal  nTreg  and  
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iTreg  development,  but  they  cannot  stably  maintain  Foxp3  expression  in  the  progeny  of  
mature  nTregs75.  This  suggests  that  factors  that  bind  to  CNS2  are  potential  regulators  of  
Treg  stability.  Indeed,  it  was  recently  reported  that  a  protein  complex  containing  
transcription  factors  Runx1/CBFβ  and  Foxp3  itself  binds  to  CNS2  in  a  demethylation-­‐‑
dependent  manner  and  this  is  critical  for  the  maintenance  of  high  level  of  Foxp3  in  
nTregs75.  This  “autoregulatory  loop”  enforced  by  Foxp3  provides  an  intriguing  model  
for  the  remarkable  stability  of  nTregs  under  homeostatic  conditions.  However,  it  might  
not  be  sufficient  to  explain  how  the  majority  of  nTregs  are  still  able  to  maintain  Foxp3  
expression  even  during  inflammation  (see  section  1.3.2).  We  and  others  have  recently  
found  that  inflammatory  stimulation  could  prone  the  silencing  of  Foxp3  expression  by  
inducing  CpG  methylation  in  the  CNS2  region.  Since  this  silencing  epigenetic  
modification  disfavors  the  binding  of  transcription  factors  known  to  regulate  foxp3,  there  
must  be  additional  factors  that  are  able  to  resist  such  modifications  to  safeguard  foxp3  
expression.  Indeed,  we  recently  identified  methyl  CpG  binding  protein  2  (MeCP2)  as  
such  a  unique  rescuer  (See  Chapter  5  for  details).  Unlike  other  traditional  transcription  
activators  such  as  Runx1  and  Foxp3,  MeCP2  favors  binding  to  methylated  DNA  and  
was  therefore  enriched  in  the  partially  methylated  CNS2  region,  where  it  promoted  local  
histone  H3  acetylation  to  counteract  the  silencing  modification.  We  further  
demonstrated  that  the  transactivation  role  of  MeCP2  for  foxp3  during  inflammation  is  
dependent  on  CREB1,  a  well-­‐‑known  partner  for  the  acetyltransferase  complex  CBP/p300:  
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in  the  absence  of  MeCP2,  the  binding  of  CREB1  to  CNS2  was  completely  abolished;  and  
when  the  activation  of  CREB1  was  blocked,  the  stabilizing  influence  of  MeCP2  on  the  
local  chromatin  structure  and  foxp3  expression  was  largely  reversed.  Thus,  in  addition  to  
the  Runx1/CBPβ/Foxp3  complex,  MeCP2  provides  an  additional  layer  of  protection  for  
foxp3  stability,  especially  under  inflammatory  conditions.    
A  fourth  regulatory  cis-­‐‑element  in  the  foxp3  locus  (CNS3)  was  identified  recently.  
CNS3  was  proposed  to  act  as  a  pioneer  element  for  de  novo  foxp3  expression,  because  the  
accessible  histone  modifications  in  CNS3  were  present  not  only  in  Tregs  that  are  actively  
expressing  Foxp3,  but  also  in  thymic  and  peripheral  Treg  precursors75.  A  NF-­‐‑κB  family  
member,  c-­‐‑Rel,  was  shown  to  bind  to  CNS3  and  critically  supports  early  Foxp3  
induction  during  Treg  differentiation.  Consistently,  mice  with  specific  deletion  of  CNS3  
or  c-­‐‑Rel  have  a  severe  block  in  nTreg  development  in  the  thymus.  It  remains  to  be  
determined  whether  c-­‐‑Rel  is  sufficient  to  induce  the  epigenetic  modifications  in  CNS3  






2. Materials and methods 
2.1 Mice 
Mice  homozygous  for  the  floxed  mir-­‐‑17-­‐‑92  allele  (Mir17-­‐‑92tm1.1Tyj/J)  and  mecp2  
allele  (B6.129P2-­‐‑MeCP2tm1Bird/J)  were  purchased  from  The  Jackson  Laboratory.  Lck-­‐‑cre  
(B6.Cg-­‐‑Tg(lck-­‐‑cre)1Cwi  N9)  and  Cd4-­‐‑cre  mice(C57BL/6Tac-­‐‑Tg(cd4-­‐‑cre)N9)  were  from  
Taconic.  Foxp3-­‐‑GFP-­‐‑Cre  BAC  transgenic  mice  were  kindly  provided  by  Dr.  Xiaoping  
Zhong  from  the  Duke  University  Medical  Center.  T  cell-­‐‑specific  miR-­‐‑17-­‐‑92  or  MeCP2  
deficient  mice  were  generated  by  crossing  floxed  mir-­‐‑17-­‐‑92  mice  or  floxed  mecp2  mice  
with  the  cd4-­‐‑cre  or  lck-­‐‑cre  mice.  Treg-­‐‑specific  MeCP2  deficient  C57BL/6  mice  were  
generated  by  crossing  floxed  mecp2  mice  with  Foxp3-­‐‑GFP-­‐‑Cre  mice.  With  speed  
congenic  service  provided  by  The  Jackson  Laboratory,  mice  carrying  MeCP2f/f  alleles  
were  back-­‐‑crossed  to  NOD  mice  carrying  Foxp3-­‐‑GFP-­‐‑Cre  BAC  transgenes.  With  
genome-­‐‑wide  marker-­‐‑assisted  selection  protocol,  after  eight  generation  of  back-­‐‑crossing,  
the  conditioned  MeCP2f/f  alleles  resides  in  mice  with  pure  NOD  background.  5C.C7  TCR  
transgenic  mice  were  from  Taconic  (B10.ARag2tm1Fwa  H2-­‐‑T18a  Tg  (Tcra5CC7,  Tcrb5CC7)lwep).  
WT  B10.A  mice  were  also  from  Taconic.  All  mice  were  maintained  under  pathogen-­‐‑free  





2.2 Quantitative PCR 
Total  RNA  was  isolated  with  miRVana  extraction  kit  (Ambion)  according  to  the  
manufacturer'ʹs  instructions.  For  mRNAs,  reverse  transcription  was  performed  with  
qScript™  Flex  cDNA  Kit  (Quanta  Biosciences)  and  gene  expression  was  quantified  by  
SYBR  Green  based  qPCR  analysis  and  normalized  to  the  level  of  SDHA  as  internal  
control.  For  miRNAs,  E.  coli  polyA  polymerase  was  employed  to  add  adenines  at  the  3'ʹ  
end  of  RNA  molecules  lacking  a  polyA  tail.  Following  oligodT  annealing,  a  universal  tag  
was  attached  to  the  3’  end  of  cDNAs  during  the  cDNA  synthesis  using  retro-­‐‑
transcriptase  superscript  III  (Invitrogen).  With  miRNA-­‐‑specific  forward  primers  and  a  
reverse  universal  primer  mix,  the  expression  of  individual  miRNAs  was  quantified  by  
SYBR  Green  based  qPCR  analysis  and  normalized  to  the  level  of  U6  as  internal  control.  
  
2.3 Western Blots 
Total  cell  extracts  were  collected  by  lysing  cells  in  RIPA  buffer  in  the  presence  of  
protease  inhibitor  cocktail  (Roche)  and  phosphatase  inhibitor  mix  I  and  II  (Sigma).  
Samples  were  fractionated  by  electrophoresis  on  a  10%  SDS  polyacrylamide  gel  
(Invitrogen)  and  electroblotted  on  to  a  PVDF  membrane.  Western  blot  was  performed  
according  to  standard  protocols  with  the  following  primary  antibodies:  anti-­‐‑STAT1,  
anti-­‐‑STAT3,  anti-­‐‑pSTAT1  (Y701),  anti-­‐‑pSTAT3  (Y705),  anti-­‐‑SOCS1,  anti-­‐‑SOCS3,  anti-­‐‑
SOCS5,  anti-­‐‑JAK1,  anti-­‐‑JAK2,  anti-­‐‑JAK3,  anti-­‐‑MeCP2,  anti-­‐‑DNMT1,  anti-­‐‑PTEN,  anti-­‐‑
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TGFβRII,  anti-­‐‑CREB1,  anti-­‐‑Bim,  anti-­‐‑p-­‐‑Smad3  (S423/425),  anti-­‐‑Smad3  (Cell  Signaling  
Technology),  anti-­‐‑DNMT3b  (Abgent),  and  anti-­‐‑β-­‐‑Actin  (Sigma).  Anti-­‐‑rabbit-­‐‑Alexa680  
and  anti-­‐‑goat-­‐‑Alexa680  (Invitrogen)  were  used  as  secondary  antibodies  and  the  
fluorescence  intensity  was  measured  on  an  Odyssey  system  (Licor).  
  
2.4 Cell sorting, staining and flow cytometry analysis 
Cell  sorting  was  performed  using  a  MoFlo  Legacy  sorter,  and  purity  of  sorted  
cells  was  determined  by  post-­‐‑sorting  to  be  at  least  98  percent  for  each  experiment.  For  
intracellular  cytokine  staining,  cells  were  stimulated  with  0.9nM  PdBU  (Phorbol  12,13-­‐‑
dibutyrate)  and  0.5µμg/mL  ionomycin  (Sigma-­‐‑Aldrich)  in  the  presence  of  5µμg/mL  
brefeldin  A  and  2µμM  monensin  (eBioscience)  for  4  hours.  Cells  were  fixed  with  2%  
paraformaldehyde,  followed  by  permeabilization  with  0.1%  saponin  (Sigma-­‐‑Aldrich)  
and  antibody  staining.  Foxp3  staining  was  performed  using  Foxp3  /  Transcription  Factor  
Staining  Buffer  Set  and  Anti-­‐‑Mouse/Rat  Foxp3  antibody  (clone  FJK-­‐‑16s)  from  
eBioscience  based  on  the  suggested  protocol.  For  DNMT1,  STAT1,  pSTAT1  (Y701),  
STAT3,  pSTAT3  (Y705)  staining,  cells  were  fixed  with  2%  paraformaldehyde  in  PBS,  
permeabilized  with  90%  methanol  in  PBS,  and  stained  with  the  appropriate  primary  
antibodies  or  isotype  control  followed  staining  with  a  Pacific  Blue  secondary  antibody.  
Fluorescence-­‐‑conjugated  antibodies  for  CD4,  CD8,  CD25,  CD44,  CD62L,  IL-­‐‑17A,  IFN-­‐‑γ,  
IL-­‐‑2,  CD90.1(Thy1.1),  CD90.2(Thy1.2)  were  purchased  from  Biolegend.  The  survival  of  
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cells  was  assessed  by  staining  with  the  Annexin  V,  7AAD  (biolegend),  and  
LIVE/DEAD®  Fixable  Violet  Dead  Cell  Stain  Kit  (Invitrogen).  The  proliferation  of  cells  
was  assessed  by  CFSE  (Invitrogen)  dilution  and  Edu  (Invitrogen)  incorporation.    
  
2.5 In vitro CD4+ T cell differentiation 
Conventional  CD4+  T  cells  from  the  lymph  nodes  and  spleens  of  different  mice  
were  stimulated  by  TCR  specific  peptides  or  plate  bound  anti-­‐‑CD3/CD28  antibodies  and  
cultured  under  various  Th-­‐‑skewing  conditions  for  4-­‐‑7  days.  Th1  skewing  condition:  
50ng/ml  recombinant  mouse  IL-­‐‑12  (Peprotech),  10µμg/ml  purified  anti-­‐‑IL-­‐‑4  (11B11),  and  
50U/ml  recombinant  mouse  IL-­‐‑2  (Peprotech)).  Th2  skewing  condition:  50U/ml  
recombinant  mouse  IL-­‐‑2,  50ng/ml  recombinant  mouse  IL-­‐‑4  (Peprotech),  10µμg/ml  
purified  anti-­‐‑IFNγ  (XNG1.2)  and  5µμg/ml  anti-­‐‑IL-­‐‑12  (BD).  Th17  skewing  condition:  
20ng/ml  recombinant  mouse  IL-­‐‑6  (Peprotech),  4ng/ml  recombinant  TGFβ  (Peprotech),  
10µμg/ml  purified  anti-­‐‑IFNγ  (XNG1.2)  and  10µμg/ml  purified  anti-­‐‑IL-­‐‑4  (11B11).  iTreg  
skewing  condition:  0.2  -­‐‑5.0ng/ml  recombinant  human  TGFβ,  50U/ml  recombinant  mouse  
IL-­‐‑2,  10µμg/ml  anti-­‐‑IL-­‐‑4  (11B11),  10µμg/ml  anti-­‐‑IFN-­‐‑γ  (XMG1.2),  and  10µμg/ml  anti-­‐‑IL-­‐‑6  
(BD).  Cytokine  production  and  Foxp3  expression  by  differentiated  CD4+  T  cells  were  




2.6 Plasmids and retrovirus transduction 
The  retroviral  Foxp3  expression  plasmid  (Addgene  plasmid  24067)  was  kindly  
provided  by  Dr.  Dan  Littman  from  New  York  University.  The  Vectors  expressing  
miRNAs  were  cloned  by  inserting  the  fragments  containing  the  “pre-­‐‑“  form  of  miRNAs  
into  the  MSCV-­‐‑PIG-­‐‑Mock  vector.  For  retrovirus  transduction,  Tcons  or  Tregs  were  
stimulated  with  TCR  specific  peptides  or  plate  bound  anti-­‐‑CD3/CD28.  18  hours  later,  
cells  were  transduced  with  retrovirus  in  a  24-­‐‑well  plate  by  spin  inoculation  at  a  speed  of  
1258g  for  90  minutes  at  37°C.  
  
2.7 miRNA target predictions and luciferase assays 
The  miRNA  target  candidates  were  predicted  using  multiple  methods  assembled  
on  the  miRecords  website  (http://mirecords.biolead.org/).  The  3’UTRs  of  mouse  pten,  tgfbr2,  
creb1,  dnmt1,  and  socs5  containing  predicted  binding  sites  of  miR-­‐‑19b,  miR-­‐‑17,  miR-­‐‑148a,  
and  miR-­‐‑124  were  amplified  from  a  3’  RACE-­‐‑ready  cDNA  library  generated  from  mouse  
T  cell  total  RNAs,  and  cloned  into  a  luciferase  reporter  right  downstream  of  the  firefly  
luciferase  gene.  For  normalization,  3T3  cell  lines  that  overexpress  individual  miRNAs  
were  co-­‐‑transfected  with  a  renilla  luciferase  vector  (pRL-­‐‑TK)  whose  expression  is  not  
affected  by  miRNA  targeting.  Luciferase  activity  was  determined  48  hours  post  
transfection  using  a  dual  luciferase  assay  kit  (Promega).  To  assess  foxp3  promoter  and  
enhancer  activity,  we  acquired  the  PGL4,  PGL4-­‐‑Pro  and  PGL4-­‐‑Pro-­‐‑CNS2  constructs78  
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from  Dr.  Yisong  Wan  at  the  University  of  North  Carolina  at  Chapel  Hill.  Jurkat  T  cells  
were  transfected  by  Nucleofector  Device  (Lonza)  with  a  non-­‐‑targeting  control  siRNA  or  
siRNA  against  human  MeCP2  (150pmol  per  sample)  (Thermo  Scientific  Dharmacon),  
together  with1µμg  reporter  plasmid  or  1µμg  of  pRL-­‐‑TK  plasmid  as  an  internal  control.  48  
hours  after  transfection,  cells  were  either  untreated,  or  treated  with  0.9  nM  PdBU  and  0.5  
µμg/ml  ionomycin  (Sigma)  for  an  additional  16-­‐‑24  hours.  Firefly  and  Renilla  Luciferase  
activities  were  then  determined.  
  
2.8 DNA methylation and chromatin immunoprecipitation (ChIP) 
analysis 
Genomic  DNA  was  purified  with  GenElute™  Mammalian  Genomic  DNA  
Miniprep  Kit  (Sigma).  Methylation  analysis  was  quantified  by  sequencing  of  genomic  
DNA  after  bisulfite  conversion  using  the  MethylDetector  kit  (Active  Motif),  PCR  
amplification  and  cloning.  Chromatin  immunoprecipitation  was  done  based  on  a  
standard  protocol  with  anti-­‐‑H3Ac,  anti-­‐‑H3K4me2,  anti-­‐‑H3K4me3,  anti-­‐‑H3K27me3    
Rabbit  polyclonal  antibody  (Millipore),  MeCP2  (D4F3)  XP®  Rabbit  monoclonal  
antibody,  CREB1  (48H2)  Rabbit  monoclonal  antibody  (Cell  Signaling),  rabbit  anti-­‐‑
DNMT1  (H300)  antibody,  mouse  anti-­‐‑DNMT3b  mAb  (52A1018)  (Santa  Cruz  
Biotechnology),  or  a  nonspecific  rabbit  anti-­‐‑mouse  IgG  (Jackson  ImmunoResearch  
Laboratories).  The  amount  of  DNA  immunoprecipitated  by  antibodies  was  quantified  
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by  qPCR  using  primers  specific  for  the  indicated  gene-­‐‑regulatory  regions  and  
normalized  to  the  input  prior  to  immunoprecipitation.    
  
  
2.9 B16 melanoma tumor model and anti-tumor responses assay 
B16/F10  melanoma  cell  line  was  a  gift  from  Dr.  Thomas  Tedder  (Duke  
University).  The  OVA-­‐‑secreting  B16/F0/OVA  cell  line  was  kindly  provided  by  Dr.  Edith  
Lord  (University  of  Rochester).  In  the  subcutaneous  melanoma  tumor  model,  different  
mice  were  anesthetized  and  injected  s.c.  on  the  shaved  right  lateral  flank  with  2x105  
B16/F10  tumor  cells  or  3x105  B16/F0/OVA  cells  in  200  µμl  sterile  PBS.  Tumor  volumes  
were  monitored  and  calculated  using  the  equation:  V  =  4  (L1  x  L22)/3,  where  V  =  volume  
(mm3),  L1  =  the  longest  radius  (mm),  L2  =  the  shortest  radius  (mm).  For  the  detailed  
analysis  of  adaptive  anti-­‐‑tumor  responses,  lymphocytes  from  the  tumor  draining  lymph  
node  were  isolated  16  days  after  tumor  cell  injection  and  activated  with  1  µμg/ml  plate-­‐‑
bound  anti-­‐‑CD3  and  anti-­‐‑CD28  antibodies  for  24  hrs  or  stimulated  with  LB27.4  APCs  
loaded  with  10  µμM  OVA  (323-­‐‑339)  for  48  hrs.  Cell  proliferation,  AICD,  and  cytokine  
production  were  measured  with  CFSE  staining,  Annexin-­‐‑V/7AAD  staining,  and  




2.10 Mouse model of delayed-type hypersensitivity reaction 
(DTH) 
Mice  were  subcutaneously  immunized  with  KLH  protein  (100µμg/mouse)  in  CFA.  
7  days  after  immunization,  mice  were  rechallenged  with  KLH  (50µμg/mouse)  or  PBS  in  
each  lateral  footpad.  48  hours  later,  footpad  swelling  was  measured  prior  to  euthanasia  
for  immunological  and  histological  analysis.    
  
2.11 Mouse model of inflammatory bowel disease (IBD) 
Naïve  T  cells  (CD4+CD25-­‐‑CD45Rbhigh)  from  different  mice  were  mixed  with  
nTregs  (CD4+CD25+)  from  different  mice  at  various  ratios,  and  injected  intraperitoneally  
into  Rag2-­‐‑/-­‐‑  recipients.  Recipients  were  weighed  throughout  the  course  of  the  
experiments  and  were  euthanized  at  the  experimental  endpoints  for  immunological  and  
histological  analysis.    
  
2.12 Mouse model of Experimental autoimmune 
encephalomyelitis (EAE) 
For  the  induction  of  EAE,  6-­‐‑10  week  old  mice  were  injected  with  200ng  pertussis  toxin  in  
200ul  PBS  per  mouse  i.p.  on  day0  and  day2.  On  day  0,  each  mouse  was  immunized  with  
100ug  MOG  peptide  emulsified  in  CFA  subcutaneously.  Mice  were  then  monitored  
closely  for  disease  severity  using  the  standard  scale:  0,  no  clinical  signs;  1,  limp  tail;  2,  
weak  paraparesis  (weak  and  incomplete  paralysis  of  one  or  two  hind  limbs);  3,  
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paraplegia  (complete  paralysis  of  two  hind  limbs);  4,  paraplegia  with  forelimb  weakness  
or  paralysis;  5,  death.  
  
2.13 In vitro Treg suppression assay 
1.0×105  CD4+CD25-­‐‑  conventional  T  cells  from  LNs  and  spleens  of  Thy1.1+  B6  mice  
were  FACS  sorted,  labeled  with  CFSE  (Invitrogen)  at  a  concentration  of  10µμM,  and  then  
mixed  with  sorted  Thy1.2+  CD4+CD25+  Tregs  from  LNs  and  spleen  of  MeCP2fl/fl  Lck-­‐‑Cre  
or  littermate  control  mice  at  different  ratios.  The  mixture  of  cells  was  then  stimulated  for  
72  hours  with  0.5ug/mL  soluble  anti-­‐‑CD3  (BioXCell)  and  0.5ug/mL  soluble  anti-­‐‑CD28  
(BioXCell)  in  the  presence  of  1×105  T  cell  depleted-­‐‑splenocytes  from  B6  mice,  which  had  
been  pre-­‐‑treated  with  50ug/ml  mitomycin  C  (Sigma)  at  37  degrees  for  1  hour  to  serve  as  
APCs.  The  proliferation  of  conventional  T  cells  were  analysed  by  CFSE  dilution.  
Cytokine  production  from  conventional  T  cells  or  Tregs  was  analysed  by  intracellular  
staining  following  4  hours  of  PdBU  and  ionomycin  stimulation.    
  
2.14 Microarray sample preparation and data analysis 
Thy1.2+  CD4+CD25+  Tregs  from  LNs  and  spleen  of  6-­‐‑8  week  old  MeCP2fl/fl  Lck-­‐‑
Cre  or  littermate  control  mice  were  sorted  and  mixed  with  CD4+CD25-­‐‑  conventional  T  
cells  from  LNs  and  spleens  of  Thy1.1+  B6  mice  at  ratio  of  1  to  4,  and  stimulated  for  72  
hours  with  0.5ug/mL  anti-­‐‑CD3  and  0.5ug/mL  anti-­‐‑CD28  in  the  presence  of  T  cell  
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depleted  splenocytes  from  B6  mice  that  served  as  APCs.  At  the  end  of  culture,  viable  
Thy1.2+  wild  type  and  MeCP2-­‐‑deficient  Treg  cells  were  sorted  and  lysed  for  RNA.  Two  
rounds  of  samples  from  different  mice  were  independently  collected.  The  global  gene  
expression  was  assessed  by  GeneChip  Mouse  Genome  430  2.0  Array  from  affymetrix  
using  service  from  the  Duke  DNA  Microarray  Core  Facility.  Microarray  data  was  
analyzed  using  the  Partek  Genomics  Suite,  with  RMA  background  correction  and  mean  
probeset  summarization  analysis  parameters  used.  Only  non-­‐‑cross-­‐‑hybridizing  probes  
that  were  declared  present  or  marginal  in  at  least  one  sample  (according  to  the  MAS5  
file)  were  considered  for  analysis.  The  normalized  expression  levels  were  then  compared  
between  WT  Tregs  and  MeCP2  KO  Tregs.  An  average  fold-­‐‑change  of  1.5  was  used  as  a  
threshold  for  differential  expression  between  the  two  samples.  For  genes  with  multiple  
probes,  the  fold  changes  were  averaged,  resulting  in  154  unique,  differentially  expressed  
genes.  
  
2.15 Fluorescence microscopy 
5C.C7  T  cells  that  were  stimulated  with  different  peptides  for  defined  durations  
were  fixed  with  4%  paraformaldehyde  on  coverslips,  permeabilized  with  0.5%  Triton  X-­‐‑
100  in  PBS,  and  stained  with  anti-­‐‑DNMT1  mAb  (Cell  signaling).  A  Cy3  Donkey  anti-­‐‑
rabbit  antibody  was  used  as  secondary  antibody  for  fluorescence  microscopy.  Imaging  
was  performed  on  a  Zeiss  Axiovert-­‐‑100TV  station  equipped  with  a  Zeiss  40X  EC  Plan-­‐‑
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Neofluar  objective  lens  (NA=1.30),  a  CoolSNAPHQ  CCD  camera  (Roper  Scientific)  and  a  
high-­‐‑speed  piezzo  Z-­‐‑motor  for  Z  stack  recording.  
  
2.16 Histology 
Footpads  and  colons  was  excised,  inflated  with  4%  paraformaldehyde  in  PBS,  
fixed  overnight  at  room  temperature,  placed  in  70%  ethanol,  embedded  with  paraffin,  
and  sent  for  H&E  staining.  The  histologic  scores  of  colon  in  IBD  model  were  assessed  as  
previously  described79  in  a  double-­‐‑blinded  setting.  
  
2.17 Statistics 
Two-­‐‑tailed  Student  t  tests  were  utilized  to  determine  whether  the  difference  
between  a  given  set  of  means  was  statistically  significant  unless  otherwise  mentioned.  




3. Dissecting miR-17-92 cluster's critical roles in 
supporting Th1 mediated immune responses and 
preventing inducible Treg differentiation: A miRNA 
modulator of T cell anti-tumor response 
The  contents  of  this  dissertation  chapter  have  been  slightly  modified  from  the  
following  publication:  
  Shan  Jiang*,  Chaoran  Li*,  Virginie  Olive,  Erik  Lykken,  Feng  Feng,  Jose  Sevilla,  
Ying  wan,  Lin  He  &  Qi-­‐‑Jing  Li  (*  equal  contribution  and  listed  in  an  alphabetic  order).  
Molecular  dissection  of  the  miR-­‐‑17-­‐‑92  cluster'ʹs  critical  dual  roles  in  promoting  Th1  
responses  and  preventing  inducible  Treg  differentiation.  Blood  118,  5487-­‐‑5497  (2011)  
3.1 Introduction 
CD4+  T  cells  are  essential  components  of  the  adaptive  immune  system  that  
regulate  immune  responses  against  foreign  pathogens  and  tumors.  Upon  antigen  
recognition,  naïve  CD4+  T  cells  undergo  activation  and  expansion,  and  then  contract  via  
programmed  cell  death1.    Specific  antigen  challenges  also  induce  CD4+  T  cells  to  
differentiate  into  distinct  T  helper  lineages  characterized  by  unique  cytokine  production  
profiles8.  Among  these  lineages,  Th1  cells,  whose  differentiation  is  controlled  by  the  
master  transcription  factor  T-­‐‑bet80,  are  specialized  for  the  clearance  of  intracellular  
infections  and  implicated  as  the  major  effectors  against  tumors81.  The  production  of  IFN-­‐‑
γ  by  these  cells  directly  eliminates  the  tumor  cell82,  induces  cytotoxic  effects  indirectly  
through  the  activation  of    macrophages83,  enhance  the  immunogenicity  of  tumor  cells  
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and  tumor  antigen  presentation84,  and  inhibits  angiogenesis85  ,  which  collectively  
constitutes  the  bulk  of  the  effector  function  of  Th1  cells  against  tumors.  Supporting  the  
key  role  of  Th1  cells  in  the  anti-­‐‑tumor  response,  mice  that  lack  IFN-­‐‑γ  or  are  insensitive  to  
IFN-­‐‑γ-­‐‑mediated  signaling  were  more  vulnerable  to  carcinoma-­‐‑induced  and  spontaneous  
tumors86-­‐‑88.  Additionally,  T  cell  survival  and  expansion  are  also  essential  for  the  
clearance  or  inhibition  of  tumor  growth  in  vivo,  a  fact  highlighted  by  the  observation  that  
tumors  utilize  various  strategies  to  suppress  T  cell  proliferation,  and  to  induce  their  
apoptosis89.  Another  remarkable  immune  evasion  mechanism  is  tumor-­‐‑induced  
conversion  of  effector  T  cells  into  inducible  Foxp3+  regulatory  T  cells  (iTregs)  and  
subsequent  accumulation  of  Treg  cells  to  transform  the  tumor  microenvironment6.  Due  
to  their  ability  to  negatively  regulate  immune  responses  through  inhibiting  APCs  and  
effector  T  cell  function90,  Treg  cells  are  suggested  to  be  one  of  the  major  barriers  to  
applying  anti-­‐‑tumor  immune  therapies91,92.  As  a  result,  enhancing  effector  T  cell  
expansion,  survival,  Th1  cytokine  production,  and  blocking  iTreg  induction  are  
currently  the  central  concerns  when  conducting  anti-­‐‑tumor  T  cell  immunotherapy.  
While  the  protein-­‐‑based  regulatory  machinery  that  operates  during  the  T  cell  response  
has  been  vigorously  explored,  we  have  recently  become  aware  of  a  novel  and  crucial  
element  modulating  T  cell  function  –  miRNA  48,52.    
miRNAs  are  21-­‐‑24  nucleotide  non-­‐‑coding  RNAs  that  regulate  gene  expression  by  
destabilizing  target  mRNAs,  leading  to  degradation  or  by  blocking  translation46.  Recent  
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studies  suggest  that  miRNA-­‐‑mediated  gene  regulation  represents  a  fundamental  layer  of  
posttranscriptional  genetic  programs  in  metazoan  genomes  that  has  broad  effects  on  
gene  expression2.  Global  disruption  of  miRNAs  caused  by  deletion  of  their  biogenesis  
machinery  had  profound  effects  on  the  development  of  B  cells93,  and  recent  studies  
indicate  that  they  were  also  critical  for  Th1/Th2  differentiation49,94  and  regulatory  T  cell  
function60,95.  In  addition  to  these  demonstrations  of  the  importance  of  miRNA  biogenesis  
in  general,  accumulating  evidence  shows  that  many  specific  miRNAs  are  differentially  
regulated  in  hematopoietic  lineages  and  suggests  that  they  play  an  important  role  in  
controlling  the  development  and  function  of  immune  cells48,52.  One  such  regulator  is  the  
miR-­‐‑17-­‐‑92  cluster.  This  cluster  of  miRNAs  is  encoded  by  a  polycistronic  miRNA  gene  
located  on  human  chromosome  13  and  has  two  paralogs:  miR-­‐‑106b-­‐‑25  on  chromosome  7  
and  miR-­‐‑106a-­‐‑363  on  the  X  chromosome96.  Unlike  most  miRNAs,  which  are  usually  
processed  from  an  independent  primary  transcript,  the  miR-­‐‑17-­‐‑92  cluster  gene  generates  
a  single  transcript  that  yields  six  individual  mature  miRNAs,  which  can  be  further  
grouped  into  three  families  based  on  the  similarity  of  their  “seed”  regions  (nucleotides  
2-­‐‑8):    the  miR-­‐‑17  family  (miRs-­‐‑17,  20,  and  18a),  the  miR-­‐‑19  family  (miRs  -­‐‑19a  and  19b),  
and  the  miR-­‐‑25  family  (miR-­‐‑92a).  miR-­‐‑17-­‐‑92  is  well  recognized  as  an  “oncomiR”  due  to  
its  potent  acceleration  of  c-­‐‑Myc-­‐‑induced  lymphoma97.  Genetic  ablation  has  clearly  
established  miR-­‐‑17-­‐‑92’s  critical  roles  in  embryonic  development98.  This  cluster  was  also  
shown  to  promote  angiogenesis  in  endothelial  cells  during  both  normal  development  
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and  tumor  growth99.  In  immune  cells,  miR-­‐‑17-­‐‑92  plays  an  integral  part  in  the  
development  of  myeloid  cells  and  B  cells98,100.  Mice  with  germ-­‐‑line  deletion  of  miR-­‐‑17-­‐‑92  
exhibit  a  severe  defect  in  adult  B  cell  development  with  an  augmentation  of  apoptosis  in  
the  pro-­‐‑B  cell  fraction  and  consequently  a  blockade  at  the  pro-­‐‑B  to  pre-­‐‑B  transition98.  
Additionally,  transgenic  mice  with  ectopic  expression  of  the  miR-­‐‑17-­‐‑92  cluster  in  
lymphocytes  developed  lymphoproliferative  disease  and  autoimmunity  as  early  as  18  
weeks  of  age.  It  was  suggested  that  the  overexpression  of  miR-­‐‑17-­‐‑92  unbalances  
lymphocyte  homeostasis  via  control  of  the  tumor  suppressor  PTEN  and  the  
proapoptotic  protein  Bim101.    
Due  to  its  extensive  roles  in  promoting  malignant  transformation  in  hematologic  
tumors102,    the  miR-­‐‑17-­‐‑92  cluster  has  been  put  forward  as  a  potential  candidate  for  
miRNA-­‐‑based  anti-­‐‑tumor  therapy.  However,  the  global  inhibition  of  miR-­‐‑17-­‐‑92  for  
cancer  therapy  is  largely  limited  by  the  lack  of  knowledge  regarding  the  physiological  
function  of  endogenous  miR-­‐‑17-­‐‑92  in  normal  tissues,  especially  in  patients’  immune  
systems,  which  may  compromise  the  efficacy  of  the  therapy.  Furthermore,  even  less  is  
known  about  the  differences  or  similarities  in  the  functions  of  individual  miRNAs  
within  the  cluster  during  antigen  responses.  Here,  combining  both  gain-­‐‑  and  loss-­‐‑of-­‐‑
function  approaches,  we  analyzed  the  physiological  roles  of  individual  miRNAs  within  
the  miR-­‐‑17-­‐‑92  cluster  in  the  regulation  of  T  cells’  effector  function.  Our  data  establish  the  
miR-­‐‑17-­‐‑92  cluster  as  a  multifaceted  and  indispensible  positive  regulator  of  CD4+  T  cells’  
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antigen  responses,  particularly  in  the  context  of  Th1  T  cell-­‐‑mediated  tumor  rejection,  
suggesting  that  global  inhibition  of  miR-­‐‑17-­‐‑92  is  likely  to  subvert  the  immune  response  
against  tumors.  Furthermore,  we  demonstrate  profound  functional  divergence  among  
the  individual  miRNAs  in  this  cluster,  with  miR-­‐‑19b  and  miR-­‐‑17  accounting  almost  
entirely  for  mir-­‐‑17-­‐‑92’s  pro-­‐‑Th1  influence,  while  miR-­‐‑18a  acts  as  an  internal  antagonist  
of  the  cluster’s  function.  
  
3.2 Results 
3.2.1 miR-19b facilitates T cell proliferation upon antigen challenge 
Upon  antigen  challenge,  we  observed  a  rapid  decline  in  the  levels  of  most  
miRNA  species  in  CD4+  T  cells.  Among  the  few  miRNAs  showing  significant  
augmentation,  the  miRNAs  comprising  the  miR-­‐‑17-­‐‑92  cluster  form  a  distinct  group,  
although  the  dynamics  of  mature  miRNA  elevation  varies  individually  (Figure  1).  These  
phenomena  prompted  us  to  explore  the  intrinsic  function  of  the  miR-­‐‑17-­‐‑92  cluster  
during  the  effector  T  cell  response  and  to  further  analyze  the  individual  functions  of  the  
component  miRNAs.    
To  characterize  miR-­‐‑17-­‐‑92’s  role  in  CD4+  T  cells’  proliferation  during  the  
expansion  phase  after  antigen  engagement,  we  first  infected  lymph  node  T  cells  from  
5C.C7  TCR  transgenic  mice  with  a  retrovirus  encoding  the  whole  primary  miR-­‐‑17-­‐‑92  
transcript.  In  addition  to  the  cluster,  our  vector  also  encoded  a  puromycin  resistance  
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gene  for  drug  selection  and  gfp  as  the  transduction  marker.  This  resulted  in  a  5-­‐‑  to  20-­‐‑  
fold  increase  of  expression  of  each  of  the  six  miRNAs  in  CD4+  T  cells,  in  comparison  to  
cells  infected  with  mock  virus  lacking  the  miRNA  expression  cassette  (Figure  2A).  T  
cells  were  then  stimulated  with  CH27  APCs  preloaded  with  the  agonist  peptide  moth  
cytochrome-­‐‑c  (MCC)  for  24  hours,  and  the  proliferation  of  CD4+  T  cells  was  analyzed  by  
EdU  staining.  As  reported  previously101,  we  noted  a  higher  percentage  of  CD4+  T  cells  in  
S  phase  for  those  cells  overexpressing  miR-­‐‑17-­‐‑92  as  compared  to  cells  expressing  the  
mock  vector  (Figure  2B).  We  then  examined  the  impact  of  reduced  miR-­‐‑17-­‐‑92  expression  
on  CD4+  T  cell  proliferation  by  analyzing  mir-­‐‑17-­‐‑92  conditional  knockout  mice,  in  which  
the  mir-­‐‑17-­‐‑92  locus  is  flanked  by  two  loxp  sites98  and  CD4-­‐‑Cre  expression  drove  T  cell  
specific  deletion  (Figure  2C).  CD4+CD25-­‐‑  conventional  T  cells  from  the  lymph  nodes  and  
spleen  were  sorted  by  FACS  and  stained  with  CFSE  dye,  stimulated  by  plate-­‐‑bound  
anti-­‐‑CD3/CD28,  and  cell  proliferation  was  examined  in  terms  of  CFSE  dilution.  
Reciprocal  to  the  enhanced  proliferation  of  CD4+  T  cells  overexpressing  miR-­‐‑17-­‐‑92,  the  
proliferation  of  CD4+  T  cells  heterozygous  or  null  for  mir-­‐‑17-­‐‑92  was  decreased  in  a  gene-­‐‑
dosage-­‐‑dependent  manner  (Figure  2D).  These  results  suggested  that  miR-­‐‑17-­‐‑92  is  
essential  for  CD4+  T  cells’  proliferation  in  vitro.  
To  determine  the  contribution  of  each  individual  miRNA  of  the  miR-­‐‑17-­‐‑92  
cluster  in  promoting  CD4+  T  cell  proliferation,  we  retrovirally  transduced  either  the  
whole  cluster  or  individual  miRNAs  back  into  miR-­‐‑17-­‐‑92  deficient  CD4+  T  cells,  and  
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analyzed  CD4+  T  cell  proliferation  via  EdU  staining.  As  expected,  reconstitution  with  the  
miR-­‐‑17-­‐‑92  cluster  rescued  the  proliferation  defect  of  miR-­‐‑17-­‐‑92  deficient  CD4+  T  cells.  
Moreover,  we  found  that  miR-­‐‑19b  alone  was  functionally  equivalent  to  the  whole  cluster  
in  enhancing  CD4+  T  cell  proliferation  (Figure  2E).  To  our  surprise,  although  it  only  
differs  from  its  family  member  miR-­‐‑19b  by  one  nucleotide  at  position  11,  miR-­‐‑19a  failed  
to  promote  the  proliferation  of  CD4+  T  cells.  Also  surprisingly,  the  expression  of  miR-­‐‑18a  
exerted  an  inhibitory  effect  on  proliferation.  These  data  suggested  that  miR-­‐‑19b  is  the  
functional  representative  of  miR-­‐‑17-­‐‑92  in  regulating  CD4+  T  cells’  proliferation  upon  
antigen  stimulation.    
3.2.2 miR-17 and miR-19b protect CD4+ T cells from activation 
induced cell death 
During  the  course  of  an  immune  response,  antigen-­‐‑reactive  T  cells  clonally  
expand  and  then  apoptotically  contract  to  maintain  immune  homeostasis1.  To  determine  
whether  miR-­‐‑17-­‐‑92  affected  activation-­‐‑induced  cell  death  (AICD)  for  CD4+  T  cells,  we  
challenged  5C.C7  T  cells  overexpressing  miR-­‐‑17-­‐‑92  with  MCC  peptide  as  described  
above  and  measured  AICD  via  Annexin  V/7AAD  staining.  We  noted  that  miR-­‐‑17-­‐‑92  
overexpression  reduced  the  proportion  of  Annexin  V+  CD4+  T  cells  compared  to  cells  
expressing  the  mock  vector  (Figure  3A).  Reciprocally,  peripheral  CD4+  T  cells  from  the  
miR-­‐‑17-­‐‑92f/f  CD4-­‐‑Cre+  and  miR-­‐‑17-­‐‑92f/+  CD4-­‐‑Cre+  mice  showed  reduced  survival  after  
anti-­‐‑CD3  /CD28  stimulation  (Figure  3B).    
    
51  
To  assess  which  miRNAs  were  functionally  responsible  for  the  cluster’s  apparent  
protective  effect,  AICD  was  measured  for  CD4+  T  cells  retrovirally  transduced  with  
individual  miRNAs.  miR-­‐‑19b  was  responsible  for  enhancing  CD4+  T  cell  survival  
following  stimulation  and  miR-­‐‑17  was  also  observed  to  rescue  miR-­‐‑17-­‐‑92  deficient  CD4+  
T  cells  from  intense  AICD.  miR-­‐‑18a  exhibited  antagonizing  behavior,  driving  massive  
apoptosis  of  CD4+  T  cells  (Figure  3C).    
3.2.3 miR-19b promotes IFN-γ production 
The  diversity  of  pathogens  demands  discrete  cytokine  combinations  from  T  
helper  cells,  and  so  an  effective  adaptive  immune  response  requires  appropriate  CD4+  T  
cell  functional  differentiation.  To  test  whether  miR-­‐‑17-­‐‑92  is  involved  in  this  process,  we  
cultured  naïve  CD4+  T  cells  from  miR-­‐‑17-­‐‑92  deficient  mice  under  Th1  conditions  in  vitro.  
While  around  half  of  the  wild  type  CD4+  T  cells  were  IFN-­‐‑γ  +,  only  10%  of  miR-­‐‑17-­‐‑92-­‐‑
deficient  CD4+  T  cells  produced  IFN-­‐‑γ,  which  they  also  produced  at  much  lower  levels  
(Figure  4A).  In  line  with  the  above  observations,  while  the  expression  levels  of  gata3  and  
il4  at  Th2  condition  were  largely  unaltered,  miR-­‐‑17-­‐‑92-­‐‑deficient  Th1  cells  exhibited  
significantly  reduced  transcription  levels  of  ifng  and  the  key  Th1  lineage  specific  factor  
tbx21  (Figure  4B).  As  before,  we  dissected  the  individual  contributions  of  the  miRNAs  in  
supporting  IFN-­‐‑γ  production.  Only  miR-­‐‑19b  was  able  to  rescue  the  capacity  of  IFN-­‐‑γ  
production  in  miR-­‐‑17-­‐‑92  deficient  Th1  cells  (Figure  4C).  Collectively,  these  results  
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demonstrated  an  indispensible  role  for  miR-­‐‑19b  in  promoting  effector  T  cells’  IFN-­‐‑γ  
production.    
3.2.4 miR-17 and miR-19b promote the in vivo Th1 response during 
delayed type hypersensitivity (DTH) 
To  investigate  whether  miR-­‐‑17-­‐‑92  facilitates  Th1  responses  in  vivo,  we  assessed  
the  ability  of  miR-­‐‑17-­‐‑92  deficient  mice  to  mount  DTH  responses.  WT  and  miR-­‐‑17-­‐‑92f/f  
CD4-­‐‑Cre+  mice  were  immunized  with  keyhole  limpet  hemocyanin  (KLH)  emulsified  in  
complete  Freund’s  adjuvant  (CFA),  and  then  re-­‐‑challenged  in  one  footpad  with  KLH  
and  with  PBS  in  the  contralateral  footpad.  In  agreement  with  a  critical  role  for  miR-­‐‑17-­‐‑92  
in  promoting  Th1  mediated  effector  function,  miR-­‐‑17-­‐‑92  deficient  mice  have  
significantly  reduced  footpad  swelling  compared  to  WT  mice  (Figure  5A).  To  determine  
the  function  of  individual  miRNAs  in  vivo,  5C.C7  T  cells  were  transduced  with  
retrovirus  encoding  miR-­‐‑17  or  miR-­‐‑19b  and  then  adoptively  transferred  into  B10A  
recipients.  These  mice  were  then  immunized  with  MCC  peptide  in  CFA,  and  DTH  was  
assessed  following  footpad  re-­‐‑challenge.  With  transferred  T  cells  expressing  miR-­‐‑17  and  
miR-­‐‑19b,  we  observed  intensified  footpad  swelling,  augmented  numbers  of  lymphocytes  
in  the  draining  lymph  node  (dLN),  as  well  as  enhanced  infiltration  in  the  footpad  
(Figure  5B,  5C,  and  5E).    In  addition,  consistent  with  its  IFN-­‐‑γ-­‐‑promoting  function  in  
vitro,  miR-­‐‑19b  substantially  enhanced  T  cells’  capacity  for  IFN-­‐‑γ  production  during  the  
DTH  response  when  examined  ex  vivo  (Figure  5D).  These  data  supported  a  general  role  
for  miR-­‐‑17  and  miR-­‐‑19b  in  facilitating  Th1  mediated  inflammatory  responses  in  vivo.      
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3.2.5 miR-17 and miR-19b inhibit iTreg differentiation 
We  further  examined  the  role  of  the  miR-­‐‑17-­‐‑92  cluster  in  the  development  and  
homeostasis  of  Treg  cells.  We  observed  no  reduction  in  the  percentage  of  natural  Treg  
(nTreg)  cells  in  the  thymus,  spleen,  or  lymph  nodes  in  miR-­‐‑17-­‐‑92f/f  Lck-­‐‑Cre+  mice  (Figure  
6A).  Foxp3+  inducible  Treg  (iTreg)  cells  are  generated  through  the  conversion  of  
CD4+CD25-­‐‑  conventional  T  cells  in  the  periphery.  We  used  an  in  vitro  differentiation  
assay103  to  examine  the  role  of  miR-­‐‑17-­‐‑92.  Overexpression  of  miR-­‐‑17-­‐‑92  significantly  
impaired  the  induction  of  Foxp3+CD25+  cells  (Figure  6B),  while  ablation  of  the  miR-­‐‑17-­‐‑92  
cluster  in  CD4+  conventional  T  cells  dramatically  enhanced  Foxp3  induction  for  various  
dosages  of  TGF-­‐‑β  treatment  in  this  in  vitro  differentiation  assay  (Figure  6C&D).  When  
the  six  miRNAs  were  expressed  individually,  miR-­‐‑17  and  19b  again  emerged  as  the  
functional  representatives,  inhibiting  iTreg  differentiation  (Figure  6E).    
3.2.6 miR-17-92 is essential for effective CD4+ T cell anti-tumor 
responses 
As  presented  above,  the  phenotypic  and  mechanistic  studies  of  miR-­‐‑17-­‐‑92  
indicate  that  this  cluster  is  a  multifaceted  promoter  of  Th1  effector  responses.  As  Th1-­‐‑
guided  effector  T  cell  function  has  been  well  established  as  a  critical  defense  mechanism  
for  immune  surveillance  and  rejection  of  tumors,  we  therefore  hypothesized  that  miR-­‐‑
17-­‐‑92  might  be  an  important  component  in  the  adaptive  immune  system’s  attempt  to  
control  tumor  progression.  We  subcutaneously  transplanted  2×105  B16/F10  melanoma  
tumor  cells  into  miR17-­‐‑92f/f  CD4-­‐‑Cre+  mice  and  monitored  tumor  growth.  In  mice  
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homozygous  or  heterozygous  for  miR-­‐‑17-­‐‑92  deletion,  the  B16  tumors  formed  faster  and  
had  significantly  accelerated  growth  in  comparison  to  the  tumors  in  wild  type  mice.  At  
day  16,  tumor  volumes  at  the  site  of  injection  were  2-­‐‑3  folds  greater  in  mice  lacking  miR-­‐‑
17-­‐‑92.  The  loss  of  a  single  copy  of  this  gene  is  sufficient  to  impair  tumor  protection  
(Figure  7A).  To  detail  the  functional  failure  of  T  cells  in  the  anti-­‐‑tumor  response,  
lymphocytes  from  tumor  dLNs  were  stimulated  with  plate-­‐‑bound  anti-­‐‑CD3/CD28  
antibodies  for  24  hours  to  measure  the  secretion  of  the  inflammatory  cytokines.  We  
found  that  both  Th1  and  Th2  cytokines  were  dramatically  reduced  in  the  lymphocyte  
culture  from  the  dLNs  of  miR-­‐‑17-­‐‑92  deficient  mice  (Figure  7B).  Although  there  was  a  
declining  trend  of  IL-­‐‑17  production  in  the  same  assay,  the  change  was  not  statistically  
significant  (Figure  7B).  To  confirm  the  critical  role  of  CD4+  T  cells  in  the  anti-­‐‑B16  tumor  
responses,  we  collected  CD4+  T  cells  from  WT  or  KO  miR-­‐‑17-­‐‑92  mice  and  CD8+  T  cells  
from  the  tumor  antigen  specific  Pmel  TCR  transgenic  mice,  and  co-­‐‑transferred  them  into  
Rag2-­‐‑/-­‐‑  mice  that  were  then  challenged  with  B16/F10  cells.  T  cell  responses  in  the  dLNs  
were  analyzed  18  days  after  tumor  transplantation.  We  found  that  deficiency  of  miR-­‐‑17-­‐‑
92  in  CD4+  T  cells  alone  significantly  impairs  the  Th1  response  to  B16  tumor  cells,  
including  a  decrease  in  cell  number  (Figure  7C)  and  IFN-­‐‑γ  production  of  CD4+  T  cells  
(Figure  7D)  in  the  dLN.  In  addition,  the  ability  of  miR-­‐‑17-­‐‑92  deficient  CD4+  T  cells  to  
help  the  CD8+  T  cells  was  also  inhibited  (Figure  7E).  
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To  further  demonstrate  that  this  deficiency  of  immune  protection  is  due  to  the  
weakness  of  antigen-­‐‑specific  T  cell  responses  against  the  tumor,  we  inoculated  mice  
subcutaneously  with  3×105  B16/F0/OVA  cells  that  ectopically  secrete  OVA  protein.  
Sixteen  days  after  transplantation,  T  cells  were  enriched  from  the  dLNs,  labeled  with  
CFSE,  and  restimulated  with  OVAII  peptide  (a.a.  323-­‐‑339)  loaded  APCs  for  48  hours.  
Upon  antigen-­‐‑specific  recall,  ova-­‐‑specific  CD4+  T  cells  exhibited  a  significant  defect  in  
proliferation  and  IFN-­‐‑γ  secretion  and  showed  enhanced  apoptosis,  all  of  which  
correspond  to  the  function  of  miR-­‐‑17-­‐‑92  as  revealed  in  vitro  (Figure  7F).  Collectively,  
these  results  suggest  that  miR-­‐‑17-­‐‑92  profoundly  regulates  T  cells’  anti-­‐‑tumor  responses  
through  strict  enforcement  on  their  Th1-­‐‑lineage  specific  functions.      
3.2.7 miR-17 facilitates effector T cell responses by targeting TGFβRII 
and CREB1 
As  presented  above,  miR-­‐‑17  played  a  key  role  in  inhibiting  AICD  of  CD4+  T  cells  
and  in  blocking  iTreg  differentiation.  To  explore  the  molecular  mechanism  of  miR-­‐‑17  
regulation,  microarray  analysis  was  performed  to  characterize  the  gene  expression  
patterns  among  wild  type  T  cells,  T  cells  with  miR-­‐‑17-­‐‑92  deletion,  and  T  cells  from  the  
knockout  background  with  miR-­‐‑17  added  back  by  retrovirus  transduction.  From  the  
analysis,  122  genes  were  up-­‐‑regulated  in  the  miR-­‐‑17-­‐‑92  deficient  CD4+  T  cells  and  
reciprocally  repressed  when  miR-­‐‑17  was  reintroduced.  We  next  searched  these  mRNAs  
for  sequence  complementary  to  miR-­‐‑17’s  seed  region.  Twenty-­‐‑two  genes  were  selected  
as  candidates  that  might  be  directly  controlled  by  miR-­‐‑17.  Based  on  the  phenotypic  
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impact  of  miR-­‐‑17  in  T  cells,  two  genes  in  this  group  attracted  our  attention:  transforming  
growth  factor,  beta  receptor  II  (tgfbr2)  and  cAMP  responsive  element  binding  protein  1  
(creb1),  both  of  which  have  been  previously  implicated  in  the  Treg  differentiation  
pathway72,104.  In  addition,  C/EBP-­‐‑β,  a  CREB1  transcriptional  target,  has  been  reported  to  
promote  apoptosis  of  macrophages  following  IFN-­‐‑γ  stimulation105.  Through  
bioinformatics  approaches,  one  conserved  miR-­‐‑17  binding  site  was  identified  in  the  
3’UTR  of  tgfbr2  and  two  sites  were  found  for  creb1  (Figure  8A).    We  verified  that  miR-­‐‑17  
can  directly  bind  to  the  3’UTR  of  tgfbr2  (Position  2388)  and  creb1  (position  6984)  mRNAs  
(Figure  8B&C)  using  luciferase  reporter  assays.  In  CD4+  T  cells  lacking  mir-­‐‑17-­‐‑92,  the  
expression  levels  of  TGFbRII  and  CREB1  were  significantly  elevated  at  both  the  mRNA  
and  protein  level,  and  these  elevations  were  completely  abolished  when  the  mir-­‐‑17  gene  
was  re-­‐‑introduced  (Figure  8D&E).  
To  validate  its  functional  relevance,  we  examined  whether  the  moderate  
reduction  of  TGFβRII  by  miR-­‐‑17  was  sufficient  to  alter  TGF-­‐‑β  signaling.  TGF-­‐‑b  binds  to  
TGFβRII,  which  initiates  the  signaling  cascade  by  recruiting  and  phosphorylating  the  
type  I  receptor.  During  Treg  differentiation,  this  receptor  activation  leads  to  Smad3  
Ser423/425  phosphorylation  and  translocation  to  its  binding  sites  within  the  foxp3  gene  
enhancer  region39,104.  We  found  that  Smad3  was  hyperphosphorylated  upon  TGFβ  
treatment  in  miR-­‐‑17-­‐‑92  deficient  T  cells,  and  this  was  diminished  by  miR-­‐‑17  ectopic  
expression  (Figure  8F).    
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The  transcription  factor  CREB1  was  shown  to  bind  to  the  CNS2  region  of  the  
foxp3  gene  in  a  DNA-­‐‑methylation-­‐‑sensitive  manner72.  To  demonstrate  the  functional  
importance  of  targeted  CREB1  suppression  by  miR-­‐‑17,  we  restored  CREB1  expression  in  
the  presence  of  miR-­‐‑17  expression  using  a  bicistronic  expression  vector  (Figure  8G).    In  
CD4+  T  cells,  the  epichromosomal  expression  of  CREB1  reversed  the  phenotype  of  miR-­‐‑
17  expression:  there  was  loss  of  protection  from  AICD  (Figure  8H)  and  rescue  of  iTreg  
differentiation  at  both  the  population  and  single  cell  levels  (Figure  8I).  Collectively,  we  
concluded  that  the  moderate  inhibition  of  TGFβRII  and  CREB1  by  miR-­‐‑17  results  in  the  
diminution  of  iTreg  lineage  commitment;  and  that  the  dampened  CREB1  expression  by  
miR-­‐‑17  is  sufficient  to  aid  T  cell  survival  against  excessive  contraction.  
3.2.8 miR-19b directly targets Pten to promote PI3K-Akt activation 
and to regulate CD4+ T cell function  
Previous  reports  have  identified  Pten,  a  negative  regulator  of  PI3  kinase  
signaling,  as  a  target  of  the  miR-­‐‑17-­‐‑92  cluster101.  The  ability  of  Pten  to  suppress  T  cell  
proliferation  and  survival  through  its  antagonizing  effect  on  the  PI3K-­‐‑Akt  pathway  is  
well  documented106.  In  addition,  the  PI3K-­‐‑Akt  pathway  has  also  been  shown  to  be  
critical  for  facilitating  Th1  differentiation  and  supporting  IFN-­‐‑γ  production107,108,  and  the  
PI3K-­‐‑AKT-­‐‑mTOR  axis  was  shown  to  inhibit  iTreg  differentiation14,109.  Therefore,  all  of  
observed  phenotypic  aspects  of  miR-­‐‑19b  in  effector  T  cells  can  be  potentially  explained  
by  the  diminution  of  Pten  expression.  Computational  prediction  revealed,  the  3’UTR  of  
pten  mRNA  contains  two  miR-­‐‑19b  and  two  miR-­‐‑17  binding  sites  highly  conserved  
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between  mouse  and  human  (Figure  9A).  To  assess  miRNA  binding  to  the  3’UTR,  we  
constructed  luciferase  reporters  with  the  full  length  pten  3’UTR.  The  reporter  was  tested  
in  NIH3T3  cell  lines  stably  overexpressing  miR-­‐‑19b,  miR-­‐‑19a,  or  miR-­‐‑17.  We  observed  
significant  suppression  of  luciferase  production  by  miR-­‐‑19b,  but  not  miR-­‐‑17  or  miR-­‐‑19a  
(Figure  9B).  Additionally,  site-­‐‑directed  mutagenesis  of  the  miR-­‐‑19  binding  motifs  within  
pten’s  3’  UTR110  completely  abolished  this  suppression  (Figure  9B),  suggesting  that  miR-­‐‑
19b  directly  binds  to  these  two  sites.  Consistently,  overexpression  of  miR-­‐‑19b  in  T  cells  
down-­‐‑regulated  endogenous  Pten  mRNA  and  protein  levels  (Figure  9C).  Reciprocally,  
mRNA  and  protein  levels  of  Pten  are  significantly  increased  in  CD4+  T  cells  lacking  the  
miR-­‐‑17-­‐‑92  gene  (Figure  9D).  
To  directly  assess  the  biochemical  consequence  of  miR-­‐‑19b  targeting,  we  
performed  live  cell  imaging  to  visualize  its  perturbation  on  PI3K  signaling  initiated  by  
TCR  antigen  recognition.  The  PH  domain  of  Akt  kinase  was  fused  with  GFP  as  a  probe  
to  monitor  the  local  production  of  PIP3  through  PI3K  activation.  miR-­‐‑19b  and  this  PH-­‐‑
GFP  probe  were  simultaneously  expressed  in  5C.C7  T  cells,  which  were  then  challenged  
with  MCC  peptide  loaded  on  APCs.  Within  10  seconds,  agonist  engagement  of  the  TCR  
led  to  PI3K  activation,  which  was  sustained  for  hours  inside  the  gradually  assembled  
immunological  synapse111.  When  we  expressed  miR-­‐‑19b  in  5C.C7  T  cells  and  followed  
the  dynamics  of  PH-­‐‑GFP  probe  recruitment  upon  stimulation,  we  did  not  detect  any  
enhancement  of  PI3K  activation  during  the  initiation  stage  (i.e.  within  10  mins  of  T:APC  
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engagement,  Figure  9E&F);  however,  when  measured  at  1  hour  post  T:APC  
engagement,  there  was  a  significant  enhancement  of  sustained  PI3K  activity  (Figure  
9E&G).  Taken  together,  these  single  cell  assays  strongly  suggest  that  the  Pten-­‐‑mediated  




Figure  1:  Dynamic  regulation  of  miR-­‐‑17-­‐‑92  expression  upon  antigen  challenge.  
(A)  Members  of  the  miR-­‐‑17-­‐‑92  cluster.  (B)  CD4+  T  cells  from  the  5C.C7  TCR  
transgenic  mice  were  stimulated  with  plate  bound  anti-­‐‑CD3/CD28  for  7  days.  
Expression  levels  of  individual  miRNAs  from  the  miR-­‐‑17-­‐‑92  cluster  at  indicated  time  




Figure  2:  miR-­‐‑19b  promotes  proliferation  of  CD4+  T  cells  upon  antigen  
challenge.  
(A  &  C)  Assessment  of  miR-­‐‑17-­‐‑92  relative  expression  in  CD4+  T  cells  by  
quantitative  real-­‐‑time  PCR  (qPCR).  Data  were  normalized  to  a  reference  small  RNA  U6.  
Bar  graph  shows  mean  ±  SEM  from  3  independent  experiments.  (A)  LN  T  cells  from  
5C.C7  TCR  transgenic  mice  were  primed  by  syngeneic  APCs  loaded  with  agonist  
peptide  MCC  (10  µμM)  and  transduced  with  retrovirus  encoding  GFP  alone  (mock)  or  
mir-­‐‑17-­‐‑92  gene  with  GFP.  Three  days  later,  CD4+GFP+  T  cells  were  FACS  sorted,  and  the  
expression  of  miRNA  was  analyzed  by  qPCR.  Data  was  normalized  to  the  mock  group.  
(B)  mir-­‐‑17-­‐‑92  genes  were  introduced  into  5C.C7  T  cells  as  described  in  (A).  Cells  were  
selected  by  puromycin  for  48  hours,  and  restimulated  with  MCC-­‐‑loaded  CH27  APCs  (10  
µμM)  for  24  hours.  EdU  was  supplied  into  the  culture  media  3  hours  prior  to  cell  fixation.  
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Percentage  of  CD4+GFP+  T  cells  in  S  phase  was  measured  by  by  the  Click-­‐‑iT  EdU  flow  
cytometry  assay.  Top:  representative  FACS  plot;  Bottom:  statistical  analysis  of  5  
independent  experiments.  (C)  Expression  of  miRNAs  in  CD4+  T  cells  from  LNs  and  
spleens  of  miR-­‐‑17-­‐‑92f/fCD4-­‐‑Cre-­‐‑  (WT),  miR-­‐‑17-­‐‑92f/+CD4-­‐‑Cre+(f/+),  and  miR-­‐‑17-­‐‑92f/fCD4-­‐‑
Cre+  (KO)  littermates.  Data  was  normalized  to  WT.  (D)  CD4+CD25-­‐‑  T  cells  from  LNs  and  
spleens  of  WT,  f/+  and  KO  littermates  were  labeled  for  10  min  at  37°C  with  
carboxyfluorescein  diacetate  succinimidyl  diester  (CFSE)  at  a  ratio  of  3x106  cells/4  mM  
chemical,  followed  by  washes  with  complete  culture  medium,  then  activated  by  1  µμg/ml  
plate-­‐‑bound  anti-­‐‑CD3  and  anti-­‐‑D28  antibodies  for  72hrs.    Left:  representative  FACS  plot  
showing  CFSE  dilution.  Tinted  peaks  represent  CFSE  stained  T  cells  without  
stimulation;  Right:  statistical  analysis  of  3  independent  experiments.  (E)  CD4+CD25-­‐‑  T  
cells  from  WT  or  KO  mice  were  primed  and  transduced  with  indicated  retroviruses.  
After  2  days  of  puromycin  selection,  cells  were  restimulated  with  anti-­‐‑CD3/CD28  for  24  
hours,  and  T  cells  in  S  phase  were  determined  by  staining  of  pulsed  EdU.  Bar  graphs  
summarize  means  ±  SEM  from  4  independent  experiments  and  data  were  normalized  to  





Figure  3:  miR-­‐‑17  and  miR-­‐‑19b  inhibit  activation-­‐‑induced  cell  death  of  CD4+  T  
cells  upon  antigen  challenge.  
(A)  Lymph  node  T  cells  from  5C.C7  TCR  transgenic  mice  were  primed  and  
transduced  with  retrovirus  encoding  GFP  or  miR-­‐‑17-­‐‑92  as  described  in  Figure  2A.  Three  
days  later,  viable  cells  were  enriched  by  density  gradient  centrifugation  and  then  
restimulated  with  CH27  loaded  with  MCC  (10  µμM)  for  24  hours,  and  the  status  of  AICD  
was  assessed  by  Annexin  V  and  7AAD  staining.  The  bar  graph  summarizes  the  means  ±  
SEM  from  4  independent  experiments.  (B)  CD4+CD25-­‐‑  T  cells  from  LNs  and  spleens  of  
WT,  f/+,  and  KO  littermates  were  stimulated  with  anti-­‐‑CD3/CD28  antibodies  for  72  
hours,  and  the  percentages  of  CD4+  T  cells  undergoing  apoptosis  were  assessed  by  
Annexin  V  and  7AAD  staining.  The  bar  graph  summarizes  means  ±  SEM  from  3  
independent  experiments.  (C)  CD4+CD25-­‐‑  T  cells  from  LN  and  spleen  of  KO  mice  were  
primed  and  transduced  with  retrovirus  encoding  individual  miRNAs  of  miR-­‐‑17-­‐‑92  as  
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described  in  Figure  2E.  Three  days  post  transduction,  viable  CD4+  T  cells  were  enriched  
and  restimulated  with  anti-­‐‑CD3/CD28  for  24  hours.  The  profiles  of  restimulation  
induced  apoptosis  were  measured  by  Annexin-­‐‑V  staining.    Bar  graphs  summarize  the  
means  ±  SEM  from  3-­‐‑5  independent  experiments.  The  statistical  significance  was  





Figure  4:  miR-­‐‑19b  is  indispensible  for  IFNγ   production  from  differentiated  
Th1  cells.  
(A  &  B)  CD4+CD25-­‐‑  T  cells  were  sorted  from  LNs  and  spleens  of  WT,  f/+,  and  KO  
littermates,  activated  by  anti-­‐‑CD3/CD28  antibodies  under  Th1  or  Th2  skewing  
conditions  for  4  days.  (A)  The  percentage  of  viable  cells  producing  IFN-­‐‑γ  and  the  mean  
florescence  intensity  (MFI)  of  IFN-­‐‑γ  under  Th1  condition  were  determined  by  
intracellular  staining  following  4  hours  of  stimulation  with  0.9  nM  PMA  and  0.5  µμg/ml  
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ionomycin  in  the  presence  of  5  µμg/ml  brefeldin  A  and  2  µμM  monensin.  The  bar  graph  
summarizes  the  means  ±  SEM  from  3  independent  experiments.  (B)  The  mRNA  levels  of  
T-­‐‑bet  and  IFN-­‐‑γ  or  Gata3  and  IL-­‐‑4  from  CD4+  T  cells  differentiated  under  the  Th1  or  Th2  
skewing  conditions  were  quantified  by  qPCR.  Data  were  normalized  to  a  reference  gene  
SDHA  and  shown  as  relative  to  WT.  The  bar  graph  shows  means  ±  SEM  from  3  
independent  experiments.  (C)  As  described  in  Figure  2E,  CD4+CD25-­‐‑  conventional  T  
cells  of  KO  mice  were  primed  and  transduced  with  retrovirus  encoding  individual  
miRNAs  within  the  miR-­‐‑17-­‐‑92  cluster,  and  then  cultured  under  the  Th1  skewing  
condition  for  4  days.  The  percentages  of  IFN-­‐‑γ  or  IL-­‐‑4  producing  cells  and  the  MFI  of  
IFN-­‐‑γ  signal  were  measured  by  intracellular  cytokine  staining.  Left:  representative  
FACS  plot;  Right:  means  ±  SEM  from  3  independent  experiments.  Statistic  analysis  was  




Figure  5:  miR-­‐‑19b  and  miR-­‐‑17  enhance  DTH  responses  in  vivo.  
(A)  WT  and  KO  mice  were  immunized  s.c.  with  100µμg  KLH  in  CFA  (Sigma)  and  
8  days  later  injected  with  50µμg  of  KLH  in  one  footpad  and  PBS  in  the  contralateral  
footpad.  Increase  in  footpad  thickness  was  measured  for  both  groups  at  48  hours  after  
secondary  challenge  (n=4).  (B-­‐‑E)  WT  B.10A  mice  were  transferred  through  tail  vein  with  
0.5×106  CD4+  T  cells  from  5C.C7  Rag2-­‐‑/-­‐‑  mice  infected  with  GFP,  miR-­‐‑17  or  miR-­‐‑19b  
expressing  retrovirus  and  immunized  s.c.  with  20µμg  of  MCC  peptide  in  CFA.  Five  days  
post  immunization,  mice  were  injected  with  20µμg  MCC  and  PBS  in  each  lateral  footpad.  
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Seventy-­‐‑two  hours  later,  the  swelling  of  footpads  (in  B)  and  the  number  of  total  
lymphocytes  from    the  popliteal  LN  (in  C)  were  measured  (n  ≥  5).  The  percentage  of  
IFN-­‐‑γ  producing  cells  within  the  GFP+  CD4+  population  in  the  DLN  was  assayed  (in  D)  
by  intracellular  staining  (n  ≥  4).  Representative  images  of  footpad  tissues  with  
hematoxylin  and  eosin  (H&E)  staining  were  shown  in  E.  *,  P<0.05;  **,  P<0.01;  ***,  




Figure  6:  miR-­‐‑19b  and  miR-­‐‑17  suppress  iTreg  differentiation.  
(A)  Percentage  of  nTregs  in  the  thymus,  spleen,  and  lymph  nodes  of  miR-­‐‑17-­‐‑
92f/fLck-­‐‑Cre-­‐‑,  miR-­‐‑17-­‐‑92f/+Lck-­‐‑Cre+,  and  miR-­‐‑17-­‐‑92f/fLck-­‐‑Cre+  mice.  (B)  5C.C7  T  cells  were  
primed,  transduced  with  retrovirus  encoding  GFP  alone  or  miR-­‐‑17-­‐‑92/GFP,  and  cultured  
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under  iTreg  differentiation  conditions  for  6  days.  The  percentage  of  Treg  cells  within  the  
CD4+GFP+  population  was  measured  by  Foxp3  staining.  The  bar  graph  summarizes  
means  ±  SEM  from  4  independent  experiments.  (C-­‐‑D)  CD4+CD25-­‐‑  T  cells  sorted  from  
LNs  and  spleens  of  WT,  f/+,  and  KO  littermates  were  cultured  under  iTreg  
differentiation  conditions  for  6  days  with  indicated  TGF-­‐‑β  doses,  and  the  percentage  of  
CD25+Foxp3+  Treg  cells  was  assessed.  (C)  Representative  FACS  plots.  (D)  Statistical  
analysis  of  4  independent  experiments  at  the  indicated  TGF-­‐‑β  dose.  (E)  5C.C7  T  cells  
were  transduced  with  individual  miRNAs  from  the  miR-­‐‑17  or  miR-­‐‑19  families,  and  
cultured  under  iTreg  differentiation  conditions  for  6  days.  The  percentage  of  
CD25+Foxp3+  cells  was  measured  by  flow  cytometry.  Bar  graphs  summarize  the  means  ±  








(A)  WT  (n=5),  f/+  (n=8)  and  KO  (n=7)  littermates  were  injected  s.c.  with  2  x  105  
B16/F10  melanoma  cells.  The  tumor  volume  was  measured  each  day  from  7  days  post  
injection  up  to  16  days  and  plotted  against  time.  Left  panel:  the  representative  tumor  
growth  curve;  right  panel:  compiled  data  from  three  independent  experiments.  
Individual  dot  represents  the  relative  tumor  volume  normalized  to  that  of  the  WT  at  12  
days  after  melanoma  cells  injection.  (B)  Lymphocytes  from  the  draining  lymph  nodes  of  
tumor  carrying  mice  were  isolated  16  days  post  B16/F10  melanoma  inoculation  and  
stimulated  with  1  µμg/ml  anti-­‐‑CD3/CD28  antibodies  for  24  hours.  Supernatants  from  the  
cultures  were  assayed  for  the  concentration  of  indicated  Th1,  Th2  and  Th17  cytokines  by  
the  cytokine  beads  array.  Each  dot  represents  data  obtained  from  an  individual  mouse  
(n=3).  (C-­‐‑E)  Sorted  CD4+CD25-­‐‑  T  cells  from  WT  or  KO  mice  were  mixed  with  Pmel  TCR  
transgenic  CD8+  T  cells  and  then  transferred  into  RAG2  deficient  mice  (CD4+CD25-­‐‑:  
1X106,  CD8+:  0.5X106/mouse)  through  i.v.  After  24  hours,  the  mice  were  challenged  with  
B16/F10  cells  (0.5X106/mouse)  through  s.c.  At  day18,  the  cells  from  DLN  were  analyzed.  
The  numbers  of  CD4+  T  (C),  IFN-­‐‑γ  +CD4+  (D)  and  IFN-­‐‑γ+CD8+  (E)  cells  in  DLN  were  
shown  (n=4).  (F)  WT,  f/+,  and  KO  littermates  were  injected  with  3×105  OVA-­‐‑secreting  
B16/F0  cells.  Sixteen  days  after  injection,  T  cells  were  enriched  from  the  DLN,  labeled  
with  CFSE,  and  stimulated  with  LB27.4  APCs  loaded  with  10  µμM  OVA  peptide  (323-­‐‑339)  
for  48  hours.  Antigen-­‐‑specific  responses  (proliferation,  AICD,  IFN-­‐‑γ  production)  were  




Figure  8:  miR-­‐‑17  modulates  CD4+  T  cells’  effector  responses  by  targeting  
TGFbRII  and  CREB1.  
(A)  Schematic  representation  of  the  putative  miR-­‐‑17-­‐‑binding  sites  in  the  3’UTR  of  
tgfbr2  and  creb1.    (B&C)  A  portion  of  the  3’UTR  of  tgfbr2  or  creb1  was  cloned  downstream  
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of  a  luciferase  reporter  and  transfected  into  an  NIH3T3  cell  line  stably  expressing  miR-­‐‑
17,  miR-­‐‑20a  or  mock  control.  The  luciferase  activity  was  measured  72  hours  after  
transfection.  Bar  graphs  show  the  means  ±  SD  of  3  (B)  or  6  (C)  independent  experiments.  
(D&E)  CD4+CD25-­‐‑  T  cells  from  WT  or  KO  mice  were  transduced  with  indicated  
retrovirus,  and  CD4+GFP+  T  cells  were  FACS  sorted  and  total  RNA  and  protein  were  
extracted  for  qPCR  (D)  and  western  blot  (E).  The  bar  graph  shows  means  ±  SEM  from  3  
independent  experiments.  (F)  T  cells  were  transduced  with  indicated  virus  and  cultured  
under  iTreg  differentiation  conditions  for  5  days.  CD4+GFP+  T  cells  were  then  sorted,  
lysed,  and  analyzed  for  Smad3  Ser423/425  phosphorylation  by  western  blot.  (G-­‐‑I)  5C.C7  
T  cells  were  primed  and  transduced  with  retrovirus  containing  both  the  CREB1-­‐‑IRES-­‐‑
GFP  expression  cassette  and  the  indicated  miR-­‐‑17  expression  cassette,  or  miR-­‐‑17  alone  
with  GFP  marker,  or  GFP  only.  (G)  Assessment  of  CREB1  expression  in  5C.C7  T  cells  by  
q-­‐‑PCR.  The  graph  shows  means  ±  SEM  from  3  independent  experiments.  (H)  Death  
profile  of  CD4+GFP+  T  cells  following  restimulation  with  anti-­‐‑CD3/CD28  antibodies.  Left:  
representative  FACS  plot;  Right:  Bar  graphs  showing  means  ±  SEM  from  3  independent  
experiments.  (I)  5C.C7  T  cells  were  transduced  as  indicated  and  cultured  under  the  iTreg  
differentiation  condition  for  5  days.  The  percentage  of  CD25+Foxp3+  cells  inside  of  CD4+  
T  cell  populations  and  the  MFI  of  the  intracellular  Foxp3  staining  were  measured.  The  
numbers  on  the  left  corner  show  the  means  ±  SEM  of  the  percentage  of  iTreg  cells  from  




Figure  9:  Pten  is  the  primary  target  of  miR-­‐‑19b  in  regulating  CD4+  T  cells’  
effector  functions.  
(A)  Schematic  illustration  of  the  predicted  targeting  sites  for  miR-­‐‑19b  and  miR-­‐‑17  
within  the  3’UTR  of  pten  mRNA.    (B)  The  full  length  3’UTR  of  pten  (Pten-­‐‑WT)  or  3’UTR  
with  mutations  at  the  two  miR-­‐‑19b  target  sites  (Pten-­‐‑MU)  were  cloned  downstream  of  a  
luciferase  reporter  and  transfected  into  NIH3T3  cell  lines  stably  expressing  the  indicated  
miRNAs.  The  luciferase  activity  was  measured  72  hours  post  transfection.  Bar  graphs  
show  the  mean  ±  SD  of  3  independent  experiments.  (C)  5C.C7  T  cells  transduced  with  
mock,  mir-­‐‑17-­‐‑92,  or  mir-­‐‑19b  were  sorted  by  FACS,  and  total  RNA  and  protein  were  
extracted  for  qPCR  and  western  blot.  (D)  Relative  expression  of  Pten  mRNA  in  
CD4+CD25-­‐‑  T  cells  from  LNs  and  spleens  of  WT,  f/+  and  KO  mice  was  measured  by  
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qPCR.  T  cells  activated  with  plate-­‐‑bound  anti-­‐‑CD3/CD28  antibodies  for  72  hours  were  
lysed  for  protein  quantification.  qPCR  data  were  normalized  to  SDHA  and  shown  as  
relative  to  mock  or  WT,  and  the  graph  shows  means  ±  SEM  for  3  independent  
experiments.  (E)  miR-­‐‑19b  mediated  regulation  on  PI3K  signaling  upon  antigen  
engagement  was  visualized  by  fluorescence  video  microscopy.  As  described  
previously111,  the  PH  domain  of  Akt  kinase  was  fused  with  GFP  as  an  imaging  probe  to  
monitor  the  production  of  PIP3  through  PI3K  activation.  miR-­‐‑19b  or  mock  vectors  were  
expressed  simultaneously  with  this  PH-­‐‑GFP  imaging  probe  in  5C.C7  T  cells,  which  were  
challenged  by  CH27  APCs  pre-­‐‑loaded  with  MCC  agonist  peptide.  Live  cell  imaging  was  
performed  to  monitor  the  initial  signaling  strength  and  the  duration  of  PI3K  activation.  
The  activity  of  PI3K  was  represented  by  measuring  the  ratio  of  the  average  probe  
fluorescent  intensity  in  the  synaptic  region  versus  the  average  intensity  in  the  rest  cell  
area.  Top  panels:  representative  montages  from  the  DIC  channel;  Bottom  panels:  
representative  montages  from  the  GFP  channel.    (F)  The  highest  level  of  probe  synaptic  
accumulation  within  the  first  10  minutes  of  T:APC  contact  was  used  as  the  mark  for  the  
maximal  activity  of  PI3K  activation  in  the  initiation  stage  (prior  to  the  formation  of  
mature  immunological  synapse)  of  TCR  signaling.  (G)  A  similar  measurement  was  





Figure  10:  Model  for  miR-­‐‑17-­‐‑92  in  regulating  CD4+  T  cell  response.  
Upon  TCR  activation,  the  abundance  of  miR-­‐‑17-­‐‑92  was  upregulated  to  promote  
CD4+  T  cell-­‐‑mediated  Th1  response.  Through  targeting  PTEN,  miR-­‐‑19b  promotes  CD4+  T  
cell  proliferation,  survival,  IFN-­‐‑γ  production,  and  inhibits  iTreg  differentiation.  miR-­‐‑17  
also  promote  T  cell  survival  and  inhibits  iTreg  differentiation  through  directly  inhibiting  
CREB1  and  TGFbR2.  On  the  other  hand,  through  a  still  unknown  mechanism,  miR-­‐‑18  





Our  studies  through  gain-­‐‑  and  loss-­‐‑of-­‐‑function  analysis  demonstrate  that  the  
miR-­‐‑17-­‐‑92  cluster  is  a  multicomponent  potentiator  that  governs  T  cells’  responses  to  
antigen  challenge  (Figure  10).  Specifically,  this  cluster  manages  the  efficacy  of  Th1  
responses  by  protecting  T  cells  from  AICD,  enhancing  T  cells’  proliferation,  facilitating  
IFN-­‐‑γ  production,  and  obstructing  iTreg  differentiation.  The  extensiveness  of  miR-­‐‑17-­‐‑
92’s  regulation  was  especially  evident  during  T  cell-­‐‑dependent  tumor  rejection,  since  
local  Th1-­‐‑guided  cytotoxicity  is  crucial  for  direct  tumor  elimination  and  indirect  
galvanization  of  macrophage  activation81,112.    Mice  with  a  T  cell-­‐‑specific  single  allele  
ablation  of  miR-­‐‑17-­‐‑92  were  extremely  vulnerable  to  B16  melanoma  transplantation,  and  
further  analysis  revealed  that  CD4+  T  cells  from  these  recipients’  draining  lymph  nodes  
were  defective  in  all  aforementioned  aspects  of  Th1  responses  upon  tumor  antigen  
challenge.    
The  miR-­‐‑17-­‐‑92  cluster  is  produced  from  a  single  transcript,  designated  
C13orf2596.  Taking  this  cluster  as  a  single  entity,  miR-­‐‑17-­‐‑92  provides  cohesive  guidance  
for  T  cells’  antigen  responses.  However,  our  data  indicate  that  the  individual  miRNAs  
within  the  cluster  are  quite  diversified  in  terms  of  their  functions.  Previously,  we  and  
others  independently  identified  miR-­‐‑19  as  the  key  components  of  this  cluster  in  
promoting  Myc-­‐‑induced  B  cell  lymphomas110,113.  In  T  cells,  miR-­‐‑19b  is  also  critical,  as  it  
comprehensively  drives  the  antigen  response  in  every  tested  aspect.  Furthermore,  the  
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regulation  provided  by  miR-­‐‑19b  is  greatly  facilitated  by  miR-­‐‑17  in  protecting  cells  from  
AICD  and  especially  in  suppressing  iTreg  differentiation.  Surprisingly,  we  noted  that  
miR-­‐‑18a  opposes  the  cluster’s  pro-­‐‑Th1  function,  primarily  through  elevation  of  AICD  
and  inhibition  of  proliferation.  Given  that  miR-­‐‑17-­‐‑92  has  been  well  recognized  as  an  
oncomiR,  we  suspect  that  miR-­‐‑18a  might  act  as  a  brake  on  the  pro-­‐‑proliferation  and  anti-­‐‑
apoptosis  functions  of  the  cluster,  which  is  a  common  phenomenon  for  proteinaceous  
oncogenes114-­‐‑116.    
The  miRNAs  comprising  the  miR-­‐‑17-­‐‑92  cluster  can  be  grouped  based  on  the  
similarity  of  their  seed  regions  (nucleotides  2-­‐‑8),  which  are  thought  to  be  especially  
critical  for  the  specificity  of  mRNA  targeting.  Our  current,  limited  knowledge  predicts  
that  a  majority  of  targets  should  be  shared  between  family  members.  However,  inside  
primary  CD4+  T  cells,  and  despite  the  very  high  degree  of  homology  within  the  miR-­‐‑17  
family,  miR-­‐‑20a  is  not  capable  of  performing  any  of  miR-­‐‑17’s  pro-­‐‑Th1  functions,  and  
miR-­‐‑18  clearly  exerts  an  antagonistic  effect.  Similar  distinction  was  also  observed  
between  miR-­‐‑19a  and  miR-­‐‑19b.  One  explanation  is  that  the  diversity  of  functionality  
might  simply  reflect  the  differences  in  their  expression  levels.  Expression  levels  between  
miR-­‐‑19a  and  miR-­‐‑19b  were  significantly  different  in  T  cells  (data  not  shown),  which  
therefore  prevents  us  from  drawing  any  solid  conclusions  about  the  functional  diversity  
inside  this  family.  Nevertheless,  our  data  does  suggest  a  potential  difference  in  the  
endogenous  processing  or  maintenance  of  these  two  miRNAs  in  effector  T  cells,  with  
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miR-­‐‑19a  being  disadvantaged.  On  the  other  hand,  inside  the  miR-­‐‑17  family,  the  
overexpression  level  and  the  absolute  copy  number  of  miR-­‐‑20a  was  equal  to  or  even  
higher  than  that  of  miR-­‐‑17  (data  not  shown).  Although  our  quantification  determined  
that  miR-­‐‑18a  is  expressed  at  a  lower  level,  the  antagonist  effect  is  so  evident  that  
distinctions  of  mRNA  targeting  become  a  more  conceivable  explanation.  In  mature  
miRNAs,  only  few  nucleotides  differ  between  miR-­‐‑17  and  miR-­‐‑20a/-­‐‑18a;  and  these  
differences  reside  outside  the  seed  region.  We  suspect  that  these  subtle  differences  are  
sufficient  to  result  in  a  significant  affinity  difference  between  the  miRNAs  and  their  
targets  to  produce  the  observed  differential  targeting.  Alternatively,  as  reported117,  the  
loop  sequence  of  the  pre-­‐‑miRNA  may  participate  in  the  process  of  target  recognition.  In  
that  case,  the  distinct  mRNA  targeting  activities  of  miR-­‐‑181a  and  miR-­‐‑181c  were  largely  
determined  by  their  divergent  pre-­‐‑miRNA  loop  sequences,  but  not  by  the  one-­‐‑
nucleotide  alteration  in  the  mature  miRNAs.  As  the  pre-­‐‑miRNA  loops  also  differ  
between  miR-­‐‑17  and  miR-­‐‑20a/-­‐‑18a,  it  is  possible  that  the  targeting  preference  between  
them  is  caused  by  differences  of  their  pre-­‐‑miRNA  loops.  Regardless,  our  results  do  
argue  that  the  sequences  outside  the  seed  region  can  also  be  an  indispensible  component  
of  the  miRNA  targeting  machinery.  
The  other  novel  pathway  identified  in  this  study  is  that  miR-­‐‑17  functions  
through  targeting  CREB1.  By  restoring  CREB1  levels  in  miR-­‐‑17-­‐‑coexpressing  T  cells,  we  
demonstrated  that  the  subtle  increase  of  this  protein  diminished  the  protection  from  
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AICD  afforded  by  miR-­‐‑17.  This  functionally  confirmed  CREB1  as  a  target  of  miR-­‐‑17,  
and,  more  importantly,  provided  the  first  evidence  that  CREB1  is  a  pro-­‐‑apoptotic  factor  
during  AICD  in  CD4+  T  cells.  The  ability  to  restrain  iTreg  differentiation  was  an  
unexpected  role  for  miR-­‐‑17.  In  accordance  with  previous  findings118,119,  we  found  that  
miR-­‐‑17  inhibits  TGF-­‐‑β  signaling  through  targeting  TGFβRII.  Biochemically,  the  
reduction  of  either  CREB1  or  TGFβRII  is  not  dramatic;  but  impacts  from  these  moderate  
adjustments  on  T  cell  function  are  not  negligible.  However,  despite  its  clear  role  during  
iTreg  differentiation,  the  loss  of  miR-­‐‑17-­‐‑92  did  not  influence  the  development  of  nTregs  
in  our  mouse  models.  One  possibility  is  that  the  moderate  protein  level  changes  of  TGF-­‐‑
bRII,  CREB1  and  Pten  caused  by  the  loss  of  miR-­‐‑17/-­‐‑19b,  while  critical  for  Foxp3  
induction  in  peripheral  conventional  T  cells,  are  not  sufficient  to  affect  thymic  nTreg  
development.  Alternatively,  miR-­‐‑17  and  miR-­‐‑19b  do  affect  the  thymic  selection  of  the  
nTreg  population,  but  in  a  more  subtle  way  (e.g.  TCR  repertoire  changes  within  the  




4. TCR and TGF-β  signaling converge on DNMT to 
control foxp3 locus methylation and iTreg 
differentiation: An epigenetic node that links 
environmental cues to DNA methylation 
The  contents  of  this  dissertation  chapter  have  been  slightly  modified  from  the  
following  publication:  
  Chaoran  Li,  Peter  J.R.  Ebert  &  Qi-­‐‑Jing  Li.  T  Cell  Receptor  (TCR)  and  
Transforming  Growth  Factor  β  (TGF-­‐‑β)  Signaling  Converge  on  DNA  (Cytosine-­‐‑5)-­‐‑
methyltransferase  to  Control  forkhead  box  protein  3  (foxp3)  Locus  Methylation  and  
Inducible  Regulatory  T  Cell  Differentiation.  J  Biol  Chem.  288(26):19127-­‐‑392012.  (2013).  
4.1 Introduction 
Recognition  of  a  peptide-­‐‑major  histocompatibility  complex  (pMHC)  displayed  
on  the  surface  of  antigen-­‐‑presenting  cells  (APCs)  by  a  specific  T  cell  receptor  (TCR)  
initiates  the  T  cell  response.  Upon  pMHC:TCR  engagement,  coordinated  downstream  
signaling  cascades  promote  naïve  CD4+  T  cells  to  undergo  massive  expansion  and  
differentiation  into  distinct  T  helper  (Th)  subsets,  such  as  Th1,  Th2,  Th17,  and  inducible  
regulatory  T  cells  (iTreg)4.  Although  the  requirement  for  TCR  signals  in  lineage  
commitment  is  universal,  accumulating  evidence  indicates  that,  besides  varying  
cytokine  environments,  differences  in  the  strength  of  TCR  signaling  can  also  have  a  
tremendous  impact  on  CD4+  T  cells’  fate  determination.  This  was  initially  discovered  by  
Bottomly  and  colleagues  and  further  confirmed  by  others:  in  general,  weak  TCR  signals  
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are  thought  to  bias  T  cells  toward  the  Th2  lineage  while  strong  TCR  signals  facilitate  the  
formation  of  the  Th1  subset120-­‐‑122.  Recently,  it  was  shown  that  the  differentiation  of  Th17  
cells  could  also  be  promoted  by  weak  TCR  activation13.  However,  the  molecular  
mechanism  governing  this  fate  determination  is  largely  unknown.      
In  addition  to  effector  T  helper  cells,  TCR  signal  strength  influences  the  
differentiation  of  CD4+Foxp3+  regulatory  T  cells  (Tregs).  Tregs  are  suppressor  T  cells  that  
play  a  dominant  role  in  the  maintenance  of  peripheral  tolerance  and  immune  
homeostasis31.  These  cells  express  the  master  transcription  factor  Foxp3,  which  is  
essential  for  their  differentiation,  maintenance  and  suppressive  function123-­‐‑126.  Mutation  
of  the  Foxp3  gene  in  humans  and  mice  results  in  lymphoproliferative  disease  that  leads  
to  severe  inflammation  in  multiple  organs  and  tissues127,128.  Based  on  their  origin  of  
development,  Tregs  have  been  categorized  into  two  types:  thymic  natural  Tregs  (nTregs)  
generated  after  thymocyte  selection,  and  peripheral  inducible  Tregs  (iTregs)  derived  
from  CD4+CD25-­‐‑  conventional  naïve  T  cells7.    nTregs  and  iTregs  share  several  common  
mechanisms  for  their  development  and  differentiation,  such  as  their  reliance  on  TCR,  IL-­‐‑
2,  and  TGF-­‐‑β  signaling.  TCR  stimulation  leads  to  the  activation  of  various  transcription  
factors  including  NFAT129,  AP1129,  CREB1130,  and  NF-­‐‑kB131,  which  were  shown  to  bind  to  
the  foxp3  locus  directly  and  regulate  its  transcription.  Paradoxically,  although  TCR  
mediated  signaling  is  absolutely  required  for  Treg  differentiation,  several  lines  of  
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evidences  suggested  that  strong  TCR  stimulation  disfavors  foxp3  induction  during  iTreg  
differentiation132 133.  However,  the  molecular  mechanism  of  this  is  still  unclear.  
In  addition  to  the  regulation  of  foxp3  by  well-­‐‑documented  transcription  factors,  
recent  studies  showed  that  foxp3  transcription  is  also  regulated  by  epigenetic  
mechanisms134,135.  It  was  shown  that  both  the  promoter  and  conserved  non-­‐‑coding  
sequence  1  (CNS1)  of  the  foxp3  gene  are  more  accessible  in  Tregs  than  in  conventional  
effector  T  cells,  as  indicated  by  increased  local  histone  acetylation  in  Tregs.  Besides  
histone  modifications,  foxp3  expression  is  also  directly  regulated  at  the  DNA  level  by  
CpG  methylation.  The  CpG  islands  within  the  promoter  region  of  foxp3  were  almost  
completely  demethylated  in  nTregs,  while  those  in  conventional  effector  T  cells  showed  
partial  methylation130,136.  In  foxp3’s  CNS2  region,  the  difference  in  methylation  is  even  
more  striking:  it  was  fully  demethylated  in  nTregs  but  completely  methylated  in  effector  
T  cells130,137.  Interestingly,  and  consistent  with  their  transient  and  unstable  Foxp3  
expression,  iTregs  had  foxp3  CpG  islands  that  were  only  partially  demethylated  in  the  
CNS2  region130.  Experiments  using  inhibitors  to  block  methylation  showed  that  changes  
in  CpG  methylation  motifs  did  affect  transcription  factor  binding  and  foxp3  expression  
in  antigen-­‐‑stimulated  conventional  T  cells.  However,  it  was  not  clear  how  this  
methylation  is  regulated  during  the  iTreg  differentiation  process.    
Here,  we  show  that  strong  TCR  signaling—elicited  by  high  affinity  ligand  or  by  
extended  ligand  exposure—inhibits  foxp3  expression  in  conventional  T  cells  at  the  
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epigenetic  level.  This  is  achieved  by  both  PLCγ-­‐‑  and  PI3K-­‐‑dependent  signaling  
downstream  of  TCR,  which  blocks  the  GSK3β-­‐‑dependent  proteasome-­‐‑mediated  
degradation  of  DNMT1  protein;  and,  by  dampening  miR-­‐‑148a,  the  miRNA  that  targets  
DNMT1  mRNA.  DNMT1,  together  with  DNMT3b,  is  then  able  to  methylate  and  
suppress  the  foxp3  locus.  Meanwhile,  TGF-­‐‑β  directly  antagonizes  these  TCR  signals  by  
promoting  drastic  downregulation  of  DNMT1  via  activation  of  p38.  Thus,  DNMT1  
represents  a  crucial  node  where  TCR  and  TGFβ  signals  converge  to  control  iTreg  fate.  
    
4.2 Results 
4.2.1 iTreg differentiation is controlled by both strength and duration 
of TCR signalling through the PI3K-Akt-mTOR and PLC pathways 
While  dissecting  the  functions  of  the  miRNAs  within  the  miR-­‐‑17-­‐‑92  cluster,  we  
identified  miR-­‐‑19b  as  an  inhibitor  of  iTreg  differentiation,  and  further  mechanistic  
analysis  indicated  that  this  was  mediated  through  inhibition  of  PTEN  expression  and  
the  consequent  prolonged  PI3K  activation  upon  TCR/CD28  signaling54.  Abbreviated  
anti-­‐‑CD3/CD28  stimulation  facilitates  in  vitro  iTreg  differentiation132;  and  previous  
adoptive  transfer  studies  have  shown  that  low  doses  of  antigen  and  lack  of  
costimulation  favor  induction  of  iTregs  in  vivo133.  Therefore,  we  hypothesized  that  iTreg  
lineage  differentiation  would  be  determined  by  the  integrated  strength  of  TCR  signaling  
based  on  both  pMHC  ligand  affinity  and  the  duration  of  ligand  availability.  To  parse  out  
the  impacts  of  ligand  affinity  and  stimulation  duration  in  regulating  iTreg  
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differentiation,  we  utilized  CD4+  T  cells  from  5C.C7  TCR  transgenic  mice,  in  which  every  
primary  T  cell  carries  a  unique  TCR138  recognizing  a  range  of  biochemically  and  
biophysically  well-­‐‑characterized  natural  and  synthetic  variants  of  the  moth  cytochrome  
C  (88-­‐‑103)  peptide  in  the  context  of  the  MHC  II  molecule  I-­‐‑Ek  139.  To  determine  the  role  of  
ligand  strength  in  regulating  iTreg  differentiation,  we  stimulated  sorted  CD4+CD25-­‐‑  
5C.C7  T  cells  using  syngeneic  APCs  loaded  with  either  the  strong  agonist  MCC,  or  a  
weak  agonist  102S140.    To  interrogate  how  the  duration  of  stimulation  influences  iTreg  
induction,  I-­‐‑Ek-­‐‑specific  antibodies  were  added  at  different  time  points  after  the  onset  of  
stimulation  (e.g.  6hrs,  18hrs);  this  treatment  blocks  TCR  engagement  with  pMHC  within  
minutes141.  Under  these  two  regimes,  and  without  addition  of  exogenous  cytokines,  we  
analyzed  the  percentages  of  Foxp3+  CD4+  T  cells  72hrs  after  initial  TCR  stimulation  
(Figure  11A).  Consistent  with  our  hypothesis,  a  minimal  percentage  of  T  cells  
upregulated  Foxp3  when  stimulated  for  a  prolonged  period  (72hrs),  regardless  of  
whether  a  strong  or  weak  antigenic  peptide  was  used.  However,  when  cells  were  
stimulated  with  the  weak  agonist  102S  for  a  shorter  period  of  time  (6hrs  or  18hrs),  we  
observed  a  substantial  frequency  of  iTreg  conversion  (Figure  11B&D).  We  further  
confirmed  that  this  elevation  of  Foxp3  expression  occurred  at  the  transcript  level  (Figure  
11C).  In  contrast,  even  with  the  shortest  tested  duration  of  stimulation,  MCC  was  unable  
to  induce  Foxp3  expression  (Figure  11B-­‐‑D).  These  data  indicate  that  although  brief  
exposure  to  weak  TCR  signaling  is  required  for  Foxp3  induction,  extensive  signaling  
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generated  from  high  affinity  ligands  and/or  a  longer  duration  of  antigen  exposure  
actually  inhibits  foxp3  expression  and  iTreg  differentiation.  We  further  evaluated  the  
impact  of  TCR  signalling  strength  and  duration  in  regulating  iTreg  differentiation  with  
CD4+  T  cells  from  wild  type  C57BL/6  mice  upon  anti-­‐‑CD3  and  anti-­‐‑CD28  antibodies  
stimulation.  As  expected,  when  sorted  CD4+CD25-­‐‑  T  cells  were  stimulated  for  72  hours,  
very  few  Foxp3+  cells  were  generated.  In  contrast,  when  cells  were  activated  for  18  hours  
and  then  maintained  without  TCR  stimulation  for  additional  54  hours,  a  substantial  
fraction  of  cells  differentiated  into  Tregs  (Figure  11E).  Furthermore,  reducing  the  
concentration  of  anti-­‐‑CD3  antibody  further  enhanced  Foxp3  induction  and  iTreg  
differentiation  (Figure  11E).  These  data  confirmed  that  both  TCR  signalling  strength  and  
duration  contribute  to  the  negative  regulation  of  iTreg  differentiation  by  extensive  TCR  
stimulation.  
Although  we  do  not  know  precisely  how  TCR  signal  strength  is  translated  into  
cell  fate  decisions,  several  previous  studies  indicate  that  the  PI3K-­‐‑Akt-­‐‑mTOR  axis  
downstream  of  TCR  activation  might  be  critical.  Blocking  of  this  pathway  with  
LY294002  or  rapamycin  after  18hrs  of  TCR  stimulation  resulted  in  robust  Foxp3  
induction  in  vitro132.  In  addition,  expression  of  a  constitutively  active  form  of  Akt  in  T  
cells  diminished  Foxp3  expression  in  peripheral  T  cells  both  in  vitro  and  in  vivo,  
suggesting  that  the  activation  of  the  PI3K-­‐‑Akt-­‐‑mTOR  axis  could  contribute  to  the  
negative  regulation  of  iTreg  differentiation  by  strong  TCR  signaling142.  To  determine  key  
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signaling  events  preventing  foxp3  expression  upon  extensive  antigen  stimulation,  we  
repeated  our  iTreg  induction  experiments  in  the  presence  of  a  series  of  small  
pharmaceutical  inhibitors  to  block  specific  pathways  downstream  of  TCR  activation.  We  
first  chose  the  regime  of  extended  weak  TCR  stimulus  (72hr  102S),  which  normally  
results  in  very  little  iTreg  induction.    In  this  setting,  consistent  with  previous  findings  
that  prolonged  PI3K-­‐‑Akt-­‐‑mTOR  activation  inhibits  iTreg  differentiation,  we  detected  a  
substantial  increase  in  iTreg  conversion  when  cells  were  treated  with  LY294002,  a  small  
inhibitor  that  blocks  both  PI3  kinase  and  mTOR  activity  (Figure  12A).  We  further  
dissected  these  two  pathways  by  treating  cells  with  PIK-­‐‑75,  which  specifically  inhibits  
the  P110α  and  P110γ  subunits  of  PI3K  at  the  dose  used,  and  with  rapamycin,  which  
inhibits  mTOR  specifically  (Figure  12A).  We  noted  that  both  inhibitors  could  
significantly  potentiate  iTreg  differentiation.  Meanwhile,  despite  having  a  dramatic  
impact  on  T  cell  proliferation143,  inhibition  of  calcineurin-­‐‑NFAT  signaling,  NFkB  
function,  or  ERK  activation  had  a  minimal  effect  on  Foxp3  induction  (Figure  12A).  
Interestingly,  we  found  that  U-­‐‑73122,  a  specific  inhibitor  of  the  PLCγ-­‐‑dependent  
hydrolysis  of  PIP2  to  IP3,  could  also  enhance  iTreg  conversion  to  a  similar  extent  as  PI3K-­‐‑
mTOR  inhibition  (Figure  12A).    
We  next  investigated  whether  inhibition  of  the  PI3K-­‐‑Akt-­‐‑mTOR  or  ZAP70-­‐‑
PLCγ  pathway  can  induce  iTregs  when  TCRs  are  engaged  with  strong  agonist.  When  we  
inhibited  the  PI3K  and  PLC  pathway  with  specific  inhibitors  at  18  hours  after  TCR  
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engagement,  cells  stimulated  with  MCC  expressed  significantly  less  Foxp3  than  those  
stimulated  with  102S  (Figure  12B&C).  On  the  other  hand,  blocking  ERK  activation  did  
not  have  any  effects  on  iTreg  conversion  (Figure  12B&C).  These  data  indicated  that  a  
short  period  (18hrs)  of  strong  PI3K  and  PLC  activation  with  MCC  peptide  is  sufficient  to  
inhibit  iTreg  induction.  Furthermore,  it  strongly  suggested  that  both  the  PI3K-­‐‑Akt-­‐‑
mTOR  axis  and  the  ZAP70-­‐‑PLCγ  pathway  are  specifically  involved  in  the  negative  
regulation  of  iTreg  differentiation  in  response  to  extensive  TCR  signalling  mediated  by  
higher  ligand  affinity  or  prolonged  duration.    
  
4.2.2 TCR signaling regulates CpG methylation at the foxp3 locus 
During  iTreg  differentiation,  foxp3  gene  expression  is  driven  by  the  activation  of  
the  transcription  factors  STAT5,  Smad3,  NFAT,  AP1,  CREB1  and  NFkB144;  the  latter  four  
of  which  are  collectively  potentiated  by  strong  and  sustained  TCR  signaling.  
Paradoxically,  in  the  absence  of  TGF-­‐‑β,  TCR  signaling  of  this  magnitude  instead  
suppresses  the  transcription  of  foxp3.  This  apparent  conundrum  suggested  that,  in  
parallel  with  transcription  factor  activation,  extensive  TCR  signaling  must  target  a  
distinct  regulatory  mechanism.  DNA  methylation  controls  the  accessibility  of  general  
and  gene-­‐‑specific  transcription  factors  toward  the  regulatory  regions  of  genes,  and  this  
has  been  demonstrated  to  be  one  of  the  central  mechanisms  controlling  foxp3  
transcription134.  We  hypothesized  that,  during  iTreg  differentiation,  differences  in  
    
90  
strength  and  duration  of  TCR  signaling  would  result  in  differential  DNA  methylation  
within  the  foxp3  regulatory  regions.  
To  examine  this,  we  evaluated  the  methylation  status  of  the  foxp3  gene  in  
different  T  cell  populations  from  male  5C.C7  mice,  including  naïve  T  cells,  T  cells  
activated  with  102S  or  MCC  for  6hrs,  and  T  cells  activated  with  102S  peptide  for  72hrs.  
As  we  sought  modifications  that  could  explain  Foxp3  induction  prior  to  iTreg  
commitment,  we  analysed  the  whole  population  (within  which  the  highest  ratio  of  
differentiated  iTregs  is  less  than  20%),  rather  than  purified  iTreg  cells  under  these  
various  conditions.  In  agreement  with  previous  reports130,136,  we  found  that  in  naïve  
CD4+  T  cells,  CpG  islands  residing  in  foxp3’s  promoter  region  were  largely  unmethylated  
(Figure  13A).  While  a  short  and  weak  stimulation  did  not  alter  the  overall  methylation  
pattern  of  the  promoter,  stronger  stimulation  in  terms  of  duration  and  ligand  affinity  
significantly  elevated  foxp3  promoter  methylation  (Figure  13A),  and  this  methylation  
pattern  mirrored  the  final  expression  level  of  Foxp3  protein  (Figure  11B).  In  addition,  the  
CpG  islands  within  foxp3’s  CNS2  region  were  completely  methylated  in  naïve  T  cells  
and  T  cells  that  had  experienced  various  TCR  stimulations  (Figure  13B).  It  was  not  
surprising  to  observe  that  the  methylation  status  in  CNS2  was  largely  unchanged  in  
conventional  CD4+  T  cells:  It  has  been  shown  that  even  in  fully-­‐‑differentiated  iTregs  
induced  by  TGF-­‐‑β  and  IL-­‐‑2  treatment,  the  CpG  islands  within  CNS2  still  remains  largely  
methylated130.  Furthermore,  while  the  genetic  modification  demonstrates  that  CNS2  is  
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rather  essential  for  the  maintenance  of  Foxp3  expression  in  mature  nTregs  75,  our  data  
validate  that  CNS2  is  likely  dispensable  for  Foxp3  induction  during  iTreg  induction.  To  
further  functionally  determine  whether  extensive  TCR  stimulation  blocks  foxp3  
expression  through  DNA  methylation,  we  stimulated  5C.C7  T  cells  with  102S  for  72hrs,  
while  also  treating  samples  at  18hrs  post  stimulation  with  5-­‐‑azacytidine,  a  cytosine  
nucleoside  analogue  that  inhibits  DNA  methylation.  In  agreement  with  our  methylation  
data,  5-­‐‑azacytidine  treatment  abrogated  the  inhibition  of  Foxp3  expression  by  prolonged  
TCR  signaling  (Figure  13C).  These  data  indicate  that  extensive  TCR  stimulation  
suppresses  iTreg  differentiation  by  enhancing  CpG  methylation  in  the  foxp3  gene’s  
regulatory  regions.  
4.2.3 TCR signaling augments levels of DNMT proteins and their 
bindings to the foxp3 locus 
We  next  examined  how  TCR  signaling  controls  DNA  methylation  within  the  
foxp3  locus.    As  one  of  the  major  DNA  methyltransferases  in  mammalian  cells,  DNMT1  
was  recently  linked  to  the  regulation  of  Foxp3  expression  in  T  cells145.  In  addition  to  its  
well-­‐‑known  function  in  maintaining  DNA  methylation  during  cell  proliferation,  
DNMT1  has  also  been  shown  to  be  associated  with  DNMT3  to  induce  de  novo  
methylation  in  CpG  islands146  and  silence  genes  in  human  cells147.  Since  we  observed  a  
substantial  change  in  DNA  methylation  in  foxp3’s  regulatory  regions,  we  hypothesized  
that  extensive  TCR  signaling  modulates  foxp3  gene  methylation  by  controlling  the  level  
of  DNMTs.  Under  various  stimulatory  conditions  that  we  employed  for  iTreg  induction,  
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mRNA  levels  of  DNMT1  (Figure  14A)  and  DNMT3b  (Figure  14B)  largely  remained  
steady.  However,  at  the  protein  level,  DNMT1  was  slightly  elevated  with  a  short  
duration  of  102S  stimulation,  and  was  dramatically  increased  when  this  stimulation  was  
prolonged  (Figure  14C).  Similarly,  DNMT3b  protein  was  also  significantly  elevated  with  
as  short  as  6  hours  of  moderate  TCR  stimulation  (Figure  14D).  Consistent  with  our  
hypothesis  that  DNMT1  mediates  iTreg  differentiation  through  interpretation  of  TCR  
signalling  strength  and  duration,  similar  magnitudes  of  DNMT1  elevation  were  caused  
by  prolonged  stimulus  with  a  weak  agonist  (102S),  as  by  a  shorter  stimulation  with  a  
strong  agonist  (MCC)  (Figure  14E&F).  To  examine  whether  DNMT1  and  Foxp3  
expression  are  inversely  correlated  under  the  permissive  condition  for  iTreg  conversion,  
we  directly  compared  DNMT1  levels  between  Foxp3+  and  Foxp3-­‐‑  populations  in  CD4+  T  
cells  with  the  same  TCR  priming.  We  employed  a  BAC  transgenic  mice  expressing  the  
GFP-­‐‑Cre  fusion  protein  under  the  control  of  the  foxp3  promoter,  in  which  GFP  
expression  faithfully  reflects  endogenous  Foxp3  expression95.  We  then  stimulated  sorted  
CD4+GFP-­‐‑  conventional  T  cells  from  these  mice  with  the  permissive  condition  optimized  
in  Figure  11E.  GFP-­‐‑  (Foxp3-­‐‑)  and  converted  GFP+  (Foxp3+)  CD4+  T  cells  were  then  sorted  
to  determine  DNMT1  expression.    In  agreement  with  a  critical  role  of  DNMT1  in  
negatively  controlling  Foxp3  expression,  we  detected  significant  lower  DNMT1  levels  in  
GFP+  cells  as  compared  to  the  GFP-­‐‑  population  (Figure  14G).  
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We  next  examined  whether  the  overall  accumulation  of  DNMT1  and  DNMT3b  
protein  by  strong  TCR  signaling  leads  to  enhanced  enrichment  of  these  two  enzymes  at  
the  foxp3  locus,  which  could  account  for  the  increased  CpG  methylation  status  in  the  
promoter  of  the  foxp3  gene.  As  shown  by  our  immunocytochemistry  experiments,  
DNMT1  protein  resides  in  small  punctate  structures  within  naïve  CD4+  T  cells’  nuclei  
(Figure  15A).    In  agreement  with  our  western  blot  results,  the  total  signal  intensity  of  
DNMT1  staining  rose  sharply  upon  stimulation  in  a  TCR-­‐‑ signal-­‐‑strength-­‐‑dependent  
manner.    Moreover,  in  contrast  to  a  few  concentrated  DNMT1  punctae  observed  in  naïve  
cells  (TCR-­‐‑0h)  or  cells  given  a  short  and  weak  priming  (102S-­‐‑6h),  T  cells  with  strong  
TCR  signaling  (102S-­‐‑72h,  MCC-­‐‑6h/72h)  had  significantly  increased  nuclear  DNMT1  
staining  not  only  with  respect  to  the  intensity  of  each  individual  puncta,  but  also  the  
number  of  punctae  (Figure  15A).  We  predicted  that  this  increased  quantity  and  
broadened  distribution  would  impact  the  occupancy  of  DNMT1  on  the  foxp3  gene’s  
regulatory  regions.  The  locus-­‐‑specific  recruitment  of  DNMT1  and  DNMT3b  was  
quantified  by  chromatin  immunoprecipitation  (ChIP).  Consistent  with  the  overall  
demethylated  status  of  promoter  CpG  islands  in  unstimulated  and  weakly  stimulated  
CD4+  T  cells,  we  did  not  detect  any  specific  DNMT1  or  DNMT3b  binding  to  the  foxp3  
promoter  in  these  two  populations  (Figure  15B&E).  In  contrast,  cells  that  were  
suboptimally  stimulated—either  with  weak  agonist  for  a  long  duration  or  with  strong  
agonist  for  a  short  duration—showed  significantly  enhanced  binding  of  DNMT1  and  
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DNMT3b  to  foxp3’s  CpG  islands  (Figure  15B&E).  Interestingly,  strong  TCR  signaling  
also  enhanced  DNMT1  occupancy  at  the  CNS2  region,  but  not  DNMT3b  occupancy  
(Figure  15C&F).    Importantly,  as  implied  by  the  local  accumulation  of  DNMT1  at  
punctae  within  the  nucleus,  we  could  demonstrate  a  degree  of  specificity  in  the  local  
recruitment  of  DNMT1  to  the  foxp3  locus.  In  agreement  with  the  fact  that  strong  
stimulation  of  5C.C7  T  cells  favours  their  Th1  lineage  differentiation,  no  significant  
DNMT1  binding  was  detected  within  the  CNS-­‐‑6  region  of  the  ifng  gene  after  MCC  
stimulation  (Figure  15D),  which  was  methylated  in  naïve  cells  but  completely  
demethylated  and  accessible  to  support  IFNγ  production  in  Th1  cells148.  This  biochemical  
evidence,  combined  with  the  associated  epigenetic  and  functional  outcomes,  indicates  
that  strong  TCR  signaling  blocks  the  accessibility  of  the  foxp3  locus  through  the  elevation  
of  DNMT1  and  DNMT3b  protein  levels,  delivery  of  these  two  enzymes  to  foxp3’s  
regulatory  region,  and  the  resultant  enhanced  local  methylation.  
4.2.4 TCR signaling stabilizes DNMT1 protein through inhibition of 
Gsk3β  activity and protection from proteasome-mediated degradation 
Based  on  the  data  presented  above,  we  hypothesized  that  there  must  be  a  
signaling  node  that  is  capable  of  receiving  signals  from  both  PI3K  and  PLCγ  pathways  
downstream  of  TCR,  and  then  integrating  these  signals  to  post-­‐‑translationally  modify  
the  level  of  DNMT1  protein.  Within  the  TCR  signaling  network,  a  good  candidate  for  
such  a  modulator  is  glycogen  synthase  kinase  3  beta  (Gsk3β).  Gsk3β  is  a  constitutively  
active  serine/threonine  protein  kinase  in  resting  cells149.  Upon  receptor  signaling,  its  
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activity  can  be  silenced  by  phosphorylation  mediated  through  PI3K-­‐‑Akt150  and/or  PLCγ-­‐‑
PKCθ  signaling151.  Interestingly,  in  some  human  tumor  cell  lines,  suppression  of  
Gsk3β  activity  upon  PI3K  activation  has  been  implicated  as  the  cause  for  stabilized  
DNMT1  protein  levels:  PI3K  prohibits  Gsk3β-­‐‑mediated  phosphorylation  of  DNMT1  and  
thus  protects  it  from  ubiquitin-­‐‑mediated  proteasomal  degradation152.  We  examined  
whether  this  DNMT1  stabilization  mechanism  is  exploited  by  TCR  signaling.  T  cells  
were  stimulated  with  102S  peptide  antigen  for  18hrs,  and  then  treated  with  a  specific  
proteasome  inhibitor,  MG-­‐‑132  or  SB-­‐‑216763,  a  specific  inhibitor  of  Gsk3β  activity152.  
When  these  cells  were  analyzed  at  the  72hr  endpoint,  both  inhibitor  treatments  partially  
but  significantly  enhanced  the  level  of  DNMT1  protein  in  response  to  weak  TCR  
signaling  (Figure  16A).  Reciprocally,  whereas  blocking  TCR  engagement,  PI3K  
activation,  or  PLC  activity  at  the  18hr  point  led  to  a  substantial  Foxp3  induction,  the  
addition  of  Gsk3β  inhibitor  could  partially  diminish  this  effect  (Figure  16B).  Overall,  
these  data  suggest  that  extensive  TCR  signaling  stabilizes  DNMT1  protein  by  inhibiting  
Gsk3β-­‐‑mediated  phosphorylation  and  proteasomal  degradation  of  DNMT1.  
4.2.5 TCR signaling elevates DNMT1 protein levels by dampening its 
miRNA modulator, miR-148a 
The  fact  that  MG-­‐‑132  and  Gsk3b  inhibitor  could  only  partially  rescue  the  level  of  
DNMT1  protein  led  us  to  speculate  that  there  is  another  layer  of  control,  possibly  at  the  
level  of  DNMT1  translation.  miRNAs  are  small  non-­‐‑coding  RNAs  that  regulate  gene  
expression  posttranscriptionally,  via  a  combination  of  mRNA  degradation  and/or  
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translational  repression,  depending  on  the  particular  miRNA153.  Since  DNMT1  transcript  
levels  were  not  altered  in  our  T  cells,  we  explored  the  possibility  that  TCR  signaling  
could  release  miRNA-­‐‑mediated  translational  inhibition  of  DNMT1  expression.    Two  
members  of  the  miR-­‐‑148  family,  miR-­‐‑148a154  and  miR-­‐‑152155,  were  previously  suggested  
to  be  direct  modulators  of  DNMT1  expression.  Upon  TCR  engagement,  expression  
levels  of  all  three  miRNAs  within  this  family,  miR-­‐‑148a,  miR-­‐‑148b,  and  miR-­‐‑152  were  
suppressed  (Figure  16C).  When  ectopically  expressed  using  a  retroviral  tool  during  T  
cell  activation,  all  three  failed  to  suppress  DNMT1  mRNA  levels  (Figure  16D).  However,  
one  of  the  three—miR-­‐‑148a—significantly  suppressed  DNMT1  expression  at  the  protein  
level  (Figure  16E).  Furthermore,  CD4+  T  cells  that  forcibly  overexpressed  miR-­‐‑148a  
enhanced  their  Foxp3  induction  significantly  (Figure  16F).  This  suggested  that  
dampening  of  miR-­‐‑148a  expression  is  a  complimentary  pathway  that  contributes  to  
TCR-­‐‑mediated  epigenetic  regulation  of  the  foxp3  gene.  
4.2.6 TGF-β  antagonizes TCR signaling by targeting DNMT1 for 
degradation via p38 activation 
In  addition  to  TCR  signal  strength,  TGF-­‐‑β  signaling  also  strongly  modulates  
iTreg  induction.  Although  72  hours  of  102S  stimulation  normally  leads  to  very  few  
iTregs,  TGF-­‐‑β  can  exert  a  dominant  effect  which  increases  the  proportion  of  iTregs  
substantially  (Figure  17A).  It  is  known  that  TGF-­‐‑β  acts  through  its  receptor  complex  to  
trigger  the  activation  of  Smad3  protein,  which  then  translocates  to  the  nucleus  and  
promotes  foxp3  transcription74.  However,  this  classical  pathway  cannot  explain  how  
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TGF-­‐‑β  overcomes  methylation-­‐‑mediated  transcriptional  silencing  within  the  foxp3  locus  
under  the  circumstance  of  strong  TCR  signaling.  We  thus  investigated  the  direct  impact  
of  TGF-­‐‑β  on  epigenetic  regulation  of  the  foxp3  gene.  When  strong  signals  from  both  the  
TCR  and  TGFβ  receptors  were  induced  simultaneously,  the  TCR-­‐‑mediated  accumulation  
of  DNMT1  protein  was  abolished  (Figure  17A&B).  The  dampening  of  DNMT1  protein  
levels  was  also  not  related  to  TGF-­‐‑β’s  inhibitory  effects  on  T  cell  proliferation:  a  
reduction  of  DNMT1  was  observed  in  each  successive  generation  when  TGF-­‐‑β  was  
present  (Figure  17B).  The  regulation  of  DNMT1  by  TGF-­‐‑β  mainly  occurred  at  the  protein  
level,  as  the  DNMT1  mRNA  level  was  not  affected  by  TGF-­‐‑β  treatment  (Figure  17C).  As  
could  be  expected  from  the  reduced  protein  level  of  DNMT1,  TGF-­‐‑β  treatment  also  
resulted  in  reduced  CpG  methylation  within  the  promoter  (Figure  17D)  region  of  foxp3.  
We  also  examined  whether  TGF-­‐‑β  signaling  can  effectively  antagonize  strong  
agonist-­‐‑induced  DNMT1  accumulation  and  iTreg  differentiation.  CD4+  T  cells  
stimulated  with  MCC  alone  for  72  hours  have  more  DNMT1  protein  accumulated  than  
those  stimulated  with  102S  for  72  hours  (Figure  18A).  Similarly,  in  contrast  to  a  
relatively  strong  impact  of  TGF-­‐‑β  signaling  on  DNMT1  accumulation  in  102S-­‐‑stimulated  
cells,  TGF-­‐‑β  could  only  moderately  downregulate  the  DNMT1  protein  in  cells  
stimulated  with  MCC  (Figure  18A).  In  agreement  with  this,  when  same  concentrations  
of  TGF-­‐‑β  were  supplemented,  MCC  induced  significantly  less  Foxp3+  cells  (Figure  18B).  
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This  suggested  that  excessive  TCR  signalling  can  antagonize  TGF-­‐‑β  effects  on  iTreg  
differentiation.  
In  addition  to  Smad-­‐‑mediated  transcriptional  regulation,  TGF-­‐‑β  can  also  initiate  
alternative  signalling  via  the  Ras-­‐‑ERK,  TAK-­‐‑MKK4-­‐‑JNK,  and  TAK-­‐‑MKK3-­‐‑6-­‐‑p38  
pathways156.  During  TCR  stimulation  of  naïve  T  cells,  ERK  activation  is  inhibited  by  
TGF-­‐‑β  treatment157,  and  this  curtailed  ERK  signaling  failed  to  increase  foxp3  expression  
(Figure  12A).  We  thus  investigated  the  potential  roles  of  the  other  two  MAPK  pathways  
in  potentially  linking  TGFβ  receptors  to  DNMT1  using  well-­‐‑established  specific  
inhibitors.  Whereas  treatment  with  a  specific  JNK  inhibitor  had  no  effect,  treatment  with  
a  p38  inhibitor  completely  abolished  TGF-­‐‑β-­‐‑induced  DNMT1  downregulation,  as  shown  
by  both  the  frequency  of  DNMT1+  cells  and  the  intensity  of  DNMT1  staining  at  the  
single-­‐‑cell  level  (Figure  17E).  Consistent  with  these  increased  DNMT1  protein  levels,  
blockade  of  the  p38  pathway  also  resulted  in  a  significant  reduction  of  Foxp3  induction  
by  TGF-­‐‑β  (Figure  17F).  These  data  suggest  that  TGF-­‐‑β  signaling  antagonizes  the  effect  of  
TCR  signaling  on  DNMT1  stabilization  and  foxp3  gene  methylation  through  the  




Figure  11:  Suboptimal  TCR  activation  in  terms  of  both  strength  and  duration  
favors  iTreg  differentiation.  
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(A)  Schematic  view  of  the  workflow  for  analyzing  the  role  of  TCR  strength  and  
duration  in  iTreg  differentiation.  Briefly,  sorted  CD4+CD25-­‐‑  T  cells  from  the  lymph  nodes  
of  5C.C7  TCR  transgenic  mice  were  labeled  with  CFSE,  cultured  with  syngeneic  T  cell-­‐‑
depleted  splenocytes  without  peptide  in  the  presence  of  10  ng/ml  recombinant  IL-­‐‑7,  or  
stimulated  by  syngeneic  T  cell-­‐‑depleted  splenocytes  loaded  with  a  strong  agonist  
peptide  MCC  (1  µμM)  or  a  weak  agonist  102S  (1  µμM).  Anti-­‐‑I-­‐‑Ek  antibody  or  small  
molecule  inhibitors  that  block  specific  pathways  were  added  at  the  indicated  time  
points.  The  percentages  of  CD4+Foxp3+  T  cells  were  analyzed  by  intracellular  staining  
and  flow  cytometry  at  72  h.  (B&D)  Percentages  of  iTregs  generated  with  the  indicated  
TCR  stimulatory  strength  and  duration  are  shown.  (B)  Representative  FACS  plot.  (D)  
Statistical  analysis.  Data  show  the  means  ±  SEM  from  three  independent  experiments.  
(C)  At  the  end  of  culture,  CD4+  T  cells  were  FACS-­‐‑sorted,  and  total  RNA  was  extracted  
for  quantitative  PCR  analysis.  Data  show  the  means  ±  SEM  from  three  independent  
experiments.  (E)  Sorted  CD4+CD25-­‐‑  T  cells  from  the  lymph  nodes  of  C57BL/6  mice  were  
labeled  with  CFSE  and  then  stimulated  with  various  concentrations  of  plate-­‐‑bound  anti-­‐‑
CD3  and  anti-­‐‑  CD28  antibody  for  18  h.  After  this,  the  cells  were  either  further  stimulated  
with  anti-­‐‑CD3  and  anti-­‐‑CD28  for  54  h  (TCR  72  h  total)  or  maintained  without  TCR  
stimulation  for  54  h  (TCR  18  h).  The  induction  of  Foxp3  was  then  examined  by  




Figure  12:  PI3K-­‐‑Akt-­‐‑mTOR  and  PLC  pathways  downstream  of  TCR  signaling  
negatively  regulate  iTreg  differentiation.  
(A)  Sorted  CD4+  CD25-­‐‑  T  cells  from  5C.C7  transgenic  mice  were  stimulated  with  
1  µμM  102S  for  72  h  as  described  in  Fig.  1A.  LY  294002  (10  µμM),  rapamycin  (25  nM),  
cyclosporin  A  (CsA),  1  µμg/ml),  IκB  kinase  inhibitor  III  (IKK,  BMS-­‐‑345541,  1  µμM),  ERK  
(ERK  inhibitor  II,  FR180204,  1  µμM),  PI3K  (PIK-­‐‑75,  100  nM),  or  PLC  (U-­‐‑73122,  1  µμM)  were  
added  at  the  indicated  time  points  to  block  specific  pathways  downstream  of  TCR  
signaling.  The  percentages  of  CD4+Foxp3+  T  cells  were  analyzed  by  flow  cytometry  at  
72h  after  TCR  activation.  The  bar  graph  shows  the  means  ±  SEM  from  three  independent  
experiments.  (B&C)  Sorted  CD4+CD25-­‐‑  T  cells  from  5C.C7  transgenic  mice  were  
stimulated  with  1  µμM  102S  or  MCC  for  72  h.  Inhibitors  that  specifically  block  the  PI3K,  
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PLC,  or  ERK  pathways  were  added  at  18  h  after  TCR  stimulation.  The  percentages  of  
CD4+Foxp3+  T  cells  were  analyzed  by  flow  cytometry  at  72  h  after  TCR  activation.  (B)  





Figure  13:  Strong  TCR  signaling  enhances  CpG  methylation  within  the  foxp3  
locus.  
(A&B)  CD4+  CD25-­‐‑  T  cells  from  male  5C.C7  transgenic  mice  were  stimulated  as  
described  in  Fig.  11A.  The  methylation  status  of  CpG  islands  within  the  foxp3  promoter  
(A)  or  foxp3  CNS2  (B)  from  these  cells  was  determined  by  bisulfite  sequencing  analysis.  
Each  row  represents  one  DNA  strand.  The  number  on  top  indicates  the  position  of  CpGs  
relative  to  the  transcription  start  site  of  the  foxp3  gene.  Open  circles,  unmethylated  
CpGs;  filled  circles,  methylated  CpGs.  Data  represent  three  independent  experiments.  
(C)  5C.C7  T  cells  were  activated  with  102S  for  72  h  while  also  being  treated  with  5-­‐‑
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azacytidine  (5-­‐‑Aza)  at  18  h  post-­‐‑stimulation.  The  percentages  of  CD4+Foxp3+  T  cells  were  





Figure  14:  DNMT1  and  DNMT3b  are  posttranscriptionally  upregulated  by  
TCR  signaling  in  a  strength-­‐‑  and  duration-­‐‑dependent  manner.  
(A&B)  CD4+CD25-­‐‑  T  cells  from  5C.C7  transgenic  mice  were  left  unstimulated  
(TCR-­‐‑0h)  or  stimulated  with  1  µμM  102S  for  6  h  (TCR-­‐‑6h)  or  72  h  (TCR-­‐‑72h)  and  then  
sorted  by  FACS.  Total  RNA  and  protein  were  extracted,  and  relative  expression  of  
dnmt1  mRNA  (A)  and  dnmt3b  mRNA  (B)  and  DNMT1  protein  (C)  DNMT3b  protein  (D)  
were  determined  by  quantitative  PCR  and  Western  blot  analysis.  In  A  and  B,  data  show  
the  means  ±  SEM  from  three  independent  experiments.  (E&F)  CD4+  CD25-­‐‑  T  cells  from  
5C.C7  transgenic  mice  were  labeled  with  CFSE  and  stimulated  as  described  in  Fig.  11A.  
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The  expression  of  DNMT1  protein  at  the  single  cell  level  was  determined  by  intracellular  
staining.  (E)  Representative  FACS  plots.  (F)  Statistical  analysis.  Data  show  the  means  ±  
SEM  from  three  independent  experiments.  (G)  Sorted  CD4+GFP-­‐‑  T  cells  from  the  lymph  
nodes  of  Foxp3-­‐‑GFP-­‐‑Cre  mice  were  stimulated  with  0.1  µμg/ml  plate-­‐‑bound  anti-­‐‑CD3  
and  1  µμg/ml  anti-­‐‑CD28  antibody  for  18  h  and  then  maintained  without  further  TCR  
stimulation  for  54  h.  GFP+  and  GFP-­‐‑  CD4+  T  cells  were  then  sorted  for  examination  of  




Figure  15:  Strong  TCR  signaling  causes  enhanced  enrichment  of  DNMT1  and  
DNMT3b  at  the  foxp3  locus.  
(A)  Representative  images  show  the  nuclear  localization  of  DNMT1.  CD4+CD25-­‐‑  
T  cells  from  5C.C7  transgenic  mice  were  stimulated  as  described  in  Fig.  11A.  The  cells  
were  then  fixed  with  4%  paraformaldehyde  on  cover  slips  and  stained  for  intracellular  
DNMT1.  DAPI  was  used  to  label  the  nucleus.  Data  represent  three  independent  
experiments.  (B–F)  Chromatin  immunoprecipitation  analysis  for  the  enrichment  of  
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DNMT1  at  foxp3  promoter  (B),  foxp3  CNS2  (C),  and  Ifng  CNS-­‐‑6  (D)  or  DNMT3b  at  foxp3  
promoter  (E)  and  foxp3  CNS2  (F)  in  5C.C7  transgenic  CD4+CD25-­‐‑  T  cells  that  were  left  
unstimulated  (TCR-­‐‑0h)  or  stimulated  as  in  A.  The  amount  of  DNA  immunoprecipitated  
by  the  DNMT1or  DNMT3b-­‐‑specific  antibody  or  a  nonspecific  control  IgG  antibody  was  
quantified  by  quantitative  PCR  using  primers  specific  for  the  indicated  gene-­‐‑regulatory  
regions  and  normalized  to  the  input  before  immunoprecipitation.  Data  show  the  means  




Figure  16:  TCR  signaling  stabilizes  DNMT1  by  inhibiting  GSK3-­‐‑β-­‐‑induced  
proteasomal  degradation  of  DNMT1  and  repressing  miR-­‐‑148a-­‐‑mediated  inhibition  of  
DNMT1  translation.  
(A)  CD4+CD25-­‐‑  T  cells  from  5C.C7  transgenic  mice  were  stimulated  with  1  µμM  
102S  for  18  h  and  treated  with  0.4  µμM  MG-­‐‑132  or  1  µμM  GSK3-­‐‑  β  inhibitor  SB-­‐‑216763  at  
18h  post-­‐‑TCR  stimulation.  The  expression  of  DNMT1  protein  at  72  h  was  quantified  by  
intracellular  staining  of  DNMT1  followed  by  flow  cytometry  analysis.  Cells  that  were  
activated  with  1  µμM  102S  for  72  h  or  1  µμM  MCC  for  18  h  without  other  treatment  were  
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used  as  controls.  Data  show  the  means  ±  SEM  from  three  independent  experiments.  (B)  
CD4+CD25-­‐‑  T  cells  from  5C.C7  transgenic  mice  were  labeled  with  CFSE  and  stimulated  
with  1  µμM  102S  for  the  indicated  durations.  1  µμM  GSK3-­‐‑  β  inhibitor  or  its  non-­‐‑functional  
analog  were  added  at  18  h  together  with  either  100  nM  PIK-­‐‑75  (PI3K-­‐‑18h)  or  1  µμM  U-­‐‑
73122  (PLC-­‐‑18h).  The  percentages  of  CD4+Foxp3+  T  cells  were  analyzed  by  flow  
cytometry  at  72  h  after  TCR  activation.  Data  represent  three  independent  experiments.  
(C)  5C.C7  CD4+CD25-­‐‑  T  cells  were  stimulated  with  1  µμM  102S  for  the  indicated  
durations.  The  CD4+  T  cells  were  then  FACS-­‐‑sorted,  and  total  RNA  was  extracted.  The  
relative  expression  of  miR-­‐‑148a,  miR-­‐‑148b,  and  miR-­‐‑152  transcript  was  quantified  by  
quantitative  PCR  analysis.  Data  show  the  means  ±  SEM  from  three  independent  
experiments.  (D)  5C.C7  CD4+CD25-­‐‑  T  cells  were  activated  with  1  µμM  102S  and  
transduced  with  retrovirus  that  encodes  GFP  only  (mock),  miR-­‐‑148a  together  with  GFP  
(miR-­‐‑148a),  miR-­‐‑148b  together  with  GFP  (miR-­‐‑148b),  and  miR-­‐‑152  together  with  GFP  
(miR-­‐‑152).  Three  days  after  transduction,  CD4+GFP+  T  cells  were  sorted  and  extracted  for  
total  protein.  DNMT1  protein  level  was  quantified  by  Western  blot  analysis.  Data  
represent  three  independent  experiments.  (E&F)  5C.C7  CD4+CD25-­‐‑  T  cells  were  primed  
and  transduced  with  mock  virus  or  miR-­‐‑148a  as  described  above  and  then  cultured  in  
the  presence  of  50  units/ml  IL-­‐‑2  and  2  ng/ml  TGF-­‐‑β  for  4  days.  The  percentages  of  CD25+  
Foxp3+  T  cells  were  analyzed  by  flow  cytometry.  (E)  Representative  FACS  plot.  (F)  




Figure  17:  TGF-­‐‑β  signaling  antagonizes  TCR-­‐‑signal-­‐‑mediated  DNMT1  
stabilization  via  the  p38  pathway.  
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(A-­‐‑C)  CD4+CD25-­‐‑  T  cells  from  5C.C7  transgenic  mice  were  labeled  with  CFSE  
and  stimulated  with  1  µμM  102S  in  the  absence  (TCR)  or  presence  of  5  ng/ml  TGF-­‐‑β  
(TCR+TGFβ)  for  72  h.  The  expression  of  DNMT1  (both  protein  and  mRNA  level)  and  
Foxp3  at  the  single  cell  level  was  quantified  by  intracellular  staining.  (A)  Representative  
FACS  plots.  (B)  Statistical  analysis.  Data  show  the  means  ±  SEM  from  three  independent  
experiments.  (C)  mRNA  level  of  dnmt1.  (D)  The  methylation  status  of  CpG  islands  in  
these  cell  foxp3  promoters  was  determined  by  bisulfite  sequencing  analysis.  Data  
represent  three  independent  experiments.  (E)  CD4+CD25-­‐‑  T  cells  from  5C.C7  transgenic  
mice  were  stimulated  with  1  µμM  102S  and  5  ng/ml  TGF-­‐‑β  in  the  presence  of  1  µμM  JNK  
inhibitor  II  (SP600125)  or  10  µμM  p38  MAP  kinase  inhibitor  III  (ML3403)  for  72  h.  The  
expression  of  DNMT1  was  determined  by  intracellular  staining.  MFI,  mean  fluorescence  
intensity.  Top,  representative  FACS  plot.  Bottom,  statistical  analysis.  Data  show  the  
means  ±  SEM  from  three  independent  experiments.  (F)  5C.C7  transgenic  CD4+CD25-­‐‑  T  
cells  were  stimulated  with  1  µμM  102S  and  5  ng/ml  TGF-­‐‑β  in  the  presence  of  10  µμM  p38  
MAP  kinase  inhibitor  III  (ML3403)  or  DMSO  for  72  h.  The  percentages  of  CD4+Foxp3+  T  
cells  were  analyzed  by  flow  cytometry.  Top,  representative  FACS  plot.  Bottom,  




Figure  18:  DNMT1  level  and  iTreg  differentiation  is  tightly  controlled  by  the  
balance  between  TCR  signaling  strength/duration  and  TGF-­‐‑β   signaling.  
(A&B)  CD4+CD25-­‐‑  T  cells  from  5C.C7  transgenic  mice  were  labeled  with  CFSE,  
and  stimulated  with  1µμM  102S  or  1µμM  MCC  in  the  absence  (-­‐‑TGF-­‐‑β)  or  presence  of  
5ng/ml  TGF-­‐‑β  (+TGF-­‐‑β)  for  72hrs.  The  expression  of  DNMT1  (A)  and  Foxp3  (B)  at  the  
single  cell  level  was  quantified  by  intracellular  staining.  Left:  Representative  FACS  plots.  




Figure  19:  Model  for  the  epigenetic  regulation  of  iTreg  differentiation  by  TCR  
and  TGFβ   signaling.  
In  naïve  CD4+  conventional  T  cells,  the  promoter  of  foxp3  gene  was  mostly  
demethylated  and  the  cells  are  poised  for  Foxp3  induction.  Weak  TCR  stimulation  
induced  only  modest  DNMT1  accumulation  so  the  foxp3  promoter  still  mostly  maintains  
demethylated.  At  the  same  time,  the  transcription  factors  (NFAT,  AP-­‐‑1)  are  activated  
and  bind  to  the  accessible  foxp3  promoter  to  promote  foxp3  transcription.  However,  
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when  CD4+  T  cells  are  stimulated  with  antigens  with  higher  affinity  or  for  longer  
durations,  the  level  of  DNMT1  and  its  enrichment  to  foxp3  locus  are  significantly  
elevated,  which  leads  to  substantial  DNA  methylation  in  the  CpG  island  of  foxp3  
promoter  and  inhibits  foxp3  transcription.  During  this  process  the  augmentation  of  
DNMT1  is  regulated  through  at  least  two  posttranscriptional  mechanisms;  that  is,  strong  
TCR  signal  inactivates  GSK3β  to  rescue  DNMT1  protein  from  proteasomal  degradation,  
and  strong  TCR  signal  suppresses  miR-­‐‑148a  to  derepress  DNMT1  mRNA  translation.  
Meanwhile,  TGF-­‐‑β  directly  antagonizes  TCR-­‐‑induced  DNA  methylation  of  foxp3  locus  
by  promoting  drastic  downregulation  of  DNMT1  via  activation  of  p38.  At  the  same  time,  









Since  it  was  first  appreciated  that  Tregs  could  be  induced  from  naïve  T  cell  
precursors158,  the  combinatorial  roles  of  TCR  signaling  and  TGF-­‐‑β  receptor  signaling  
have  been  well  established  as  important  determinants  of  foxp3  transcriptional  
activation74,129-­‐‑131.  Here  we  have  identified  multiple  pathways  by  which  signaling  
through  TCR  and  TGFbR  converge  to  control  the  protein  level  of  DNMT1,  an  epigenetic  
modifier  that  we  and  others145  have  shown  to  strongly  influence  foxp3  locus  accessibility  
and  iTreg  differentiation  (Figure  19).  Our  data  suggest  that  DNMT1-­‐‑mediated  
methylation  in  foxp3  locus  is  likely  aided  by  DNMT3b.  Upon  short  TCR  stimulation,  
prior  to  strong  DNMT1  elevation,  a  significant  accumulation  of  DNMT3b  protein  is  
observed  (Figure  14C&D).  However,  this  cellular  accumulation  does  not  translate  into  
increased  DNMT3b  occupancy  within  the  foxp3  promoter  region,  which  was  only  
observed  in  cells  receiving  a  prolonged  stimulation  (Figure  15E).  This  suggests  that  there  
are  additional  factors  required  for  the  recruitment  of  DNMT3b  to  the  foxp3  promoter.  
Previous  studies  showed  that  DNMT1  and  DNMT3b  co-­‐‑localize  and  directly  associate  
with  each  other  through  the  N-­‐‑terminal  domain146,  which  indicates  that  sufficient  
accumulation  of  DNMT1  triggered  by  a  prolonged  TCR  stimulation  may  be  required  to  
recruit  or  anchor  DNMT3b  to  the  foxp3  locus.  Therefore,  our  model  suggests  DNMT1  




In  its  role  as  a  signal  integrator,  we  believe  that  DNMT1  represents  the  node  
where  TCR-­‐‑based  self/non-­‐‑self  discrimination  converges  with  environmentally-­‐‑cued  
danger  signals.  TCR  signals  mitigate  miR-­‐‑148a-­‐‑mediated  DNMT1  translation  inhibition,  
and  also  relieve  GSK3β-­‐‑mediated  DNMT1  protein  degradation  via  PI3K  and  PLC-­‐‑γ  
signaling  (Figure  16).  Because  TCRs  with  high  avidity  for  self-­‐‑antigens  are  preferentially  
deleted  or  converted  to  nTregs  in  the  thymus,  stronger  TCR  signaling  can  be  interpreted  
via  higher  DNMT1  levels  as  an  indication  of  foreignness,  which  then  favors  foxp3  
methylation.  CD28  costimulation  can  provide  an  independent  indication  of  foreignness,  
as  its  ligands  are  induced  on  APCs  by  signaling  in  response  to  microbial  and  viral  
products.    CD28  signaling  can  then  also  feed  in  to  regulation  of  DNMT1  by  enhancing  
TCR-­‐‑induced  PI3K  activity,  inhibiting  GSK3β,  stabilizing  DNMT1,  and  further  favoring  
foxp3  methylation.  Meanwhile,  naïve  T  cells  maintain  an  only  partially  methylated  foxp3  
promoter,  presumably  because  the  level  of  DNMT1  attained  by  tonic/homeostatic  TCR  
signaling  is  below  the  threshold  needed  for  foxp3  methylation.  Finally,  healthy  or  tumor  
tissues  can  exert  influence  on  T  cell  priming  by  secreting  TGF-­‐‑β,  which  can  act  via  p38  to  
antagonize  strong  TCR  signaling  by  diminishing  DNMT1  protein,  impeding  foxp3  
methylation,  and  pushing  the  balance  of  immunity  toward  iTreg-­‐‑mediated  tolerance.  
Whereas  transcription  factors  such  as  NFAT  can  be  activated  within  minutes,  
and  less  than  one  hour  of  TCR  signaling  is  sufficient  to  drive  T  cells  into  the  proliferative  
cycle141,  DNMT1  accumulates  and  methylates  foxp3  over  the  course  of  days.    This  
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mechanistic  and  temporal  segregation  of  epigenetic  control  from  transcription  factor-­‐‑
mediated  control  could  allow  T  cells  to  gauge  the  duration  of  TCR  signaling  over  long  
periods  (which  likely  represents  the  persistence  of  antigen).    Furthermore,  by  
segregating  the  commitment  to  proliferation  from  the  commitment  to  silence  foxp3,  T  
cells  can  make  the  decision  for  clonal  expansion  shortly  upon  antigen  encounter,  but  can  
integrate  signals  over  the  following  days  before  finalizing  their  iTreg  vs.  Th  fate.    This  
dichotomous  commitment  process  may  thus  support  the  adaptive  immune  response’s  
dual  requirement  for  rapidity  of  response  on  the  one  hand,  and  accuracy  of  pathogenic  
discrimination  on  the  other.  In  line  with  this  possibility,  it  is  noteworthy  that  human  
naïve  T  cells  transiently  express  Foxp3  during  priming,  even  when  their  eventual  fate  is  
an  effector  Th  lineage159,160.    In  the  DNMT1-­‐‑centric  view,  this  would  represent  the  early  
activity  of  NFAT/NFkB/AP1  on  a  naïve  T  cell’s  partially-­‐‑methylated  foxp3  promoter,  
which  would  only  be  completely  repressed  by  DNMT1-­‐‑mediated  methylation  after  a  
much  longer  course  of  TCR  signaling.  
Overall,  it  is  a  well-­‐‑appreciated  concept  that  T  cells  interpret  subtle  differences  
between  antigens  and  between  antigens’  contextual  cues  to  enact  their  fate  decision;  and,  
that  it  is  epigenetic  modifications  that  enforce  the  heritage  of  differentiated  T  cells70,161-­‐‑163.    
Our  data  illustrate  a  mechanism  whereby  TCR  signaling  and  environmental  cues  can  
target  the  epigenetic  machinery  directly  in  order  to  instruct  differentiating  T  cells.  
Unlike  most  cell  types,  in  which  differentiation  and  proliferation  are  in  general  mutually  
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exclusive,  T  cells  acquire  their  identities  in  the  midst  of  rapid  proliferation.  It  would  be  
difficult  to  imagine  how  T  cells  could  employ  transcription  factor  activation  as  a  
heritable  mechanism:  first,  in  the  absence  of  ligands,  the  activation  status  of  TCR141  or  
transcription  factors  (e.g.  NFAT164)  can  only  be  maintained  within  the  range  of  minutes  
following  ligand  withdrawal,  and  so  would  be  unlikely  to  preserve  their  activation  state  
between  mother  and  daughter  cells;  second,  the  newly  divided  daughter  cell  makes  brief  
contact  with  APCs  in  vivo165,  which  likely  gives  them  different  antigen  experience  than  
their  mother  cells.  In  contrast,  direct  TCR-­‐‑driven  epigenetic  reprogramming  can  mark  
mother  cells’  antigen  experiences  in  the  genome  during  the  commitment  to  cell  division,  
which  then  keeps  daughter  T  cells  poised  according  to  their  mothers’  lineage  choice.  
These  features  are  also  not  likely  to  be  exclusive  to  the  iTreg  lineage  choice.    The  Th2  
and  Th17  lineages  are  also  antagonized  by  strong  TCR  signal  strength,  and  il-­‐‑4  and  il-­‐‑17  
are  both  expressed  in  a  methylation-­‐‑sensitive  manner13,120-­‐‑122.  Thus,  upon  TCR  activation,  
it  may  be  possible  that  DNMT1  or  another  epigenetic  mechanism  also  controls  master  




5. MeCP2 enforces Foxp3 expression to determine 
nTregs’ resilience to inflammation: A key epigenetic 
regulator controlling Foxp3 maintenance 
The  contents  of  this  dissertation  chapter  have  been  slightly  modified  from  the  
following  manuscript  that  was  current  under  review  at  Immunity.    
Chaoran  Li*,  Shan  Jiang*,  Si-­‐‑Qi  Liu,  Erik  Lykken,  Lin-­‐‑Tao  Zhao,  Jose  Sevilla,  Bo  
Zhu  and  Qi-­‐‑Jing  Li.  (*  equal  contribution).  MeCP2  enforces  Foxp3  expression  to  
determine  natural  regulatory  T  cells’  resilience  to  inflammation.  
5.1 Introduction 
Methyl-­‐‑CpG  binding  protein  2  (MeCP2)  is  an  X-­‐‑chromosome  linked  nuclear  
protein166  that  binds  methylated  DNA167,168,  and  has  been  reported  to  play  bifunctional  
roles  in  regulating  gene  expression169.  As  the  docking  of  MeCP2  can  recruit  Histone  
deacetylases  (HDAC)170  and  DNA  (cytosine-­‐‑5)-­‐‑methyltransferase  1  (DNMT1)171  to  
methylated  CpG  elements,  this  protein  has  traditionally  been  considered  to  be  a  
transcription  repressor.  However,  recent  genome-­‐‑wide  studies  have  revealed  that  
MeCP2  can  also  bind  avidly  to  unmethylated  CpG  DNA  and  facilitate  the  transcription  
of  a  large  proportion  of  genes169,172.  Specifically,  MeCP2  was  shown  to  associate  directly  
with  transcription  activators  such  as  cAMP  responsive  element  binding  protein  1  
(CREB1)  in  promoters,  where  they  synergistically  promote  gene  expression169.  Thus,  the  
current  consensus  is  that,  depending  on  the  genomic  context,  MeCP2  acts  as  either  a  
transcriptional  repressor  or  activator173.  
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Previous  studies  have  centered  almost  exclusively  on  MeCP2’s  role  in  the  central  
nervous  system.  This  is  attributed  to  the  fact  that  loss-­‐‑of-­‐‑function  mutations  in  the  mecp2  
locus  is  the  etiological  cause  of  95%  of  typical  Rett  Syndrome  (RTT)174,175.  RTT  is  a  
devastating  disorder  that  afflicts  1  in  10,000  females  and  whose  symptoms  are  largely  
neurodevelopmental176.  Based  on  the  limited  immunological  studies  on  RTT  patients,  
however,  hints  of  immunological  abnormalities  have  gradually  emerged:  
polymorphisms  within  the  human  mecp2  locus  have  recently  been  associated  with  an  
increased  susceptibility  to  systemic  lupus  erythematosus  (SLE)177,178  and  primary  
Sjögren’s  syndrome  (pSS)179,  suggesting  that  mecp2  gene  mutations  may  also  contribute  
to  the  pathogenesis  of  inflammatory  diseases;  and  a  cohort  study  also  demonstrated  
significantly  elevated  levels  of  IgG  against  food  proteins  in  the  sera  of  RTT  patients180,  
which  may  reflect  the  possibility  of  gut  inflammation  or  breakdown  of  the  intestinal  
barrier;  most  intriguingly,  the  transplantation  of  wild  type  (WT)  bone  marrow  
successfully  arrested  RTT  disease  in  MeCP2  null  mice181.  Nevertheless,  apart  from  these  
correlative  studies,  MeCP2’s  causative  role  in  immune  regulation  remains  largely  
unexplored.  
As  potent  suppressors  of  inflammation,  CD4+  CD25+  regulatory  T  cells  (Tregs)  
are  an  indispensable  T  cell  subset  responsible  for  peripheral  tolerance  and  immune  
homeostasis31.  Foxp3  is  the  master  regulator  of  the  Treg  gene  expression  program,  and  
consequently  Foxp3  mutation  in  both  humans  and  mice  is  sufficient  to  trigger  the  
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development  of  severe  lymphoproliferative  autoimmune  disorders124,182-­‐‑187.  Foxp3  is  
essential  both  for  driving  natural  Treg  (nTreg)  development  within  the  thymus,  and  for  
maintaining  lineage  identity  and  suppressive  function  of  peripheral  Tregs:  deletion  of  
Foxp3  specifically  in  post-­‐‑thymic  mature  Tregs  completely  abolishes  their  ability  to  
suppress  the  onset  of  effector  T  cell-­‐‑mediated  autoimmunity188.  Extensive  studies  on  the  
molecular  mechanisms  regulating  Foxp3  expression5  have  revealed  that  many  
transcription  factors,  including  NFAT39,73,  AP-­‐‑173,  Smad339,  STAT536,189,  NF-­‐‑kB131,  Ets-­‐‑1190,  
GATA378,  Foxo1/3191  and  CREB172,    bind  directly  to  the  foxp3  locus  to  promote  its  
expression  during  Treg  differentiation,  and  the  Foxp3/Runx1/CBFb  protein  complex  has  
recently  been  suggested  to  confer  the  heritable  maintenance  of  Foxp3  expression  
through  an  autoregulatory  loop75,192.    
In  addition  to  these  “trans”  regulatory  factors,  the  expression  of  Foxp3  is  also  
tightly  controlled  at  the  epigenetic  level193.    Besides  the  promoter,  three  “cis”-­‐‑regulatory  
regions  including  three  Conserved  Non-­‐‑Coding  sequences  (CNS)  within  the  foxp3  locus  
are  essential  in  regulating  Foxp3’s  expression.  Interestingly,  genetic  ablation  of  these  
individual  elements  revealed  a  division  of  labour  in  gene  regulation75:  for  instance,  
CNS1,  which  contains  the  NFAT-­‐‑Smad3  binding  sites39,  is  critical  for  the  peripheral  
induction  of  Foxp3  expression  in  conventional  T  cells  that  drives  inducible  Treg  
differentiation;  on  the  other  hand,  CNS2  is  specifically  required  for  the  maintenance  of  
Foxp3  expression  in  daughter  cells  during  nTreg  cell  division.    Of  note,  the  CNS2  
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genomic  region  is  composed  of  multiple  highly  conserved  CpG  islands72,  which  suggests  
that  the  maintenance  of  Foxp3  expression  is  potentially  enforced  by  CpG-­‐‑associated  
epigenetic  regulators.    As  MeCP2  is  a  CpG  island-­‐‑binding  protein  and  known  epigenetic  
regulator,  we  considered  that  MeCP2  might  potentially  play  some  role  in  orchestrating  
foxp3  gene  transcription.  
In  this  study,  using  genetic  approaches  that  delete  MeCP2  specifically  in  Treg  
cells,  we  examined  the  role  of  MeCP2  in  regulating  Treg  homeostasis.  We  find  that,  
although  MeCP2  is  dispensable  for  the  initial  induction  of  Foxp3  expression  during  
thymus-­‐‑derived  nTreg  development  and  in  vitro–induced  Treg  (iTreg)  differentiation,  it  
is  essential  for  maintaining  the  stable  expression  of  Foxp3  and  the  lineage  identity  of  
mature  nTregs  during  inflammation.  
  
5.2 Results 
5.2.1 MeCP2 ablation does not affect iTreg differentiation or nTreg 
development 
While  dissecting  the  role  of  the  miRNA  cluster  miR-­‐‑17-­‐‑92  in  regulating  T  cells’  
effector  response,  we  biochemically  identified  MeCP2  as  a  novel  target  of  miR-­‐‑19b  (data  
not  shown).  miR-­‐‑19b  promotes  CD4+  T  cell  effector  responses,  in  part  through  
suppressing  the  differentiation  of  inducible  regulatory  T  cells  (iTregs)54.    This  led  to  our  
hypothesis  that  miR-­‐‑19b  blocks  iTreg  conversion  by  dampening  the  expression  of  
MeCP2,  a  foxp3  locus-­‐‑associated  protein  (data  not  shown  and  Lal  et  al194).  To  determine  
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this  functional  linkage,  we  initially  crossed  mice  carrying  conditional  mecp2  alleles  with  
mice  expressing  the  Cre  recombinase  transgene  under  the  control  of  the  proximal  Lck  
promoter.  In  this  way,  we  attained  T  cell-­‐‑specific  deletion  of  the  mecp2  gene  as  early  as  
the  late  DN2  stage.  Contradictory  to  our  initial  hypothesis,  when  CD4+CD25-­‐‑  
conventional  T  cells  from  MeCP2f/y  Lck-­‐‑Cre  mice  or  their  wild  type  littermates  were  
purified  by  FACS  sorting  and  cultured  under  various  iTreg  skewing  conditions,  we  
found  no  significant  differences  in  the  generation  of  Foxp3+  iTreg  cells  (Figure  20A-­‐‑C).  
This  indicated  that,  at  least  in  vitro,  it  is  unlikely  that  a  functional  linkage  exists  between  
miR-­‐‑19b  and  MeCP2  during  iTreg  differentiation,  and  that  MeCP2  is  dispensable  for  the  
de  novo  expression  of  Foxp3  in  conventional  CD4+  T  cells.  Furthermore,  the  thymic  nTreg  
development  was  entirely  intact  in  the  MeCP2f/y  Lck-­‐‑Cre  animals  (Figure  20D&E).  
5.2.2 Young adult mice with Treg-specific MeCP2 deletion develop 
spontaneous T cell activation 
To  examine  the  role  of  MeCP2  specifically  in  mature  nTregs,  we  crossed  mice  
carrying  conditional  mecp2  alleles  with  BAC  transgenic  mice  expressing  Cre  and  GFP  
proteins  under  the  control  of  the  foxp3  promoter95.  This  allows  us  to  specifically  ablate  
the  mecp2  gene  after  T  cells  establish  their  commitment  into  the  Treg  lineage  (Figure  
21A).  The  ablation  of  Mecp2  protein  did  not  change  the  relative  size  of  CD25+Foxp3+  
population  within  the  pool  of  CD4+  T  cells  (Figure  21B).  However,  in  mice  as  young  as  8  
to  10  weeks  of  age,  we  observed  a  significant  increase  in  the  total  number  of  cells  in  the  
lymph  nodes  from  MeCP2f/y  Foxp3-­‐‑GFP-­‐‑Cre  mice  (Figure  21C).  In  addition,  the  
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proportion  of  CD4+  T  cells  adopting  an  activated  phenotype  (CD44hi  CD62Llo)  in  the  
spleen  and  lymph  nodes  of  MeCP2f/y  Foxp3-­‐‑GFP-­‐‑Cre  mice  was  significantly  increased  
(Figure  21D&E).  We  then  examined  the  cytokine  production  of  the  CD4+Foxp3-­‐‑  T  cells  in  
these  mice:    Treg-­‐‑specific  deletion  of  MeCP2  resulted  in  significantly  elevated  levels  of  
IL-­‐‑17  producing  conventional  CD4+  T  cells  (Figure  21F&G).  When  these  mice  were  aged  
for  more  than  6  months,  while  there  were  no  immunopathologies  of  the  kidney,  liver  or  
lung  (data  not  shown),  MeCP2f/y  Foxp3-­‐‑GFP-­‐‑Cre  mice  frequently  developed  skin  lesions  
near  the  neck  area  and  further  histological  analysis  unveiled  extensive  inflammatory  
infiltration  (Figure  22).    Collectively,  these  data  suggest  that  MeCP2  expression  in  Tregs  
is  required  to  enforce  immune  homeostasis  in  vivo.  
5.2.3 MeCP2-deficient nTregs fail to suppress effector T cell-mediated 
colitis in vivo 
Although  immune  activation  in  MeCP2f/y  Foxp3-­‐‑GFP-­‐‑Cre  mice  is  apparent,  this  
inflammation  is  relatively  mild  compared  to  the  severe  lymphoproliferation  in  Treg  
depleted  mice195.  In  agreement  with  this,  MeCP2f/y  Foxp3-­‐‑GFP-­‐‑Cre  mice  and  their  wild  
type  littermate  controls  had  comparable  percentages  of  CD25+Foxp3+  CD4+  T  cells  in  the  
peripheral  lymphoid  organs  as  well  as  in  the  thymus  (Figure  21B).  However,  loss  of  
MeCP2-­‐‑deficient  Tregs  over  time  might  be  obscured  by  the  inflammation-­‐‑induced  
compensatory  expansion  of  Tregs38,78,  or  the  continuous  Treg  output  from  the  thymus.  
To  rule  out  these  possibilities,  we  examined  the  functionality  of  MeCP2-­‐‑deficient  Tregs  
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using  a  classical  T  cell  adoptive  transfer  model  for  the  induction  of  systemic  colitis  in  
lymphopenic  hosts.  
We  sorted  Thy1.2+  CD25+GFP+  Treg  cells  from  MeCP2f/y  Foxp3-­‐‑GFP-­‐‑Cre  or  
MeCP2x/y  Foxp3-­‐‑GFP-­‐‑Cre  mice,  mixed  them  with  wild  type  Thy1.1+  naïve  conventional  
CD4+  T  cells,  and  transferred  them  into  RAG2-­‐‑/-­‐‑  recipients  (Fig.  23A).  For  lineage  tracing,  
Tregs  (Thy1.2+)  and  conventional  CD4+  T  cells  (Thy1.1+)  were  labelled  with  different  
congenic  markers.  As  expected,  WT  Tregs  were  capable  of  mitigating  the  development  
of  severe  colitis  in  recipient  mice,  monitored  by  both  weight  changes  and  histological  
analysis.  In  contrast,  mice  receiving  co-­‐‑transfers  of  conventional  T  cells  and  MeCP2-­‐‑
deficient  Tregs  manifested  more  severe  colitis  symptoms  characterized  by  dramatic  
weight  loss  (Fig.  23B),  massive  leukocyte  infiltration,  and  severe  mucosal  tissue  damage  
in  the  colon  (Fig.  23C&D).  Accompanying  this  inflammation,  the  numbers  of  total  
splenocytes  (Fig.  23E)  and,  more  specifically,  Thy1.1+  effector  T  cells  (Fig.  23F),  were  
significantly  elevated  in  recipients  co-­‐‑transferred  with  MeCP2-­‐‑deficient  Tregs.  
Furthermore,  upon  MeCP2  deletion,  although  the  number  of  Thy1.2+  cells  was  
comparable  (Fig.  23H),  we  observed  a  significant  reduction  of  the  percentage  of  Foxp3+  
Tregs  in  the  Thy1.2+  population  and  dampened  Foxp3  expression  at  the  individual  cell  
level  (Fig.  23G).  Consequently,  the  frequency  of  inflammatory  cytokine-­‐‑producing  cells  
of  conventional  T  cell  origin  (Thy1.1+)  was  significantly  increased  (Fig.  23I).  Overall,  
    
127  
these  data  suggest  that  MeCP2  expression  in  Tregs  critically  supports  their  ability  to  
suppress  T  effector  cell-­‐‑mediated  inflammation  in  vivo.  
5.2.4 MeCP2 deficient Tregs are competent in suppressing effector T 
cell activation during short-term culture 
At  least  two  potential  mechanisms  may  account  for  the  failure  of  MeCP2  
deficient  nTregs  in  suppressing  inflammation:  firstly,  either  independent  of  or  in  
conjunction  with  Foxp3,  MeCP2  acts  as  a  master  regulator  controlling  the  expression  of  
effector  molecules  that  directly  execute  immune  suppression;  alternatively,  MeCP2  may  
be  essential  in  maintaining  Foxp3  expression  to  enforce  the  nTreg  lineage  identity,  
specifically  under  inflammatory  conditions.  We  first  examined  whether  MeCP2  
modulates  effector  molecule  expression  with  a  standard  in  vitro  suppression  assay.  
Thy1.2+  MeCP2-­‐‑deficient  nTregs  were  co-­‐‑cultured  with  Thy1.1+  wild  type  conventional  T  
cells  at  various  ratios,  and  stimulated  with  soluble  anti-­‐‑CD3/CD28  in  the  presence  of  
antigen  presenting  cells  for  a  short-­‐‑term  (3  days)  in  vitro  (Figure  24A).  Under  these  
conditions,  the  absence  of  MeCP2  did  not  affect  the  viability  of  Tregs  (Figure  24B),  
expression  of  Foxp3  (Figure  24C),  or  ratio  of  conversion  from  regulatory  to  effector  T  cell  
(Figure  24D).  Using  effector  T  cells  proliferation,  as  well  as  the  IL-­‐‑2  and  IFN-­‐‑γ  cytokine  
production  as  functional  readouts  of  Treg-­‐‑mediated  immune  inhibition,  we  found  no  
significant  differences  in  the  suppressive  capacities  of  WT  and  MeCP2  deficient  nTregs  
(Figure  24E&F).  Yet,  under  this  lineage-­‐‑unbiased  condition,  we  consistently  observe  a  
moderate,  but  reproducible,  increase  in  IL-­‐‑17  production  from  conventional  T  cells  when  
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co-­‐‑cultured  with  MeCP2-­‐‑deficient  Tregs  (Figure  24G),  which  mirrored  the  enhanced  IL-­‐‑
17  production  by  conventional  T  cells  in  intact  MeCP2f/y  Foxp3-­‐‑Cre-­‐‑GFP  mice  (Figure  
21F&G).  
At  the  end  of  these  mixed  cultures,  we  sorted  the  remaining  viable  Thy1.2+  Tregs  
to  further  analyze  their  expression  of  a  panel  of  molecules  known  to  be  crucial  for  Tregs’  
suppressive  function.  This  panel  included  the  effector  molecules90  CD25,  IL-­‐‑10,  TGFβ,  
perforin,  granzyme  B,  CTLA4,  LAG3,  CD39,  GITR,  IL-­‐‑35;  as  well  as  their  upstream  
regulators  Blimp1196,  IRF4196  (for  Il10)  and  Foxo  transcription  factors  (for  ctla4)197.    
Consistent  with  comparable  functional  outcomes,  we  found  that  at  the  transcriptional  
level,  the  suppressive  machinery  of  MeCP2-­‐‑deficient  Tregs  was  largely  intact  (Figure  
24H).  
5.2.5 MeCP2 is critical for maintaining Foxp3 expression in nTregs 
during inflammation in vitro 
We  next  examined  the  alternative  hypothesis  that  MeCP2  is  essential  for  the  
long-­‐‑term  maintenance  of  Foxp3  expression  during  inflammation.  Yang  et  al.  previously  
showed  that  in  vitro  treatment  of  nTregs  with  inflammatory  cytokines,  such  as  IL-­‐‑6,  
causes  a  gradual  loss  of  Foxp3  expression42.  To  determine  whether  MeCP2  ablation  
facilitated  this  process,  we  stimulated  MeCP2-­‐‑sufficient  or  -­‐‑deficient  nTregs  with  anti-­‐‑
CD3/28,  IL-­‐‑2,  and  IL-­‐‑6.  As  a  non-­‐‑inflammatory  control,  these  nTregs  were  also  cultured  
with  only  anti-­‐‑CD3/28  and  IL-­‐‑2.  We  found  that  without  IL-­‐‑6,  both  wild  type  and  MeCP2-­‐‑
deficient  Tregs  could  maintain  Foxp3  expression.  However,  when  IL-­‐‑6  was  added  into  
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the  culture,  MeCP2  deficient  nTregs  demonstrated  an  accelerated  loss  of  Foxp3  
expression,  both  at  the  protein  (Figure  25A)  and  mRNA  level  (Figure  25E):  while  no  
significant  difference  was  evident  on  day  3,  extending  the  cultures  to  five  and  seven  
days  showed  that  the  percentage  of  MeCP2-­‐‑deficient  Treg  cells  that  maintained  CD25  
and  Foxp3  expression  was  merely  half  of  that  seen  in  the  WT  cells  (Figure  25A).  We  also  
monitored  the  survival  and  proliferation  of  Tregs  to  exclude  the  possibility  that  this  
decrease  in  percentage  was  caused  by  altered  cell  death  or  proliferation  of  MeCP2-­‐‑
deficient  Tregs  (Figure  25B&C).  In  addition,  accompanying  the  accelerated  loss  of  Foxp3  
expression,  IL-­‐‑17  production  from  MeCP2-­‐‑deficient  Tregs  was  significantly  elevated  
(Figure  25D).  This  elevated  Treg-­‐‑to-­‐‑effector  conversion  supports  our  hypothesis  that  
MeCP2  preserves  the  characteristics  of  Tregs  in  response  to  IL-­‐‑6-­‐‑mediated  foxp3  
silencing  in  vitro.  
Since  Foxp3  is  required  to  enforce  the  transcriptional  program  of  Tregs71,  we  also  
assessed  whether  the  expression  of  Treg  signature  genes  was  disrupted  by  MeCP2  
deficiency  in  this  inflammatory  setting.  As  expected,  accompanying  the  significant  
reduction  of  foxp3  transcripts  in  MeCP2-­‐‑deficient  Tregs,  many  Treg  signature  genes  that  
regulate  Treg  function  were  downregulated  (Figure  25E).  In  contrast,  genes  that  have  
been  suggested  to  act  in  parallel  with  Foxp3  to  control  Treg  function,  such  as  Foxo1  
198and  Foxo3,  were  either  unchanged  or  even  slightly  elevated  (Figure  25E).  
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Next,  we  expanded  the  panel  of  inflammatory  stimulation  to  other  lineage  
specific  cytokines  such  as  IL-­‐‑12,  IFN-­‐‑γ  (for  Th1  responses)  and  IL-­‐‑4  (for  Th2  responses).  
In  general,  we  observed  that  these  cytokines  were  much  weaker  modifiers  of  Foxp3  
expression  (Figure  26).  Nevertheless,  although  we  did  not  detect  overt  differences  in  
Foxp3  expression  after  5  days  of  cytokine  stimulations,  we  found  that,  on  day  7,  Th1  and  
Th2  cytokines  also  induced  a  more  severe  reduction  of  CD25  and  Foxp3  expression  in  
Tregs  with  MeCP2  ablation  (Figure  26).    These  data  suggested  that,  under  a  broad  range  
of  inflammatory  conditions,  MeCP2  in  Treg  cells  may  be  universally  involved  in  
protecting  Foxp3  expression  in  vitro.  
5.2.6 MeCP2 is critical for maintaining Foxp3 expression in nTregs 
during inflammation in vivo 
We  took  a  similar  adoptive  transfer  approach  to  examine  the  role  of  MeCP2  in  
sustaining  Foxp3  expression  in  vivo.  We  sorted  Thy1.2+  CD25+GFP+  nTreg  cells  from  
MeCP2f/y  Foxp3-­‐‑GFP-­‐‑Cre  or  MeCP2x/y  Foxp3-­‐‑GFP-­‐‑Cre  mice,  and  mixed  them  with  
Thy1.1+  CD4+CD25-­‐‑  Tcon  cells  at  a  1:2  ratio  before  co-­‐‑transfer  into  RAG2-­‐‑/-­‐‑  mice  (Figure  
27A).  A  1:2  ratio  of  nTreg:Tcon  allowed  us  to  recover  enough  Thy1.2+  T  cells  for  reliable  
endpoint  analysis  after  a  long  term  transplantation.  Three  weeks  after  transfer,  the  mice  
were  sacrificed  and  T  cells  of  the  Thy1.2+  nTreg  origin  were  analyzed.  In  mice  carrying  
WT  nTreg,  a  majority  of  the  Thy1.2+  population  remained  Foxp3+  (Figure  27B);  in  
contrast,  the  MeCP2-­‐‑deficient  Tregs  exhibited  a  dramatic  loss  in  Foxp3  expression  
(Figure  27B).  A  significant  portion  of  these  ex-­‐‑Tregs  were  converted  into  IL-­‐‑17-­‐‑  and/or  
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IFN-­‐‑γ-­‐‑producing  effector  cells  (Figure  27C&D).    Coordinately,  conventional  T  cells  co-­‐‑
transferred  with  MeCP2-­‐‑deficient  Tregs  also  showed  augmented  proinflammatory  
cytokine  production  (Figure  27E).    
Using  two  models  of  autoimmunity,  we  further  examined  the  role  of  MeCP2  in  
sustaining  Foxp3  expression  during  inflammation  in  intact  MeCP2f/f  or  f/y  Foxp3-­‐‑GFP-­‐‑Cre  
mice.  Non-­‐‑obese  diabetic  (NOD)  mice  are  susceptible  to  developing  autoimmune  
insulin-­‐‑dependent  diabetes  mellitus,  and,  the  pancreatic  autoimmune  lesion  in  these  
mice  is  associated  with  diminishment  of  local  Tregs199,200.  Taking  a  Speed  Congenic  
approach,  we  crossed  conditional  MeCP2  allele  and  Foxp3-­‐‑GFP-­‐‑Cre  BAC  transgene  to  
mice  on  the  NOD  background.  In  aged  diabetic  mice,  the  percentage  of  Tregs  was  
comparable  between  WT  and  MeCP2f/f  Foxp3-­‐‑GFP-­‐‑Cre  NOD  mice  (Figure  27F).  
However  at  the  single  cell  level,  MeCP2-­‐‑deficient  NOD  Tregs  exhibited  a  moderate  but  
consistent  reduction  in  Foxp3  expression  (Figure  27F).  Coordinately,  CD4+  T  cells  from  
pancreatic  draining  lymph  nodes  and  spleens  of  MeCP2f/f  Foxp3-­‐‑GFP-­‐‑Cre  NOD  mice  
produced  significantly  elevated  levels  of  IFN-­‐‑γ  (Figure  27G&H).  We  next  examined  the  
role  of  MeCP2  in  Treg  maintenance  during  experimental  autoimmune  encephalomyelitis  
(EAE),  which  is  characterized  by  strong  Th17  and  Th1-­‐‑mediated  inflammation  in  the  
central  nervous  system.  We  found  that  upon  disease  induction,  although  the  
percentages  of  Tregs  in  the  spinal  cord  were  comparable  between  WT  and  MeCP2f/y  
Foxp3-­‐‑GFP-­‐‑Cre  mice  (KO)  mice  (data  not  shown),  Foxp3  expression  in  individual  
    
132  
MeCP2-­‐‑deficient  Tregs  was  consistently  reduced  (Figure  27J).  Coordinately,  MeCP2f/y  
Foxp3-­‐‑GFP-­‐‑Cre  mice  exhibited  accelerated  disease  onset,  more  severe  symptoms  (Figure  
27I),  as  well  as  enhanced  pro-­‐‑inflammatory  cytokine  production  (in  particular,  an  
increased  IL-­‐‑17+IFN-­‐‑γ+  population)  from  effector  T  cells  in  the  spinal  cords  (Figure  27K).  
Taken  together,  these  data  suggest  that  MeCP2  is  critical  to  maintain  Foxp3  expression  
in  Tregs  during  inflammation  in  vivo.  
5.2.7 Restoring Foxp3 expression sufficiently rescues the 
competence of MeCP2-deficient Tregs to suppress inflammation in 
vivo 
Recent  studies  demonstrated  that,  besides  the  expression  of  Foxp3,  
epigenetically,  nTreg  development  also  requires  a  Treg-­‐‑specific  CpG  
hypomethylation201.  In  our  case,  the  incompetence  of  MeCP2-­‐‑deficient  Tregs  in  
suppressing  inflammation  could  also  be  influenced  by  certain  undetected  epigenetic  
modifications.  To  further  determine  causality  between  MeCP2,  Foxp3,  and  immune  
protection,  we  transduced  MeCP2-­‐‑deficient  Tregs  with  retrovirus  that  ectopically  
expresses  Foxp3  transcripts,  and  then  examined  their  ability  to  suppress  systemic  colitis  
in  the  aforementioned  adoptive  transfer  model  (Figure  28A).  Five  weeks  after  the  initial  
transfer,  we  confirmed  that  the  retroviral  expression  restored  Foxp3  protein  expression  
in  MeCP2-­‐‑deficient  Tregs  to  that  of  wild  type  levels  (Figure  28B).  Coordinately,  we  
observed  a  complete  rescue  of  Treg  identity  at  the  population  level  (Figure  28C),  and,  
more  importantly,  a  complete  rescue  of  their  competence  to  suppress  the  colitis  
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development,  as  reflected  by  the  maintained  body  weight  (Figure  28D)  and  diminished  
colon  pathology  (Figure  28E&F).    Taken  together,  these  data  indicated  that  the  critical  
role  of  MeCP2  in  immune  protection  is  to  maintain  a  stable  Foxp3  expression.  
5.2.8 During inflammation, defective Foxp3 maintenance in MeCP2-
deficient Tregs in is not caused by accelerated proliferation or 
enhanced inflammatory cytokine signaling 
Our  data  indicated  that  MeCP2  was  important  for  bolstering  foxp3  expression  
specifically  in  response  to  inflammation-­‐‑induced  transcriptional  silencing,  but  not  for  de  
novo  transcription  of  foxp3  per  se.  It  was  previously  reported  that  foxp3  silencing  may  be  
attributed  to  TCR-­‐‑induced  Treg  proliferation75.  To  investigate  the  molecular  mechanism  
by  which  MeCP2  sustains  Foxp3  expression,  we  first  examined  whether  the  MeCP2-­‐‑
supported  Foxp3  expression  depends  on  T  cell  cycling.  Using  CFSE  dilution  to  
distinguish  cell  generations,  we  found  that  the  loss  of  Foxp3  expression  does  occur  with  
a  higher  incidence  in  Tregs  that  have  undergone  extensive  cell  divisions.  However,  this  
occurred  in  both  wild  type  and  MeCP2-­‐‑deficient  groups  (Figure  29A&B).  In  this  assay,  
we  also  excluded  the  possibility  that  the  enhanced  loss  of  Foxp3  expression  in  MeCP2-­‐‑
deficient  Tregs  was  a  result  of  accelerated  Treg  proliferation:  the  proliferative  capacity  
between  wild  type  and  MeCP2-­‐‑deficient  Tregs  were  almost  identical  (Figure  29A);  and  
in  each  generation,  MeCP2-­‐‑deficient  Tregs  displayed  a  more  pronounced  reduction  in  
Foxp3  expression  (Figure  29B).  Furthermore,  it  has  been  recently  shown  that,  during  the  
development  of  acute  murine  graft-­‐‑versus-­‐‑host  disease,  STAT3  activation  downstream  
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of  IL-­‐‑6  stimulation  destabilizes  Foxp3  expression  in  Tregs202.  We  examined  whether  the  
deletion  of  mecp2  gene  enhances  IL-­‐‑6  signalling.  Again,  in  MeCP2-­‐‑deficient  Tregs,  as  
reflected  by  Tyr705  phosphorylation,  there  were  no  obvious  alterations  in  STAT3  
activation  in  response  to  IL-­‐‑6  stimulation  (Figure  29C).  
5.2.9 MeCP2 opposes foxp3 gene silencing by recruiting CREB1 and 
enforcing local histone acetylation in the foxp3 CNS2 region 
Among  the  identified  cis-­‐‑elements  known  to  be  important  for  foxp3  gene  
regulation,  the  promoter  and  CNS2  region  contain  CpG  islands72  that  could  potentially  
recruit  MeCP2.  Using  chromatin  immunoprecipitation  (ChIP),  we  examined  the  
interaction  between  MeCP2  and  cis-­‐‑elements  under  different  conditions.  In  freshly  
isolated  WT  nTreg  cells,  CpG  islands  within  the  promoter  and  CNS2  regions  of  foxp3  
were  almost  completely  unmethylated  (Figure  30A&B).    Somewhat  surprisingly,  these  
regions  were  still  partially  occupied  by  MeCP2  protein,  suggesting  that  MeCP2  can  bind  
to  unmethylated  DNA  elements  in  both  regions  (Figure  31A).  However,  in  the  presence  
of  TCR  stimulation  and  inflammatory  cytokines,  although  the  DNA  sequence  within  the  
foxp3  promoter  remained  largely  unmethylated,  methylation  was  rapidly  initiated  across  
the  entire  CNS2  region  (Figure  31B).  Accordingly,  MeCP2  protein  was  preferentially  
recruited  to  and  accumulated  within  the  CpG-­‐‑methylated  CNS2  region  (Figure  31A).  
To  determine  the  functional  importance  of  inflammation-­‐‑induced  MeCP2  
recruitment  to  the  foxp3  locus,  we  first  examined  the  status  of  DNA  CpG  methylation  in  
freshly  isolated  MeCP2-­‐‑deficient  nTregs.  The  loss  of  MeCP2  resulted  in  a  comparable,  or  
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even  a  modest  reduction,  in  DNA  methylation  at  both  the  promoter  and  CNS2  region  
(Figure  30).  Therefore,  MeCP2  is  not  likely  to  be  responsible  for  foxp3  methylation,  and,  
methylation  itself  cannot  explain  the  protective  effect  of  MeCP2  on  foxp3  gene  
expression.  To  identify  a  possible  positive  gene  regulatory  function  for  MeCP2,  we  next  
scanned  the  status  of  histone  H3  acetylation—a  known  mediator  of  chromatin  
accessibility—in  all  regulatory  regions  of  the  foxp3  gene.  Under  noninflammatory  
conditions,  the  ablation  of  MeCP2  did  not  affect  H3  acetylation  in  the  promoter,  CNS1  
and  CNS3  region,  but  reduced  H3  acetylation  in  the  CNS2  region  by  43%  (Figure  31C).    
When  the  MeCP2-­‐‑deficient  Tregs  were  stimulated  with  anti-­‐‑CD3/28  and  inflammatory  
cytokines,  the  H3  acetylation  defect  in  the  CNS2  region  was  even  more  drastic,  reaching  
a  mere  18%  of  wild  type  levels  (Figure  31E,  DMSO  panel).    Thus  it  seemed  likely  that  
MeCP2  recruitment  to  the  CNS2  region  might  be  important  for  sustaining  chromatin  
accessibility  via  H3  histone  acetylation,  and  that  inflammation-­‐‑induced  CNS2  
methylation  might  specifically  recruit  MeCP2  to  counteract  methylation-­‐‑mediated  
chromatin  silencing.  
Consistent  with  our  data  from  the  MeCP2  ChIP,  mice  with  a  knock-­‐‑in  deletion  of  
foxp3’s  CNS2  demonstrated  that  CNS2  is  primarily  responsible  for  the  maintenance  of  
Foxp3  transcription,  in  contrast  to  its  initial  induction75.  Various  transcription  factors,  
including  STAT5,  NF-­‐‑kB,  Ets-­‐‑1,  GATA3,  Foxo1/3,  the  Foxp3/Runx/CBFb  complex  and  
CREB1  have  been  identified  to  operate  within  this  region5.  Among  these  transcription  
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factors,  CREB1  forms  a  histone  acetyltransferase  complex  with  CBP/p300,  and  is  also  
known  to  partner  with  MeCP2  to  synergistically  activate  the  transcription  of  
somatostatin  (Sst)  in  neurons169.  We  therefore  hypothesized  that,  in  nTregs  exposed  to  
inflammatory  stimuli,  MeCP2-­‐‑mediated  protection  of  foxp3  expression  might  also  
depend  on  CREB1.  To  this  end,  we  examined  the  binding  of  CREB1  to  foxp3  regulatory  
elements  under  inflammatory  stimuli  in  the  presence  or  absence  of  MeCP2.  CREB1  
expression  levels  were  similar  between  wild  type  and  MeCP2-­‐‑deficient  Tregs  (data  not  
shown),  and  CREB1  bound  avidly  to  the  foxp3  CNS2  in  wild  type  Tregs;  however,  this  
binding  was  completely  abolished  in  the  absence  of  MeCP2  (Figure  31D).  Consistent  
with  a  possible  role  for  CREB1  in  MeCP2-­‐‑dependent  histone  accessibility,  we  observed  
that  H3  acetylation  within  the  CNS2  region  was  reduced  by  5.6-­‐‑fold  in  the  MeCP2-­‐‑
ablated  Tregs.  Furthermore,  when  CREB1  activation  was  blocked  with  the  PKA  
pathway-­‐‑specific  inhibitor  H89203,  the  MeCP2-­‐‑dependent  H3  acetylation  of  CNS2  was  
largely  abrogated  (Figure  31E).  Taken  together,  these  results  suggest  that  at  the  foxp3  
locus,  recruitment  of  the  CREB1  transcription  factor/acetyltransferase  complex  is  
MeCP2-­‐‑dependent,  and  that  epigenetic  regulation  enacted  by  MeCP2  in  response  to  
inflammation  is  mediated  through  CREB1.  
Finally,  to  determine  whether  MeCP2-­‐‑mediated  epigenetic  modulation  at  the  
CNS2  region  functionally  impacts  foxp3  gene  transcription,  luciferase  reporter  constructs  
containing  either  the  foxp3  promoter  alone,  or  the  foxp3  promoter  together  with  the  
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CNS2  region  were  transfected  into  Jurkat  T  cells  as  described  previously78.  MeCP2  
siRNA  was  co-­‐‑transfected  to  assess  the  role  of  MeCP2  in  regulating  CNS2  activity.  
Transfected  Jurkat  T  cells  were  then  treated  with  Phorbol  12,13-­‐‑dibutyrate  (PdBU)  plus  
ionomycin  to  mimic  TCR  activation.  In  agreement  with  its  previously  reported  enhancer  
activity,  the  presence  of  the  CNS2  region  significantly  boosted  TCR-­‐‑induced  luciferase  
reporter  activity.  When  MeCP2  was  silenced  to  20%  of  its  normal  expression  level  (insert  
in  Figure  31F),  foxp3  promoter  activity  was  not  affected,  but  we  observed  a  significant  
reduction  in  CNS2-­‐‑dependent  transcription  (Figure  31F).  Therefore,  we  conclude  that  
MeCP2-­‐‑dependent  chromatin  remodeling  specifically  at  the  CNS2  region  is  an  
important  contributor  to  foxp3  expression,  especially  in  the  face  of  inflammatory  signals  




Figure  20:  MeCP2  ablation  does  not  affect  iTreg  differentiation  and  nTreg  
development.  
(A-­‐‑C)  CD4+CD25-­‐‑  conventional  T  cells  were  sorted  from  the  lymph  nodes  and  
spleens  of  MeCP2f/y  Lck-­‐‑Cre  mice  or  their  wild  type  littermates  and  cultured  under  iTreg  
differentiation  conditions  for  5  days  (1ug/ml  anti-­‐‑CD3  &  anti-­‐‑CD28,  0.1  -­‐‑1.0  ng/ml  
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recombinant  human  TGFβ  (Peprotech),  50U/ml  recombinant  mouse  IL-­‐‑2  (Peprotech),  10  
µμg/ml  anti-­‐‑IL-­‐‑4  (11B11),  10  µμg/ml  anti-­‐‑IFN-­‐‑γ  (XMG1.2),  and  10  µμg/ml  anti-­‐‑IL-­‐‑6  (BD)).  
The  percentage  of  Treg  cells  was  measured  by  CD25  and  Foxp3  staining.  (A)  Gating  of  
CD4+CD25-­‐‑  conventional  T  cells  and  CD4+CD25+  Tregs  during  sorting  and  their  Foxp3  
expression.  (B)  Representative  FACS  plots  showing  the  percentage  of  differentiated  
iTregs  as  measured  by  CD25  and  Foxp3  staining.  (C)  Summary  of  iTreg  differentiation  
showing  means  ±  SEM  of  three  independent  experiments.  (D-­‐‑E)  Percentage  of  
CD25+Foxp3+  Tregs  in  the  thymi  and  peripheral  lymphoid  organs  of  MeCP2f/y  Lck-­‐‑Cre  
mice  or  their  wild  type  littermates.  Bar  graph  shows  means±  SEM  of  data  from  three  




Figure  21:  Mild  immune  activation  in  young  adult  MeCP2f/y  Foxp3-­‐‑GFP-­‐‑Cre  
mice.  
(A)  MeCP2  expression  was  examined  by  western  blot  in  sorted  CD4+CD25-­‐‑GFP-­‐‑  
Tcon  and  CD4+CD25+GFP+  Treg  cells  from  the  spleen  and  lymph  nodes  (LNs)  of  
MeCP2x/y  Foxp3-­‐‑GFP-­‐‑Cre  (FGC)  or  MeCP2f/y  Foxp3-­‐‑GFP-­‐‑Cre  (FGC)  mice.  (B-­‐‑G)  
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Lymphocytes  from  the  thymus,  LNs,  and  spleen  of  8-­‐‑10  week  old  MeCP2f/y  Foxp3-­‐‑GFP-­‐‑
Cre  or  littermate  control  mice  were  isolated  for  enumeration  of  cell  numbers  and  flow  
cytometry  analysis.  Data  shows  means  ±  SEM  (n=5).  (B)  Percentage  of  CD25+Foxp3+  cells  
in  CD4+  T  cells.  (C)  Absolute  cell  numbers  in  the  LNs  and  spleen.  (D&E)  Expression  of  
CD44  and  CD62L  on  the  surface  of  CD4+Foxp3-­‐‑  T  cells  from  LNs  and  spleens.  (F&G)  
Lymphocytes  isolated  freshly  ex  vivo  were  stained  for  intracellular  cytokines  after  4  
hours  of  stimulation  with  0.9nM  PdBU  and  0.5µμg/mL  ionomycin  in  the  presence  of  




Figure  22:  Aged  MeCP2f/y  Foxp3-­‐‑GFP-­‐‑Cre  mice  frequently  develop  skin  lesions  
near  the  neck  area.  
Histological  analysis  of  aged  MeCP2f/y  Foxp3-­‐‑GFP-­‐‑Cre  mice.  Skin  from  the  neck  
area  of  26-­‐‑week  old  MeCP2f/y  Foxp3-­‐‑GFP-­‐‑Cre  mice  or  their  wild  type  littermates  was  
removed,  fixed,  and  stained  with  hematoxylin  and  eosin.  Images  shown  represent  at  




Figure  23:  MeCP2-­‐‑deficient  Tregs  are  impaired  in  suppressing  effector  T  cell  
mediated  colitis.  
(A-­‐‑I)  5.0×105  CD25-­‐‑  CD45RBhi  CD4+  T  cells  from  wild  type  Thy1.1+  B6  mice  (WT  
Tcon)  were  sorted  and  mixed  with  2.0×104  Thy1.2+  CD4+CD25+  GFP+  Tregs  from  MeCP2f/y  
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Foxp3-­‐‑GFP-­‐‑Cre  (n=4)  or  MeCP2x/y  Foxp3-­‐‑GFP-­‐‑Cre  (n=6)  littermate  control  mice,  prior  to  
co-­‐‑transfer  into  RAG2-­‐‑/-­‐‑  recipient  mice.  (A)  Schematic  representation  of  the  workflow.  (B)  
Weight  changes  of  recipient  mice  after  adoptive  transfer  were  normalized  to  their  initial  
body  weights  before  transfer.  Data  shows  means  ±  SEM.  (C-­‐‑D)  Recipient  mice  were  
euthanized  4  weeks  later.  Colon  tissues  were  isolated  for  histopathologic  analysis.  (C)  
Representative  images  of  colon  tissues  with  hematoxylin  and  eosin  staining.  (D)  
Summary  of  the  histopathologic  scores.  (E)  Absolute  number  of  splenocytes.  (F)  
Absolute  number  of  CD4+Thy1.1+  cells  in  spleens.  (G)  Percentage  of  Foxp3+  cells  among  
Thy1.2+  cells  and  MFI  of  Foxp3  staining  in  Foxp3+  Tregs.  (H)  Absolute  number  of  
CD4+Thy1.2+  cells  in  spleens.  (I)  Lymphocytes  from  spleens  were  stimulated  by  PdBU  
and  ionomycin  for  4  hours  and  stained  for  intracellular  cytokines.  Left:  Representative  





Figure  24:  MeCP2-­‐‑deficient  Tregs  are  competent  in  suppressing  effector  T  cell  
activation  during  short-­‐‑term  culture  in  vitro.  
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CD4+CD25-­‐‑  conventional  T  cells  from  LNs  and  spleens  of  Thy1.1+  B6  mice  were  
FACS  sorted,  labeled  with  carboxyfluorescein  succinimidyl  ester  (CFSE),  mixed  with  
Thy1.2+  CD4+CD25+  Tregs  from  LNs  and  spleen  of  MeCP2f/y  Lck-­‐‑Cre  or  littermate  control  
mice  at  the  indicated  ratios,  and  stimulated  with  0.5ug/mL  anti-­‐‑CD3  and  0.5ug/mL  anti-­‐‑
CD28  in  the  presence  of  T  cell  depleted  splenocytes  (as  APCs)  from  B6  mice  for  72  hours.    
(A)  Schematic  representation  of  the  workflow.  (B-­‐‑D)  The  survival  (B),  Foxp3  
maintenance  (C),  and  cytokine  production  (D)  from  wild  type  or  MeCP2-­‐‑deficient  Tregs  
(Thy1.2+)  as  shown  by  LIVE/DEAD  Fixable  Violet  Dead  Cell  Staining  and  intracellular  
staining,  respectively.  Data  shown  represents  three  independent  experiments.  (E-­‐‑G)  The  
suppression  of  effector  T  cell  (Thy1.1+)  proliferation  (E)  and  cytokine  production  (F&G)  
by  MeCP2-­‐‑sufficient  or  -­‐‑deficient  Tregs  (Thy1.2+)  as  shown  by  CFSE  dilution  and  
intracellular  staining.  Bar  graphs  show  Means  ±  SEM  of  three  independent  experiments.    
(H)  Viable  wild  type  and  MeCP2-­‐‑deficient  Thy1.2+  Treg  cells  from  the  4:1  Tcon:Treg  
culture  were  sorted  and  expression  of  genes  that  are  critical  for  Treg  suppressive  





Figure  25:  MeCP2  is  required  for  the  maintenance  of  Foxp3  expression  in  Tregs  
during  inflammatory  cytokine  stimulation  in  vitro.  
CD4+CD25+  Tregs  from  LNs  and  spleens  of  MeCP2f/y  Lck-­‐‑Cre  or  their  wild  type  
littermate  control  mice  were  sorted,  labelled  with  CFSE,  and  stimulated  with  1ug/mL  
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plate  bound  anti-­‐‑CD3  and  1ug/mL  plate  bound  anti-­‐‑CD28  in  the  presence  of  50U/mL  IL-­‐‑
2  with  or  without  50ng/mL  IL-­‐‑6  for  3-­‐‑7  days  (n=5).  (A)  The  percentages  of  viable  cells  
retaining  CD25  and  Foxp3  expression  at  indicated  time  points  were  measured  by  flow  
cytometry.  (B)  The  percentages  of  viable  cells  at  the  indicated  time  points  were  
determined  by  LIVE/DEAD  Fixable  Violet  Dead  Cell  Staining.  (C)  The  proliferation  of  
viable  cells  at  the  indicated  time  points  were  determined  by  CFSE  dilution.  (D)  Cytokine  
production  from  viable  wild  type  or  MeCP2-­‐‑deficient  ex-­‐‑Tregs  was  analysed  by  
intracellular  staining  following  4  hours  of  PdBU  and  ionomycin  stimulation.  (E)  Viable  
wild  type  and  MeCP2-­‐‑deficient  Treg  cells  after  5  days  of  culture  were  sorted  and  
expression  of  Treg  signature  genes  was  determined  by  qPCR.  Data  shows  means  ±  SEM  







Figure  26:  The  maintenance  of  Foxp3  expression  in  MeCP2-­‐‑deficient  Tregs  was  
moderately  impaired  following  stimulation  by  several  inflammatory  cytokines.  
CD4+CD25+  Tregs  from  LNs  and  spleens  of  MeCP2fl/fl  Lck-­‐‑Cre  or  their  wild  type  
littermate  control  mice  were  sorted  and  stimulated  with  1ug/mL  plate  bound  anti-­‐‑CD3  
and  1ug/mL  plate  bound  anti-­‐‑CD28  in  the  presence  of  50U/mL  IL-­‐‑2  in  conjugation  with  
20ng/mL  IL-­‐‑12  or  20ng/mL  IFN-­‐‑γ,  or  20ng/mL  IL-­‐‑4  for  7  days  (n=3).  The  percentages  of  
viable  cells  retaining  CD25  and  Foxp3  expression  at  indicated  time  points  were  




Figure  27:  MeCP2  is  critical  for  maintaining  Foxp3  expression  in  nTregs  during  
inflammation  in  vivo.  
(A-­‐‑E)  2.0×105  CD4+CD25-­‐‑  T  cells  from  Thy1.1+  WT  B6  mice  were  sorted  and  mixed  
with  1.0×105  Thy1.2+  CD4+CD25+  GFP+  Tregs  from  MeCP2f/y  Foxp3-­‐‑GFP-­‐‑Cre  (KO)  or  
MeCP2x/y  Foxp3-­‐‑GFP-­‐‑Cre  (WT)  littermate  control  mice,  and  the  mixture  was  co-­‐‑
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transferred  into  RAG2-­‐‑/-­‐‑  mice.  Recipient  mice  were  euthanized  3  weeks  after  transfer  for  
flow  cytometry  analysis.  Bar  graphs  in  B&D  show  Means  ±  SEM  of  six  mice.  (A)  
Schematic  view  of  the  workflow.  (B)  Percentage  of  Thy1.2+CD4+  T  cells  before  transfer  
and  those  that  maintain  Foxp3  expression  in  the  mesenteric  lymph  nodes  (mLNs)  and  
spleens  of  recipient  mice  (n=6).  (C&D)  Cytokine  production  from  Thy1.2+  cells  in  the  
mLNs  and  spleens  of  recipient  mice  as  determined  by  intracellular  staining  (n=6).  (E)  
Absolute  number  of  Thy1.1+  effector  T  cells  that  produce  IL-­‐‑17  and  IFN-­‐‑g  in  the  mLNs  
and  spleens  of  recipient  mice  (WT:  n=4;  KO:  n=5).  (F-­‐‑H)  MeCP2f/f  alleles  were  transferred  
to  pure  NOD  inbred  background  by  speed  congenic  approach.  With  T  cells  from  
pancreatic  draining  lymph  nodes  (dLN)  and  spleens  of  30-­‐‑week-­‐‑old  WT  NOD  or  
MeCP2f/fFoxP3-­‐‑GFP-­‐‑Cre  (KO)  littermate  mice,  the  percentage  of  Foxp3+  Tregs  and  
expression  level  of  Foxp3  in  Foxp3+  Tregs  (F)  and  IFN-­‐‑γ  and  IL-­‐‑17  production  (G&H)  by  
CD4+  T  cells  were  examined  by  intracellular  staining  ex  vivo  (n=4).  (I-­‐‑K)  EAE  was  
induced  in  MeCP2f/y  Foxp3-­‐‑GFP-­‐‑Cre  (KO)  or  MeCP2x/y  Foxp3-­‐‑GFP-­‐‑Cre  (WT)  littermate  
control  mice  by  immunization  with  MOG  peptide  emulsified  in  CFA,  and  mice  were  
sacrificed  at  day  22  for  cell  analysis.  (I)  Clinical  scores  over  time  (Left)  and  area  under  
curve  (Right).  (J)  MFI  of  Foxp3  expression  in  Tregs  from  the  spinal  cord  of  WT  or  KO  
mice.  (K)  Percentage  and  number  of  CD4+Foxp3-­‐‑  cells  that  produce  proinflammatory  




     
Figure  28:  Ectopic  expression  of  Foxp3  restores  the  capacity  of  MeCP2-­‐‑deficient  
Tregs  to  suppress  effector  T  cell-­‐‑mediated  colitis  in  vivo.  
Thy1.2+  CD4+CD25+  Tregs  from  LNs  and  spleen  of  MeCP2f/y  Lck-­‐‑Cre  or  their  wild  
type  littermate  control  mice  were  sorted  and  stimulated  with  1ug/mL  anti-­‐‑CD3  and  anti-­‐‑
CD28  in  the  presence  of  50U/mL  IL-­‐‑2.  18  hours  later,  cells  were  transduced  with  
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retrovirus  that  encodes  the  foxp3  coding  sequence  together  with  GFP  (Foxp3)  or  GFP  
alone  (mock).  Two  days  later,  5.0×104  Thy1.2+GFP+  Tregs  were  sorted  and  mixed  with  
5.0×105  naïve  conventional  T  cells  (CD25-­‐‑  CD45RBhi  CD4+)  from  wild  type  Thy1.1+  B6  
donors,  and  then  transferred  into  RAG2-­‐‑/-­‐‑  mice.  Colon  pathology  and  phenotype  of  
transferred  cells  were  analyzed  5  weeks  after  adoptive  transfer.  (A)  Schematic  view  of  
the  workflow.  (B&C)  Percentage  of  recovered  Foxp3+  cells  from  the  Thy1.2+  origin  and  
MFI  of  Foxp3  expression  in  Foxp3+  Tregs.  (B)  Representative  FACS  plots.  (C)  Summary  
of  results  from  various  experimental  groups.  Each  symbol  represents  one  single  
recipient  mouse.  (D)  Weight  changes  during  the  colitis  progression.  The  weight  of  
recipients  at  different  time  points  was  normalized  to  initial  body  weight  of  individual  
mouse  before  transfer.  Data  shows  means  ±  SEM.  (E-­‐‑F)  Colon  immunopathology  of  
recipient  mice  was  indicated  by  the  ratio  of  colon  weight  vs.  length  (E)  and  illustrated  by  




Figure  29:  The  defect  of  MeCP2-­‐‑deficient  Tregs  to  maintain  Foxp3  during  
inflammation  is  not  caused  by  accelerated  proliferation  or  enhanced  inflammatory  
cytokine  signaling.  
(A-­‐‑B)  CD4+CD25+  Tregs  from  LNs  and  spleens  of  MeCP2fl/fl  Lck-­‐‑Cre  or  their  wild  
type  littermate  control  mice  were  sorted,  labelled  with  CFSE,  and  stimulated  with  
1ug/mL  plate  bound  anti-­‐‑CD3  and  1ug/mL  plate  bound  anti-­‐‑CD28  in  the  presence  of  
50U/mL  IL-­‐‑2  and  50ng/mL  IL-­‐‑6  for  4  days.  The  proliferation  (A)  and  the  percentages  of  
viable  cells  retaining  Foxp3  expression  within  each  generation  of  cell  cycle  (B)  were  
measured  by  flow  cytometry.  (C)  CD4+CD25+  Tregs  from  LNs  and  spleens  of  MeCP2fl/fl  
Lck-­‐‑Cre  or  their  wild  type  littermate  control  mice  were  sorted  and  stimulated  with  
50ng/mL  IL-­‐‑6  for  15  minutes.  The  phosphorylation  of  STAT3  downstream  of  IL-­‐‑6  
receptor  signalling  was  measured  by  intracellular  staining  and  flow  cytometry.  Data  




Figure  30:  Mecp2-­‐‑deficient  nTregs  have  normal  CpG  methylation  patterns  in  
the  promoter  and  CNS2  of  the  foxp3  locus.  
CD4+CD25+GFP+  nTregs  were  sorted  from  the  lymph  nodes  and  spleens  of  
Mecp2x/y  Foxp3-­‐‑GFP-­‐‑Cre  (WT)  or  Mecp2f/y  (KO)  mice,  and  the  methylation  status  in  the  
promoter  (A)  and  CNS2  (B)  of  foxp3  locus  was  analyzed  by  bisulfite  sequencing.  
Numbers  on  the  x-­‐‑axes  indicate  the  position  of  CpGs  relative  to  the  transcription  start  
site  of  the  foxp3  gene.  Bar  graphs  show  the  data  quantified  from  sequencing  of  at  least  




Figure  31:  MeCP2  occupies  the  foxp3  CNS2  region  and  regulates  its  chromatin  
accessibility  through  recruitment  of  CREB1.  
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(A)  Freshly  isolated  Tregs  from  LNs  and  spleens  of  wild  type  B6  mice  or  Tregs  
that  were  stimulated  with  anti-­‐‑CD3/CD28,  50U/mL  IL-­‐‑2  and  50ng/mL  IL-­‐‑6  for  5  days  
were  subject  to  ChIP  analysis  for  MeCP2  enrichment  at  the  foxp3  promoter  and  CNS2  
region.  Results  show  the  enrichment  ratios  of  immunoprecipitations  using  rabbit  anti-­‐‑
MeCP2  versus  nonspecific  rabbit  IgG.  The  bar  graph  shows  Means  ±  SEM  of  three  
independent  experiments.  (B)  CD4+CD25+GFP+  nTregs  were  sorted  from  lymph  nodes  
and  spleen  of  Mecp2x/y  Foxp3-­‐‑GFP-­‐‑Cre  (WT)  and  stimulated  with  anti-­‐‑CD3/CD28,  
50U/mL  IL-­‐‑2  and  50ng/mL  IL-­‐‑6  for  5  days.  The  methylation  status  in  the  promoter  and  
CNS2  of  foxp3  locus  was  analyzed  by  bisulfite  sequencing.  Numbers  on  the  x-­‐‑axes  
indicate  the  position  of  CpGs  relative  to  the  transcription  start  site  of  the  foxp3  gene.  Bar  
graphs  show  the  data  quantified  from  sequencing  at  least  ten  clones  for  each  sample.  
Data  shown  represents  three  independent  experiments.  (C)  Freshly  isolated  CD4+  
CD25+GFP+  Tregs  sorted  from  lymph  nodes  and  spleens  of  MeCP2f/y  Foxp3-­‐‑GFP-­‐‑Cre  
mice  (KO)  or  MeCP2x/y  Foxp3-­‐‑GFP-­‐‑Cre  mice  (WT)  were  analyzed  for  histone  H3  
acetylation  at  various  cis-­‐‑elements  within  the  foxp3  locus  by  ChIP  (n=3).  Means  ±  SEM  
are  shown.  (D)  ChIP  analysis  for  the  enrichment  of  CREB1  at  the  foxp3  promoter  and  
CNS2  region  in  WT  or  KO  Tregs  that  were  stimulated  with  anti-­‐‑CD3/CD28,  IL-­‐‑2  and  IL-­‐‑
6  for  5  days.  Results  show  the  enrichment  ratios  of  immunoprecipitation  using  rabbit  
anti-­‐‑CREB1  versus  nonspecific  rabbit  IgG.  The  bar  graph  shows  Means  ±  SEM  of  three  
independent  experiments.  (E)  Histone  H3  acetylation  of  CNS2  in  WT  or  KO  Tregs  that  
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were  stimulated  with  anti-­‐‑CD3/CD28,  IL-­‐‑2  and  IL-­‐‑6  for  5  days  in  the  presence  or  absence  
of  5µμM  PKA  pathway  inhibitor  H89  (Calbiochem)  (n=3).  Means  ±  SEM  are  shown.  (F)  
Luciferase  reporter  assays.  Reporter  constructs  of  PGL4,  PGL4  linked  with  Foxp3  
promoter  (PGL4-­‐‑Pro),  or  PGL4  linked  with  Foxp3  promoter  and  CNS2  (PGL4-­‐‑Pro-­‐‑
CNS2)  were  transfected  into  Jurkat  T  cells  together  with  non-­‐‑targeting  control  siRNA  or  
siRNA  against  MeCP2.  48hrs  later,  cells  were  either  untreated  or  treated  with  PdBU  and  
ionomycin  for  16-­‐‑24  hours,  and  lysed  for  analysis  of  luciferase  activity  (n=3).  Insert:  the  
efficiency  of  siRNA  treatment  was  examined  by  western  blot  48hrs  after  transfection.  





Tregs’  pivotal  role  in  immune  tolerance  demands  that  they  possess  a  dedicated  
molecular  mechanism  to  maintain  stable  Foxp3  expression  when  challenged  by  an  
inflammatory  environment.  In  this  study,  we  show  that  MeCP2  is  a  crucial  player  in  the  
epigenetic  machinery  that  determines  Tregs  resilience  in  the  face  of  inflammation.  
Interestingly,  the  function  of  MeCP2  is  dedicated  specifically  to  the  maintenance  as  
opposed  to  the  induction  of  Foxp3.  In  the  absence  of  immune  activation,  MeCP2  is  
dispensable  for  Foxp3  expression,  both  during  nTreg  and  iTreg  lineage  commitment  
(Figure  20).  In  contrast,  upon  inflammation,  MeCP2  is  crucial  for  Foxp3  maintenance  
and  Treg-­‐‑enforced  immune  homeostasis.  Mechanistically,  the  distinguishing  feature  is  
that  Mecp2  binds  to  methylated  DNA  with  enhanced  affinity.  TCR  activation  and  
inflammatory  cytokine  signaling  subject  the  foxp3  locus  to  gene  silencing  by  promoting  
DNA  methylation  in  its  CNS2  region  (Figure  31B),  and  whereas  this  modification  is  
known  to  occlude  transcription  factor  binding75,77,  We  show  that  it  also  reciprocally  
recruits  MeCP2  to  associate  specifically  with  CNS2  and  thereby  rescues  foxp3  
transcription  via  local  histone  H3  acetylation.    Specifically,  the  docking  of  MeCP2  
achieves  this  by  recruiting  CREB1  (Figure  31D)  and  potentially  the  CREB1  binding  
partner,  CBP/p300204  histone  acetyltransferase  to  CNS2.  Previous  studies  using  mass  
spectrometry  have  demonstrated  that  the  direct  interaction  between  CREB1  and  MeCP2  
synergistically  promotes  the  expression  of  a  wide  range  of  genes  in  the  hypothalamus169.  
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In  nTregs,  we  detected  simultaneous  and  MeCP2-­‐‑dependent  binding  of  these  two  
proteins  to  the  CNS2  region  (Figure  31A&D).  This  interaction  between  CREB1  and  
MeCP2  may  be  direct  or  indirect:  it  may  also  be  possible  that  MeCP2  associates  with  
other  coactivators  to  maintain  a  locally  accessible  chromatin  structure,  thereby  indirectly  
facilitating  the  binding  of  CREB1  in  the  absence  of  physical  interaction.  In  either  case,  
the  result  is  that  MeCP2  provides  an  important  epigenetic  safeguard  that  confers  Tregs  
with  resistance  to  inflammation-­‐‑induced  foxp3  silencing.  
Due  to  its  association  with  Rett  Syndrome,  prior  studies  on  MeCP2  have  been  
centered  almost  exclusively  on  the  central  nervous  system.  Patients  with  Rett  Syndrome  
show  no  overt  abnormalities  in  the  first  6  months  of  life,  but  they  subsequently  develop  
a  profound  neurodevelopmental  disorder  characterized  by  devastating  periods  of  
regression,  which  result  in  permanent  cognitive  impairment.  Although  immune  attack  
against  the  central  nervous  system  was  suspected  to  be  the  etiological  factor  of  Rett  
Syndrome  in  the  early  90s,  in-­‐‑depth  pathological  analysis  failed  to  provide  any  evidence  
for  autoimmunity.  Using  a  mouse  model  of  Treg-­‐‑specific  MeCP2  gene  ablation,  we  have  
identified  spontaneous  CD4+  T  cell  activation  in  young  adult  mice,  a  secondary  effect  of  
defective  Treg-­‐‑mediated  immune-­‐‑suppression.  Interestingly,  this  inflammatory  
phenotype  vanished  when  mecp2  was  deleted  in  all  T  cells  using  CD4-­‐‑Cre  or  Lck-­‐‑Cre  to  
drive  gene  depletion.  This  was  a  strong  indication  that  the  loss  of  MeCP2  in  other  T  cell  
subsets  might  compensate  for  Treg  dysfunction  and  prevent  the  onset  of  overt  
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autoimmunity.  Indeed,  we  have  examined  the  function  of  MeCP2  in  effector  T  cell  
lineages  and  found  that  MeCP2-­‐‑deficient  effector  CD4+  T  cells  are  severely  impaired  in  
their  production  of  inflammatory  Th1  and  Th17  cytokines  (See  Chapter  6).  Nonetheless,  
it  is  clear  that  T  cell  immunity  is  not  normal  in  these  animals:    further  analysis  of  the  role  
of  MeCP2  in  other  immune  lineages  will  help  to  elucidate  the  regulatory  nature  of  this  
protein  in  the  immune  system,  and  possibly  in  the  neural  system  as  well.
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6. MeCP2 reinforces STAT3 signaling and effector T cell 
differentiation by controlling miR-124-mediated 
suppression of SOCS5: An important epigenetic 
regulator of Th1 and Th17 differentiation 
The  contents  of  this  dissertation  chapter  have  been  slightly  modified  from  the  
following  manuscript  that  was  current  under  revision  at  Science  Signaling.    
Shan  Jiang*,  Chaoran  Li*,  Gabrielle  McRae,  Erik  Lykken,  Jose  Sevilla,  Siqi  Liu,  
Ying  Wan  &  Qi-­‐‑Jing  Li.  (*  equal  contribution  and  listed  in  an  alphabetic  order).  MeCP2  
reinforces  STAT3  signaling  and  effector  T  cell  differentiation  by  controlling  miR-­‐‑124-­‐‑
mediated  suppression  of  SOCS5.  
6.1 Introduction 
Methyl-­‐‑CpG  binding  protein  2  (MeCP2)  was  initially  identified  as  a  nuclear  
protein  binding  to  cytosine-­‐‑methylated  DNA  within  dinucleotide  CpG  elements167,168.  In  
early  studies,  MeCP2  was  described  as  a  transcription  silencer,  because  it  appeared  to  
maintain  dinucleotide  methylation  of  target  genes  and  to  recruit  the  corepressor  Sin3A  
and  histone  deacetylases  (HDACs)170,205.  However,  recent  biochemical  and  genomics  data  
suggest  that,  rather  than  strictly  a  silencer,  MeCP2  acts  as  a  multifunctional  regulator  of  
gene  transcription173,206  and  is  actively  involved  in  RNA  splicing  207,  chromatin  
remodeling208,209,    and  transcriptional  activation169,172.  
MeCP2  is  especially  relevant  in  biomedicine  due  to  its  role  in  Rett  syndrome  
(RTT)174,210,  a  progressive  neurodevelopmental  disorder  that  manifests  in  young  girls  at  a  
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ratio  of  1:10,000211,212.  Heterozygous  loss-­‐‑of-­‐‑function  mutations  in  the  mecp2  gene  
underlie  the  etiology  for  more  than  95%  of  typical  RTT  patients174,175  ,  yet  the  resultant  
molecular  pathology  remains  largely  elusive173.  The  neurodegeneration  phenotype  of  
RTT  is  the  result  of  loss-­‐‑of-­‐‑MeCP2  specifically  in  neuronal  cells  213,214,  and  is  unlikely  to  
rely  on  immune  cell  dysfunction215,216.    However,  MeCP2  expression  is  not  limited  to  the  
brain,  and  more  recent  data  has  implicated  it  in  the  regulation  of  immunological  
disorders.    Specifically,  polymorphisms  of  mecp2  in  humans  have  been  linked  to  
increased  susceptibility  to  autoimmune  diseases  such  as  Systemic  lupus  erythematosus  
(SLE)177,178  and  primary  Sjogren’s  syndrome  (pSS)179;  moreover,  MeCP2  has  been  found  in  
association  with  CpG  elements  within  the  regulatory  regions  of  the  foxp3  gene194,  
although  the  functional  consequence  of  this  association  is  yet  to  be  examined.  
Thus,  although  RTT  does  not  appear  to  be  phenotypically  linked  to  immune  cell  
dysregulation,  we  postulated  that  MeCP2’s  role  in  neuronal  cells  and  in  T  cells  might  
nonetheless  be  mechanistically  linked  by  some  common  molecular  pathways.  We  
therefore  generated  T-­‐‑cell-­‐‑specific  MeCP2-­‐‑ablated  mice,  in  order  to  investigate  the  
potential  role  of  MeCP2  in  T  cell  function  and  immune  regulation.  Mechanistically,  our  
investigation  identified  miRNA  miR-­‐‑124  as  a  direct  downstream  effector  of  MeCP2-­‐‑
mediated  epigenetic  regulation.  Functionally,  the  MeCP2-­‐‑miR-­‐‑124-­‐‑SOCS5  axis  is  
indispensable  for  inflammatory  cytokine-­‐‑induced  STAT3  activation  in  CD4+  T  cells,  and,  





6.2.1 MeCP2 is critical for the commitment of naive CD4+ T cells to the 
Th17 lineage 
Previously,  we  identified  MeCP2  as  an  important  “safe  guard”  that  governs  
Tregs’  resistance  to  inflammation-­‐‑induced  destabilization  (See  Chapter  5).  Mice  with  a  
specific  deletion  of  MeCP2  in  Tregs  developed  spontaneous  inflammation  as  young  as  8  
weeks.  Interestingly,  when  CD4-­‐‑Cre  transgenes  were  employed  to  induce  MeCP2  
deletion  in  both  natural  Tregs  (nTregs)  and  conventional  T  cells  (Tcon),  we  failed  to  
observe  any  obvious  disruption  of  immune  homeostasis  (Figure  32).  This  suggests  that  
the  loss  of  MeCP2  in  other  T  cell  subsets  might  compensate  for  Treg  dysfunction  and  
prevent  the  onset  of  overt  autoimmunity.  To  examine  the  intrinsic  autoinflammatory  
potential  of  conventional  CD4+  T  cells  (Tcon),  sorted  CD4+CD25-­‐‑CD45Rbhigh  naïve  Tcon  
cells  from  MeCP2-­‐‑deficient  or  WT  mice,  in  combination  with  WT  regulatory  T  (Treg)  
cells,  were  transferred  into  lymphopenic  Rag2-­‐‑/-­‐‑  recipients  at  a  25:1  ratio  to  induce  
autoimmune  colitis.  Mice  that  received  WT  Tcon  cells  developed  severe  experimental  
colitis  evidenced  by  the  continuous  loss  in  body  weight;  surprisingly,  instead  of  
promoting  inflammation,  the  transfer  of  MeCP2-­‐‑deficient  Tcon  conferred  recipient  mice  
with  disease  resistance  (Figure  33B).  Further  histopathology  analysis  of  the  colon  
illustrated  a  striking  difference  in  inflammatory  leukocyte  infiltration  and  the  integrity  
of  mucosal  tissue  architecture  (Figure  33C).  In  this  transfer  model,  the  aberrant  
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generation  of  Th17  cells  against  host  microbiota  has  been  demonstrated  to  be  the  major  
cause  of  intestinal  inflammation217.  Accordingly,  in  the  mesenteric  lymph  nodes  of  mice  
bearing  MeCP2-­‐‑deficient  Tcon  cells,  the  proportion  of  IL-­‐‑17a  producing  CD4+  T  cells  was  
significantly  reduced  (Figure  33D).  
In  response  to  specific  immunization  conditions,  Tcon  cells  proliferate,  contract  
and  differentiate  into  various  T  helper  cell  lineages  to  orchestrate  proper  immune  
responses  related  to  host  defense  and  tolerance8.  Defects  in  any  of  these  steps  could  
account  for  the  reduced  autoinflammatory  Th17  population  observed  with  MeCP2  
deletion.  To  further  dissect  the  intrinsic  defect  of  MeCP2-­‐‑deficient  Tcon  cells  during  
inflammation,  we  backcrossed  CD4-­‐‑Cre+mecp2f/f  or  mecp2f/y  mice  with  strains  carrying  the  
LLO118  TCR  transgene218,  which  recognizes  the  dominant  Listeria  monocytogenes  
antigen  (a.a.190-­‐‑205  of  the  Listeriolysin  O  protein)  in  the  context  of  the  I-­‐‑Ab  MHC  class  II  
molecule  .  Upon  in  vitro  stimulation  with  LLO190-­‐‑205  peptide-­‐‑loaded  APCs,  CD4+  Tcon  
cells  proliferated,  and  then  contracted,  comparably  in  the  presence  or  absence  of  MeCP2  
protein  (Figure  33G&H).  However,  when  we  cultured  these  cells  under  Th17-­‐‑polarizing  
conditions  in  vitro,  MeCP2-­‐‑deficient  Tcon  cells  exhibited  severe  defects  in  IL-­‐‑17a  
production  (Figure  33E).  Consistent  with  this,  the  mRNA  levels  of  il-­‐‑17a,  il-­‐‑17f,  and  the  
master  transcription  factor  for  the  Th17  lineage,  rorc,  were  significantly  suppressed  in  
MeCP2-­‐‑deficient  Th17  cells  (Figure  33F).  
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6.2.2 MeCP2 is required for the commitment of naive CD4+ T cells to 
the Th1 lineage 
IFN-­‐‑γ  producing  Th1  cells  represent  another  critical  lineage  mediating  the  onset  
and  progression  of  autoimmune  diseases219,220.  We  examined  whether  MeCP2  plays  any  
role  in  Th1  lineage  differentiation.  When  naïve  T  cells  were  cultured  in  vitro  under  Th1-­‐‑
polarizing  conditions,  the  production  of  IFN-­‐‑γ  in  MeCP2-­‐‑deficicent  CD4+  T  cells  was  
significantly  suppressed  (Figure  34A).  To  validate  this  phenotype  in  vivo,  we  sorted  and  
transferred  WT  or  MeCP2-­‐‑deficient  LLO118  T  cells  into  TCRα-­‐‑/-­‐‑  recipients,  and  
immunized  recipient  mice  subcutaneously  with  LLO190-­‐‑205  peptide.  The  effector  T  cells  
generated  in  vivo  were  rechallenged  with  the  same  antigen  to  assess  their  lineage  
commitment.  As  observed  in  vitro,  MeCP2-­‐‑deficient  CD4+  T  cells  were  significantly  
impaired  in  Th1  differentiation  (Figure  34B).  To  exclude  the  possibility  that  this  
phenotype  is  limited  to  the  LLO118  TCR,  we  directly  challenged  WT  or  CD4-­‐‑Cre+mecp2f/y  
mice  with  KLH  protein  through  the  footpad  to  induce  delayed-­‐‑type  hypersensitivity  
(DTH),  a  classical  Th1-­‐‑dominated  response.  Defects  in  Th1  responses  were  apparent  in  
mice  with  T-­‐‑cell-­‐‑specific  deletion  of  MeCP2,  as  characterized  by  limited  footpad  
swelling  (Figure  34C),  reduced  inflammatory  infiltration  (Figure  34D),  and  reduced  
numbers  of  Th1  cells  in  the  draining  lymph  node  (Figure  34E).  Collectively,  our  data  
indicate  that  MeCP2  is  an  indispensable  factor  that  drives  the  differentiation  of  Th1  and  
Th17  cells  in  vitro  and  in  vivo.  
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6.2.3 MeCP2 is indispensable for activation of STAT3 and STAT1 in 
CD4+ T cells 
To  develop  distinct  and  stable  effector  T  cell  lineages  from  naïve  precursors,  
CD4+  T  cells  respond  to  signals  from  APCs  and  the  cytokine  environment  by  activating  
lineage-­‐‑specific  transcription  factors,  which  then  fundamentally  remodel  local  
chromatin  structures  surrounding  master  cytokine  genes  in  order  to  cement  their  lineage  
choices3,8.  Since  MeCP2  primarily  functions  at  the  epigenetic  level,  we  first  examined  
whether  the  loss  of  MeCP2  directly  impaired  the  accessibility  of  the  il17  and  ifng  loci.  
With  chromatin  immunoprecipitation  (ChIP)  assays,  we  examined  histone  acetylation  
and  methylation  status  (H3Acy,  H3K4me2,  H3K4me3  and  H3K27me3)  across  critical  
regulatory  regions  of  the  il17  and  ifng  genes  in  MeCP2-­‐‑deleted  T  cells.  Despite  minor  
differences  within  some  regions,  no  unidirectional  changes  in  the  accessibility  of  these  
master  cytokine  genes  could  be  identified  (Figure  35).  Because  the  lineage  choice  of  
naïve  CD4+  T  cells  is  primarily  determined  by  their  response  to  different  environmental  
cytokines,  we  next  considered  whether  MeCP2  ablation  impacted  cytokine  signaling.    
Cytokines  activate  various  transcription  factors  within  the  family  of  signal  transducer  
and  activator  (STAT)  proteins8:    in  particular,  the  Th17  lineage  is  specified  by  STAT3  
activation221-­‐‑223.  In  both  naïve  and  antigen-­‐‑primed  CD4+  T  cells,  the  deletion  of  MeCP2  
did  not  alter  the  expression  or  induction  of  STAT3  protein;  however,  it  did  dampen  IL-­‐‑6-­‐‑
induced  phosphorylation  of  STAT3  (Tyr  705),  the  hallmark  of  STAT3  activation  (Figure  
36A).  Similarly,  upon  IFN-­‐‑γ  stimulation,  MeCP2  deficiency  also  significantly  inhibited  
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STAT1  activation  (Figure  36B),  a  signaling  intermediate  crucial  for  Th1  differentiation.  
Collectively,  these  data  indicate  that  the  loss  of  MeCP2  results  in  the  inhibition  of  
multiple  STAT  protein  signaling  pathways.  
6.2.4 SOCS5 accumulation in MeCP2-deficient CD4+ T cells 
Upon  cytokine  stimulation,  STAT3  signaling  is  tightly  controlled  by  JAK  kinase  
activation  and  various  negative  feedback  mechanisms,  including  those  mediated  by  the  
suppressor  of  cytokine  signaling  (SOCS)  family  proteins224.    Using  qPCR,  we  profiled  the  
expression  of  70  genes  related  to  STAT  signaling  (Figure  37A)  in  naïve  and  Th1-­‐‑  or  Th17-­‐‑
polarized  T  cells.  These  tests  failed  to  identify  any  significant  differences  between  WT  
and  MeCP2-­‐‑deleted  T  cells  at  the  mRNA  level  (Figure  37B  and  data  not  shown).  
However,  at  the  protein  level,  we  consistently  observed  a  dramatic  increase  of  SOCS5  
protein  in  naïve  MeCP2-­‐‑deficient  CD4+  T  cells  (Figure  37C&D);  Upon  prolonged  antigen  
and  IL-­‐‑6  stimulation,  the  loss  of  MeCP2  also  resulted  in  an  elevated  accumulation  of  
SOCS5  protein  (Figure  37E),  which  spanned  the  duration  of  Th17  lineage  specification.  
6.2.5 SOCS5 negatively regulates STAT3 activation and naïve CD4+ T 
cell commitment to the Th17 lineage 
Unlike  SOCS1  and  SOCS3,  studies  on  the  function  of  SOCS5  in  lymphocytes  
remain  limited225,226,  and  its  impact  on  Th17  differentiation  is  unknown.  However,  
SOCS5  has  been  identified  as  a  potent  STAT3  inhibitor  in  M1  macrophages227.  Using  
retroviral  transduction,  we  ectopically  expressed  SOCS5  in  primary  LLO118  T  cells  to  
mimic  the  effect  of  MeCP2  deletion.  With  a  relatively  modest  augmentation  of  SOCS5  
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expression  (Figure  38A),  T  cell  responses  to  IL-­‐‑6  stimulation  in  vitro  were  impaired  
(Figure  38B).  To  assess  the  role  of  SOCS5  in  vivo,  we  competitively  transferred  equal  
numbers  of  GFP-­‐‑expressing  mock  Thy1.1+  and  SOCS5-­‐‑overexpressing  Thy1.2+  LLO118  T  
cells  into  TCRα-­‐‑/-­‐‑  recipients,  and  activated  these  T  cells  by  subcutaneous  LLO190-­‐‑205  
antigen  challenge.  After  5  days  of  in  vivo  conditioning,  we  assessed  the  Th17  
differentiation  of  these  T  cells.  Like  their  MeCP2-­‐‑deficient  counterparts,  SOCS5-­‐‑
expressing  T  cells  showed  a  significant  defect  in  Th17  differentiation  at  both  the  
population  level  and  on  a  per-­‐‑cell  basis  (Figure  38C&D).  To  further  determine  whether  
this  defect  was  absolute  or  was  the  result  of  competitive  disadvantage,  we  transferred  
each  of  these  two  T  cell  populations  into  separate  recipients  and  challenged  them  with  
the  same  immunization  protocol.  In  this  setting,  ex  vivo  examination  (Figure  38E)  and  in  
vitro  antigen  rechallenge  (Figure  38F)  revealed  even  more  pronounced  defects  in  the  
Th17  differentiation  potential  of  SOCS5-­‐‑expressing  LLO  T  cells.  Similarly,  enforced  
SOCS5  expression  also  resulted  in  defective  STAT1  activation  (Figure  38G)  and  Th1  
differentiation  (Figure  38H-­‐‑J).  Taken  together,  we  propose  that  in  MeCP2  deficient  T  
cells,  the  impaired  STAT  signaling  and  constraints  on  T  cell  differentiation  are  primarily  




6.2.6 MeCP2 positively regulates the transcription of pri-mmu-miR-
124-1 in CD4+ T cells 
What  underlies  the  accumulation  of  SOCS5  in  MeCP2  deficient  T  cells?  One  
possibility  is  that  MeCP2  functions  as  a  transcriptional  repressor  of  SOCS5  expression.  
However,  the  impact  of  MeCP2  loss  on  SOCS5  expression  (Figure  39C,  Left  panel)  is  not  
statistically  significant  at  the  mRNA  level.  Therefore,  we  speculated  that  MeCP2  
regulates  SOCS5  expression  in  T  cells  indirectly  at  the  posttranscriptional  level.  
miRNAs  are  one  of  the  principle  molecular  machineries  responsible  for  
posttranscriptional  regulation46.  Although  the  majority  of  miRNA-­‐‑mediated  repression  
involves  at  least  moderate  mRNA  destabilization,  11-­‐‑16%  of  the  regulation  is  attributed  
solely  to  translational  inhibition228.  Based  on  the  divergent  levels  of  mRNA  and  protein,  
we  speculated  that  miRNAs  may  be  key  modulators  for  SOCS5  protein  expression.  
Using  qPCR,  we  analyzed  the  expression  profiles  of  ~400  miRNAs  from  WT  and  
MeCP2-­‐‑deficient  cells.  Due  to  MeCP2’s  role  in  neural  cells,  we  narrowed  our  analysis  by  
focusing  on  miRNAs  that  downregulated  in  both  MeCP2-­‐‑deficient  mouse  CD4+  T  cells  
and  primary  human  astrocytes  (Figure  39A).  We  found  five  miRNAs  that  were  
downregulated  in  both  cell  types;  among  these  candidates,  miR-­‐‑124  was  
computationally  predicted  to  target  socs5  mRNA  at  a  highly  conserved  site  (Figure  39A).  
miR-­‐‑124  is  one  of  the  most  abundant  miRNAs  expressed  in  the  vertebrate  central  
nervous  system229.  Loss  of  miR-­‐‑124  is  known  to  cause  severe  defects  in  neuronal  
maturation  and  survival230.  In  addition,  recent  clinical  study  suggested  that  the  
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expression  of  miR-­‐‑124  can  be  dynamically  modulated  in  human  T  cells  from  sepsis  
patients,  and,  its  upregulation  limited  the  anti-­‐‑inflammatory  effects  of  steroid  
treatment231.  To  assess  absolute  abundance  of  miR-­‐‑124  in  CD4+  T  cells,  we  quantitated  
the  copy  number  of  miR-­‐‑124.  With  this  assay,  we  estimated  miR-­‐‑124  to  be  in  the  range  of  
4X107  copies/mg  total  RNA  in  naïve  CD4+  T  cells  (Figure  39B).  This  cellular  
concentration  is  similar  to  that  of  miR-­‐‑19b,  a  miRNA  executing  comprehensive  
regulatory  functions  over  T  cells  effector  responses54.  With  the  loss  of  MeCP2,  the  
expression  of  miR-­‐‑124  was  consistently  suppressed  in  naïve  CD4+  T  cells  (Figure  39C,  
right  panel).  
Mature  miR-­‐‑124  can  be  generated  from  three  distinct  precursor  transcripts  that  
are  coded  within  three  highly  conserved  genomic  loci  (pri-­‐‑miR-­‐‑124-­‐‑1  on  chr.14,  pri-­‐‑miR-­‐‑
124-­‐‑2  on  chr.3,  pri-­‐‑miR-­‐‑124-­‐‑3  on  chr.2.).  As  previously  demonstrated  in  the  nervous  
system230,  the  pri-­‐‑miR-­‐‑124-­‐‑1  locus  is  also  the  dominant  precursor  of  mature  miR-­‐‑124  
expression  in  T  cells:  transcriptional  levels  of  pri-­‐‑miR-­‐‑124-­‐‑2  and  pri-­‐‑miR-­‐‑124-­‐‑3  are  below  
the  detection  limit  in  our  quantitative  PCR  assays.  Based  on  information  collected  from  
the  ENCODE  project,  the  proximate  regulatory  regions  for  pri-­‐‑miR-­‐‑124-­‐‑1  transcription  
locates  within  the  -­‐‑4.7kb  to  +3.5kb  region  surrounding  its  transcription  initiation  site.  
Our  ChIP  assays  showed  that  in  naïve  T  cells,  MeCP2  readily  associates  with  multiple  
CpG  islands  within  the  -­‐‑2.8kb  to  +2.4kb  region  (Figure  39D).  Using  H3K4  dimethylation  
as  an  epigenetic  marker,  we  also  examined  the  genomic  accessibility  and  transcriptional  
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capacity  of  these  regions.  In  wild  type  CD4+  T  cells,  the  -­‐‑2.8kb  and  -­‐‑1.6kb  regions,  which  
were  associated  with  enriched  MeCP2  binding,  constituted  regions  with  higher  
accessibility.  Most  importantly,  loss  of  MeCP2  protein  reduced  the  accessibility  across  
this  locus  (Figure  39E).  Furthermore,  with  mecp2  deletion,  the  reduced  chromatin  
accessibility  resulted  in  dampened  pri-­‐‑miR-­‐‑124-­‐‑1  transcription  in  naïve  CD4+  T  cells  
(Figure  39F).  These  data  suggested  a  direct  role  for  MeCP2  in  promoting  pri-­‐‑miR-­‐‑124-­‐‑1  
transcription.  
6.2.7 miR-124 inhibits the translation of socs5 in CD4+ T cells 
To  determine  whether  miR-­‐‑124  represents  the  missing  link  that  bridges  MeCP2  
deficiency  with  SOCS5  accumulation,  we  first  used  a  luciferase-­‐‑based  reporter  assay  to  
verify  that  the  predicted  targeting  site  in  the  SOCS5  3’UTR  (Figure  40A)  was  specifically  
targeted  for  suppression  by  miR-­‐‑124  (Figure  40B).  Furthermore,  when  miR-­‐‑124  was  
ectopically  introduced  into  antigen-­‐‑primed  LLO118  T  cells,  it  dampened  the  expression  
of  SOCS5  protein  (Figure  40C)  without  any  significant  impact  on  SOCS5  mRNA  (Figure  
40D),  mirroring  the  pattern  of  expression  seen  in  T  cells  with  mecp2  ablation.  In  primed  
WT  T  cells,  during  IL-­‐‑6-­‐‑induced  signaling,  the  forced  miR-­‐‑124  expression  dramatically  
delayed  dephosphorylation  of  STAT3  (Figure  40E),  reinforcing  the  idea  that  the  primary  
target(s)  of  miR-­‐‑124  are  negative  regulatory  elements  of  STAT3  signaling.  Finally,  we  
used  a  retroviral  vector  to  restore  miR-­‐‑124  levels  in  MeCP2-­‐‑deficient  T  cells  back  to  WT  
levels.  The  restoration  of  miR-­‐‑124  partially  rescued  STAT3  activation  in  T  cells  harboring  
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MeCP2  mutation  (Figure  40F).  Phenotypically,  the  exogenous  miR-­‐‑124  significantly  
augmented  Th17  differentiation,  in  both  WT  and  MeCP2-­‐‑deficient  LLO118  T  cells.  
Statistically,  the  restoration  of  miR-­‐‑124  in  MeCP2-­‐‑deficient  T  cells  fully  rescued  IL-­‐‑17  
production  at  both  the  population  level  and  on  a  per-­‐‑cell  basis  (Figure  40G&H).    Thus,  
miR-­‐‑124-­‐‑mediated  SOCS5  targeting  could  account  for  the  impaired  Th17  differentiation  




Figure  32:  No  spontaneous  T  cell  activation  in  mecp2-­‐‑KO  mice.  
(A&B)  Percentages  of  effector  cells  in  (A)  CD4+  T  cells  and  (B)  CD8+  T  cells  from  





Figure  33:  MeCP2  is  indispensible  for  the  commitment  of  naive  CD4+  T  cells  
into  the  Th17  lineage.  
(A)  Naïve  CD4+CD25-­‐‑  T  cells  from  CD4-­‐‑Cre+mecp2x/x  or  CD4-­‐‑Cre+mecp2x/y  (WT)  
and  CD4-­‐‑Cre+mecp2f/f  or  CD4-­‐‑Cre+mecp2f/y  (KO)  littermates  were  sorted  by  flow  
cytometry.  The  expression  of  MeCP2  protein  in  these  cells  was  detected  by  Western  blot  
(WB).  (B-­‐‑D)  CD4  +CD25-­‐‑CD45Rbhigh  naïve  T  cells  from  WT  or  KO  mice  were  mixed  with  
WT  nTreg  at  a  25:1  ratio  and  injected  intraperitoneally  (i.p.)  into  Rag2-­‐‑/-­‐‑  recipient  mice  to  
induce  IBD.  (B)  Changes  in  body  weights  of  Rag2-­‐‑/-­‐‑  recipient  mice  are  presented  as  
percentages  of  their  original  weights.  Data  reflecting  group  averages  from  one  
experiment  (error  bars,  s.e.m.;  n=5),  representative  of  four  independent  experiments  is  
shown.  (C)  Histological  sections  of  colon  tissues  with  H&E  staining.  (D)  The  percentage  
of  IL-­‐‑17a  producing  CD4+TCRβ+  cells  in  mesenteric  LN  (nWT=4;  nKO=8).  Results  represent  
four  independent  experiments.  (E&F)  Lymphocytes  from  LLO118  TCR  transgenic  WT  
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and  KO  littermates  were  cultured  in  vitro  under  Th17  skewing  conditions  for  4  days.  (E)  
The  percentage  of  IL-­‐‑17a  producing  CD4+  T  cells  (left),  as  quantified  from  three  
independent  experiments  (right).  (F)  CD4+  T  cells  were  sorted  and  the  relative  amounts  
of  il-­‐‑17a,  il-­‐‑17f  and  rorc  mRNA  was  measured  by  qPCR.  Data  was  normalized  to  a  
reference  gene,  SDHA,  and  shown  relative  to  the  WT.  (G&H)  Lymphocytes  from  
LLO118  TCR  transgenic  WT  or  KO  mice  were  labeled  with  CFSE,  and  stimulated  with  
LLO190-­‐‑205  peptide  for  3  days.  The  proliferation  (G)  and  cell  death  (H)  of  CD4+  T  cells  were  




Figure  34:  MeCP2  is  indispensible  for  IFNγ  production  by  Th1  cells.  
(A)  Lymphocytes  from  LLO118  TCR  transgenic  WT  and  KO  littermates  were  
activated  with  LLO190-­‐‑205  peptide  under  Th1-­‐‑skewing  conditions  in  vitro  for  4  days.  The  
percentage  of  IFNγ  -­‐‑producing  CD4+  T  cells  was  detected  by  intracellular  staining.  Data  
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shown  is  representative  of  three  independent  experiments.  (B)  Naïve  CD4+CD25-­‐‑  T  cells  
from  LLO118  TCR  transgenic  WT  or  KO  mice  were  transferred  into  TCRα-­‐‑/-­‐‑  recipient  
mice  (n=4)  primed  in  vivo  by  subcutaneous  immunization  with  LLO190-­‐‑205  peptide  
emulsified  in  CFA.  Five  days  after  immunization,  splenocytes  of  recipient  mice  were  
challenged  in  vitro  with  LLO190-­‐‑205  peptide  (5uM)  for  48  hours  and  IFNγ  production  in  
CD4+  T  cells  were  detected  by  intracellular  staining.  (C-­‐‑E)  DTH  response  of  WT  and  KO  
littermates  induced  by  KLH  immunization,  as  measured  by  (C)  footpad  swelling,  (D)  
histology  of  footpad  tissues  by  H&E  staining  and  (E)  the  percentage  of  IFNγ-­‐‑producing  





Figure  35:  Normal  chromatin  accessibility  of  the  il17  and  ifng  loci  in  MeCP2-­‐‑
deficient  naïve  CD4+CD25-­‐‑  T  cells.  
(A-­‐‑C)  Histone  modifications  of  different  cis-­‐‑elements  within  the  (B)  il17  and  (C)  
ifng  loci  in  naïve  CD4+CD25-­‐‑  were  measured  by  chromatin  immunoprecipitation  
analysis.  The  histone  modifications  of  β2m  and  vh7183  loci  of  CD4+  T  cells  shown  in  (A)  
    
180  
serve  as  positive  and  negative  controls,  respectively.  The  bar  graph  shows  Means  ±  SEM  





Figure  36:  MeCP2  is  necessary  for  activating  the  STAT3  and  STAT1  signaling  
pathways  in  CD4+  T  cells.  
(A)  CD4+CD25-­‐‑  T  cells  sorted  from  WT  and  mecp2-­‐‑KO  littermates  were  stimulated  
with  IL-­‐‑6  (50ng/mL)  for  30  minutes,  and  the  amounts  of  total  and  phosphorylated  
STAT3  (Tyr705)  were  determined  by  intracellular  staining  and  flow  cytometry.  Naïve  
CD4+  T  cells  (left);  primed  CD4+  T  cells  with  anti-­‐‑CD3  and  anti-­‐‑CD28  stimulation  for  48  
hours  (right).    Data  shown  is  representative  of  four  independent  experiments.  (B)  
CD4+CD25-­‐‑  T  cells  sorted  from  the  WT  and  KO  littermates  were  stimulated  with  IFNγ  
(10ng/mL)  for  10  minutes.  Total  STAT1  and  phospho-­‐‑STAT1  (Tyr701)  were  then  





Figure  37:  SOCS5  accumulation  in  mecp2-­‐‑deficient  CD4+  T  cells.  
(A)  List  of  genes  whose  mRNA  amount  were  measured  by  qPCR.  (B)  The  mRNA  
level  of  several  positive  and  negative  regulators  of  the  JAK-­‐‑STAT  pathway.  (C&D)  The  
amount  of  SOCS  and  JAK  protein  in  naive  CD4+CD25-­‐‑  cells.  (D)  Quantification  of  SOCS5  
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protein  expression  in  CD4+CD25-­‐‑  cells  from  seven  independent  experiments.  Data  was  
normalized  to  β-­‐‑actin  and  shown  relative  to  the  WT.  (E)  CD4+CD25-­‐‑  T  cells  primed  with  
anti-­‐‑CD3,  anti-­‐‑CD28  and  IL-­‐‑6  (50ng/mL)  for  different  durations  were  assessed  for  




Figure  38:  SOCS5  negatively  regulates  STAT3  activation  and  naïve  CD4+  T  cell  
commitment  to  the  Th17  lineage.  
(A&B)  Lymphocytes  from  LLO118  TCR  transgenic  mice  were  retrovirally  
transduced  with  either  an  empty  GFP  vector  (mock),  or  a  mouse  socs5  overexpression  
vector  (SOCS5),  and  sorted  for  CD4+GFP+  cells  72  hours  after  infection.  (A)  The  
expression  of  SOCS5  protein  in  these  cells  was  detected  by  WB.  (B)  The  cells  were  
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treated  with  IL-­‐‑6  (50ng/mL)  for  10  or  30  minutes,  and  phospho-­‐‑STAT3  (Tyr705)  was  
detected  by  intracellular  staining  and  flow  cytometry.  The  plot  (at  far  right)  summarized  
results  from  three  independent  experiments.  For  each  group  of  samples,  the  mean  
fluorescence  intensity  of  pStat3  signal  at  the  30  mins  time  point  was  normalized  by  its  
pre-­‐‑activation  level  (time  zero).  (C&D)  Lymphocytes  from  LLO118  TCR  transgenic  mice  
with  different  Thy-­‐‑markers  were  retrovirally  transduced  with  either  the  mock  (Thy1.1+),  
or  SOCS5  overexpression  (Thy1.2+)  vector.  Following  intravenous  competitive  transfers  
of  mock  and  SOCS5  (CD4+GFP+)  cells  (n=8;  1:1  ratio),  TCRα-­‐‑/-­‐‑  recipient  mice  were  
immunized  subcutaneously  with  LLO190-­‐‑205  peptide  emulsified  in  CFA.  Five  days  after  
immunization,  splenocytes  from  recipient  mice  were  rechallenged  with  LLO190-­‐‑205  
peptide  and  cultured  under  Th17  skewing  condition  in  vitro.    48  hours  later,  IL-­‐‑17a  
producing  CD4+  T  cells  were  enumerated  by  intracellular  staining.  (C)  Percentage  of  IL-­‐‑
17a  producing  CD4+  T  cells.  (D)  MFI  of  IL-­‐‑17a  staining.  (E&F)  Mock  and  SOCS5  cells  
from  LLO118  TCR  transgenic  mice  were  separately  transferred  into  two  groups  of  
TCRα-­‐‑/-­‐‑  recipient  mice  intravenously  (n=5)  and  immunized  as  in  (C&D).  Seven  days  
after  immunization,  recipient  mice  were  rechallenged  by  footpad  injections  of  LLO190-­‐‑205  
peptide.  (E)  48  hours  after  rechallenge,  the  percentages  of  IL-­‐‑17a  producing  CD4+  cells  in  
the  peripheral  LN  and  spleen  were  measured  ex  vivo  by  intracellular  staining.  (F)  
Splenocytes  from  recipient  mice  were  challenged  with  LLO190-­‐‑205  peptide  for  48  hours  in  




Figure  39:  MeCP2  positively  regulates  the  transcription  of  pri-­‐‑mmu-­‐‑miR-­‐‑124-­‐‑1  
in  CD4+  T  cells.  
(A)  List  of  miRNAs  significantly  down-­‐‑regulated  in  CD4+  T  cells  and  primary  
human  astrocytes  upon  deletion  of  MeCP2  (p<0.05).  (B&C)  Total  RNA  from  naïve  
CD4+CD25-­‐‑  cells  was  extracted  and  the  amount  of  socs5  mRNA  (B&C)  and  miR-­‐‑124  
(right  panel  of  C)  was  detected  by  q-­‐‑PCR.  (D)  ChIP  analysis  for  the  enrichment  of  
MeCP2  at  the  pri-­‐‑mmu-­‐‑miR124-­‐‑1  gene  locus  in  naïve  CD4+CD25-­‐‑  T  cells.  Data  shown  is  
representative  of  two  independent  experiments.  (E)  ChIP  analysis  for  Lysine  4  
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dimethylation  of  histone  H3  within  the  regulatory  region  of  the  pri-­‐‑mmu-­‐‑miR124-­‐‑1  gene  
locus  in  naïve  CD4+  T  cells.  Data  shown  is  representative  of  two  independent  
experiments.  (F)  The  relative  amount  of  pri-­‐‑mmu-­‐‑miR-­‐‑124-­‐‑1  transcript  in  naïve  T  cells  




Figure  40:  miR-­‐‑124  inhibits  the  translation  of  socs5  in  CD4+  T  cells.  
(A)  Schematic  representation  of  the  putative  miR-­‐‑124  binding  site  within  the  
socs5  3´UTR.  The  sequences  of  socs5  3´UTR  containing  putative  miR-­‐‑124  binding  sites  
from  different  species  are  shown  in  the  table.  (B)  The  entire  3’UTR  of  murine  socs5  (WT)  
or  3’UTR  carrying  miR-­‐‑124  seed  region-­‐‑binding  sites  mutations  were  cloned  into  
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pmirGLO  downstream  of  the  firefly  luciferase  reporter  gene.  pmirGLO-­‐‑mSOCS5-­‐‑3UTR  
was  transiently  transfected  into  an  NIH3T3  cell  line  stably  expressing  miR-­‐‑124,  and  
luciferase  activity  was  measured  72  hours  post-­‐‑  transfection.  Bar  graphs  show  the  means  
±  SEM  of  three  independent  experiments.  Paired  t-­‐‑tests  were  employed  to  determine  the  
statistic  significance.  (C&D)  CD4+  T  cells  from  LLO118  TCR  transgenic  mice  were  
retrovirally  transfected  with  either  mock  or  miR-­‐‑124  overexpression  vector.  72  hours  
after  infection,  CD4+GFP+  cells  were  sorted  and  their  socs5  (C)  protein  and  (D)  mRNA  
expression  were  measured  by  WB  and  qPCR,  respectively.  Data  shown  is  representative  
of  three  independent  experiments.  (E-­‐‑F)  CD4+  T  cells  from  LLO118  TCR  transgenic  WT  
and  KO  littermates  were  retrovirally  transfected  with  either  mock  or  miR-­‐‑124  
overexpression  vector.  Previously  primed  T  cells  were  stimulated  with  50ng/ml  IL-­‐‑6  and  
the  dynamics  of  STAT3  activation  were  monitored  by  Phospho-­‐‑Flow  analysis  of  Y705  
phosphorylation;  analysis  was  pre-­‐‑gated  on  CD4+GFP+  virally-­‐‑infected  T  cells.  (E)  The  
dynamics  of  STAT3  activation  in  WT  CD4+  T  cells  in  the  presence  and  absence  of  
enforced  miR-­‐‑124  expression;  (F)  The  dynamics  of  STAT3  activation  in  WT  CD4+  T  cells  
and  MeCP2  KO  CD4+  T  cells  in  the  presence  and  absence  of  enforced  miR-­‐‑124  
expression;  (G-­‐‑H)  CD4+  T  cells  from  LLO118  TCR  transgenic  WT  and  KO  littermates  
retrovirally  transfected  with  either  mock  or  miR-­‐‑124  overexpression  vector  were  
cultured  under  Th17  skewing  conditions.  Four  to  six  days  post-­‐‑transfection,  IL-­‐‑17a  
production  in  CD4+GFP+  T  cells  was  detected  by  intracellular  staining.  (G)  The  
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percentage  of  IL-­‐‑17a+  cells  among  CD4+GFP+  cells  representing  six  independent  
experiments.  (H)  MFI  of  IL-­‐‑17a  staining.  Upper  left:  WT+  mock  VS  KO+  mock;  Upper  
right:  WT+  mock  VS  WT+  miR124;  Bottom  left:  KO+  mock  VS  KO+  miR-­‐‑124;  Bottom  




Figure  41:  MeCP2-­‐‑miR-­‐‑124-­‐‑SOCS5  axis  regulates  CD4+  T  cell  differentiation.  
Left:  in  wild  type  CD4+  T  cells,  MeCP2  promotes  pri-­‐‑miR-­‐‑124  transcription  and,  
consequently,  suppresses  SOCS5  expression.  This  suppression  licenses  CD4+  T  cells  for  
efficient  Th17  differentiation;  Right:  in  MeCP2  deficient  CD4+  T  cells,  the  accumulation  
of  SOCS5  attenuates  STAT3  signaling  and  impairs  the  Th17  lineage  commitment.    





In  this  chapter,  we  dissected  the  function  of  MeCP2  in  T  cells  and  determined  
that  MeCP2  is  required  for  conventional  T  cell  differentiation  (Figure  41).  
Mechanistically,  we  showed  that  MeCP2  plays  a  critical  role  in  multiple  cytokine  
signaling  pathways  by  supporting  miR-­‐‑124  expression  and  restraining  negative  
feedback  that  targets  STAT3.    
Loss-­‐‑of-­‐‑function  mutations  of  Mecp2  lead  to  RTT  in  humans,  but  overexpression  
also  leads  to  the  MECP2  duplication  syndrome  (MDS),  a  neurological  disorder  with  
remarkably  similar  symptoms  to  RTT232.    We  believe  that  this  might  reflect  the  dual  
regulatory  role  of  MeCP2:    MeCP2  is  capable  of  recruiting  machineries  for  both  DNA  
methylation171  and  histone  acetylation169.    For  a  specific  regulatory  region,  deletion  of  
MeCP2  therefore  results  in  both  enhanced  DNA  demethylation  and  reduced  histone  
acetylation,  although  the  overall  impact  of  loss-­‐‑of-­‐‑MeCP2  in  this  region  is  
predominantly  transcriptional  inhibition.  Overexpression  of  MeCP2,  on  the  other  hand,  
could  potentially  counteract  local  demethylation  and  result  in  a  mechanistically  distinct  
but  phenotypically  similar  suppression  of  transcription.  Therefore,  we  speculate  that,  for  
certain  genes,  the  overarching  role  of  MeCP2  in  transcriptional  regulation  could  be  
switchable  from  supportive  to  suppressive,  depending  on  its  dosage.  This  phenomenon  
manifests  itself  in  the  immune  system  as  well.    Clinically,  patients  with  MDS  experience  
recurrent  respiratory  tract  infections  233,  and  it  was  recently  reported  that  MeCP2-­‐‑
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overexpressing  mice  are  defective  in  mounting  efficient  Th1  responses  against  
Leishmania  major  infection  234.  Yet,  immunodeficiency  was  not  found  among  RTT  
patients.  We  speculate  that  this  apparent  discrepancy  results  from  differential  degrees  of  
MeCP2  loss-­‐‑of-­‐‑function:  immune  function  is  intact  in  the  majority  of  RTT  patients  
bearing  heterozygous  mutations  of  Mecp2,  and,  we  also  failed  to  detect  significant  
defects  in  Th1/17  differentiation  in  mouse  T  cells  harboring  heterozygous  Mecp2  
deletion,  whereas  profound  immune-­‐‑deficiency  ensued  upon  homozygous  loss  of  
Mecp2.  
Because  early  studies  identified  MeCP2  as  a  transcriptional  silencer,  more  recent  
work  has  largely  focused  on  MeCP2’s  role  in  regulating  gene  expression  at  the  mRNA  
level169,235,236.    However,  this  view  is  somewhat  at  odds  with  expression  profiling  studies  
on  samples  from  RTT  patients,  which  have  shown  that  only  a  limited  subset  of  genes  are  
mis-­‐‑regulated  at  the  mRNA  level237,238.  Using  mecp2-­‐‑deleted  mouse  models,  expression  
differences  were  identified  for  additional  genes,  but  most  changes  were  very  subtle169,239.    
In  T  cells,  we  found  that  the  major  defect  associated  with  MeCP2  deletion  was  in  STAT  
signaling,  which  was  caused  by  the  accumulation  of  SOCS5  protein:  yet  none  of  these  
changes  were  detectable  at  the  mRNA  level.  Especially  in  wild  type  naïve  T  cells,  the  
divergence  between  levels  of  SOCS5  mRNA  and  protein  is  striking:  abundant  mRNA  
does  not  result  in  even  a  modest  amount  of  protein.  This  strongly  indicated  that  active  
posttranscriptional  suppression  of  SOCS5  is  required  for  optimal  and  sustained  T  cells  
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responses  to  cytokine  stimulation.  We  identified  miR-­‐‑124  as  the  responsible  suppressive  
factor,  whose  expression  is  tightly  controlled  by  MeCP2.  If  a  similar  miRNA-­‐‑mediated  
mechanism  operates  in  the  signaling  networks  of  neuronal  and  glial  cells,  it  would  likely  
do  so  without  marked  changes  in  mRNA  expression,  and  might  therefore  be  more  
difficult  to  detect  with  traditional  transcriptome  analyses.  
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7. General Discussion and Future Directions 
7.1 Harnessing miRNAs in T cells for tumor immunotherapy 
Our  identification  of  miR-­‐‑17-­‐‑92  as  a  comprehensive  endogenous  modulator  of  
CD4+  T  cells’  anti-­‐‑tumor  response  puts  it  forward  as  a  putative  candidate  for  adoptive  
cell  transfer  (ACT)  based  tumor  immunotherapy.  ACT  relies  on  the  isolation,  selection,  
and  expansion  of  tumor-­‐‑infiltrating  lymphocyte  (TIL)  with  certain  specificity  in  vitro,  
followed  by  autologous  infusion  back  into  the  patient  that  have  received  “preparative  
lymphodepletion”  by  chemotherapy  or  irradiation240.  Paradoxically,  although  this  
regimen  is  capable  of  generating  a  large  number  of  antigen-­‐‑specific  T  cells  that  enrich  
into  the  tumor,  the  efficacy  of  ACT  has  been  just  partial  and  majority  of  patients  failed  to  
respond  to  this  therapy.  This  discrepancy  could  be  largely  attributed  to  the  presence  of  
immunosuppressive  barriers  existed  in  the  tumor  microenvironment.  Indeed,  several  
immunosuppressive  molecules  (such  as  PD1,  CTLA4,  TIM3,  LAG3,  IL-­‐‑10)  were  enriched  
in  the  tumors  and  negatively  control  TIL  proliferation  and  survival241,242.  Importantly,  
TGFβ,  a  key  cytokine  involved  in  tumor  pathogenesis,  could  strongly  inhibit  IFN-­‐‑γ  
production  from  T  cells243  and  promote  the  conversion  of  effector  CD4+  T  cells  into  
Tregs74.  Recently,  genetic  engineering  of  T  cells  aiming  to  overcome  these  
immunosuppressive  barriers  has  been  suggested  as  a  promising  way  to  improve  the  
efficacy  of  ACT-­‐‑based  immunotherapy240.  miRNAs  are  attractive  targets  to  enhance  anti-­‐‑
tumor  responses  because  i)  they  are  increasingly  recognized  as  effective  regulator  of  T  
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cell  function,  and  ii)  it  is  more  straightforward  to  manipulate  miRNAs  as  compared  to  
traditional  protein  target  based  immune  modulation.    
Our  findings  in  chapter  3  of  this  dissertation  suggest  that  miR-­‐‑17-­‐‑92  could  be  
such  a  promising  miRNA  target  to  improve  the  efficacy  of  ACT-­‐‑based  immunotherapy  
due  to  its  multiple  functions  to  benefit  T  cell  anti-­‐‑tumor  immunity.  First,  we  found  that  
overexpression  of  miR-­‐‑17-­‐‑92  in  CD4+  T  cells  could  significantly  enhance  cell  proliferation  
and  survival  during  T-­‐‑cell  recall  response  in  vitro.  This  may  lead  to  improved  expansion  
and  persistency  of  transferred  T  cells  in  the  tumors.  We  are  now  testing  this  idea  in  an  
allograft  model  of  B16  melanoma.  Second,  we  showed  that  enhanced  miR-­‐‑17-­‐‑92  level  
could  effectively  boost  IFN-­‐‑γ  production  from  CD4+  T  cells,  which  is  critical  for  an  
effective  anti-­‐‑tumor  response  through  multiple  pathways.  Lastly,  the  ability  of  miR-­‐‑17-­‐‑
92  to  inhibit  iTreg  differentiation  makes  it  a  perfect  candidate  to  overcome  the  
immunosuppressive  barrier  for  ACT  based  therapy.  We  previously  found  that  when  
wild  type  antigen-­‐‑specific  CD4+  T  cells  were  transferred  into  tumor-­‐‑bearing  mice,  
majority  of  cells  that  infiltrate  into  tumor  became  Tregs  (unpublished  observations).  This  
will  not  only  blunt  the  intrinsic  effector  function  of  these  CD4+  T  cells,  but  also  harm  the  
overall  anti-­‐‑tumor  efficacy  through  suppression  of  other  cell  types.  There  are  at  least  two  
reasons  why  iTreg  induction  is  favored  in  the  tumor  microenvironment.  First,  many  
tumors  antigens  are  weakly  immunogenic  and  induce  low-­‐‑strength  TCR  signals,  which  
favors  iTreg  induction.  Secondly,  the  high  concentration  of  TGFβ  in  the  tumor  
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microenvironment  is  a  strong  inducer  for  iTreg  differentiation.  miR-­‐‑17-­‐‑92  is  a  good  
candidate  to  overcome  both  of  these  two  tolerogenic  mechanisms:  by  targeting  PTEN,  
miR-­‐‑17-­‐‑92  enhances  PI3K-­‐‑Akt  activation  and  TCR  signaling  strength;  and,  by  inhibiting  
TGFβRII,  miR-­‐‑17-­‐‑92  blunts  TGFβ  signaling.  We  are  now  actively  testing  whether  
overexpression  of  miR-­‐‑17-­‐‑92  in  CD4+  T  cells  could  indeed  effectively  inhibit  iTreg  
conversion  in  the  tumor  microenvironment,  and  ultimately,  enhance  the  efficacy  of  ACT  
cancer  immunotherapy.    
In  addition  to  miR-­‐‑17-­‐‑92,  we  are  also  actively  pursuing  for  other  miRNAs  that  
control  T  cell  anti-­‐‑tumor  responses.  Particularly,  we  are  currently  screening  for  miRNAs  
whose  expression  levels  are  modulated  by  immunosuppressive  cytokines  (IL-­‐‑10,  TGFβ,  
and  IL-­‐‑35)  that  are  enriched  in  the  tumor  microenvironment.  We  hypothesize  that  
miRNAs  that  are  universally  downregulated  by  these  cytokines  may  be  potential  
“master  miRNAs”  controlling  T  cell  anti-­‐‑tumor  response  and  overexpression  or  
restoration  the  level  of  them  in  T  cells  may  be  an  effective  means  to  overcome  the  
immunosuppressive  barrier  in  the  tumor  microenvironment.    
  
7.2 Regulation of global miRNA abundance by TCR signaling 
Upon  T  cell-­‐‑antigen  engagement,  we  and  others  observed  a  global  reduction  of  
the  abundance  of  miRNAs  in  CD4  T  cells  (data  not  shown  and  Bronevetsky  et  al  244).  On  
one  hand,  this  unique  feature  prompted  us  to  characterize  the  function  of  the  few  
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miRNAs  that  are  specifically  upregulated  by  TCR  stimulation,  such  as  miR-­‐‑17-­‐‑92.  On  
the  other  hand,  it  also  urged  us  to  dissect  the  biological  meaning  and  molecular  
mechanisms  underlying  the  global  reduction  of  miRNA  abundance  upon  TCR  
activation.  It  has  been  suggested  that  this  global  reduction  of  miRNA  abundance  is  at  
least  in  part  mediated  through  the  posttranscriptional  downregulation  of  Ago  
proteins244,  the  key  component  of  miRISC.  It  was  also  proposed  that  the  high  abundance  
of  miRNAs  in  naïve  T  cells  may  serve  as  a  “brake”  against  induction  of  gene  expression,  
and  upon  T  cell  activation,  they  are  globally  suppressed  to  promote  expression  of  genes  
that  are  important  for  T  cell  differentiation  and  effector  function244.  Consistent  with  this  
notion,  cells  that  have  a  global  disruption  of  miRNA  machinery  are  more  prone  to  
differentiate  into  cytokine-­‐‑producing  effector  T  helper  cells  upon  TCR  activation.  
However,  in  addition  to  the  intrinsic  effects  on  T  cells,  the  global  reduction  of  miRNA  
abundance  may  also  have  other  biological  functions,  and  it  may  also  be  regulated  by  
other  mechanisms.  First,  the  downregulation  of  Ago  proteins  by  TCR  signaling  is  less  
likely  to  account  for  the  early  changes  of  miRNA  levels  upon  TCR  activation.  We  found  
that  as  early  as  6  hours  after  TCR  activation,  the  global  reduction  of  miRNA  abundance  
was  already  evident.  However,  it  was  not  until  48  hours  of  TCR  stimulation  that  the  
downregulation  of  Ago  proteins  became  obvious  244.  This  suggests  that  additional  
mechanisms  must  be  involved  to  control  the  early  reduction  of  miRNA  levels.  Indeed,  
accompanying  the  loss  of  majority  miRNAs  in  T  cells  upon  activation,  we  could  detect  a  
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significant  elevation  of  these  miRNAs  in  the  culture  supernatant  as  early  as  6  hours.  
More  interestingly,  it  was  recently  shown  that  miRNA  and  miRISC  were  associated  with  
intracellular  vesicles  and  they  could  be  secreted  and  taken  up  by  other  cells245.  This  
suggests  that  upon  TCR  activation,  T  cells  may  actively  exocytose  or  secrete  miRNAs  
out  of  the  cells.  Why  do  T  cells  want  to  dump  miRNAs  out?  One  possibility  is  that  
through  the  immunological  synapse-­‐‑directed  secretion,  T  cells  may  actively  transfer  
certain  miRNAs  into  antigen-­‐‑presenting  cells  (APCs)  to  regulate  their  function.  For  
example,  during  germinal  center  reactions,  T  follicular  helper  (Tfh)  cells  may  transfer  
certain  miRNAs  into  B  cells.  These  miRNAs  might  be  important  to  support  B  cell  
maturation  and  class  switching.  We  are  now  testing  this  hypothesis  by  screening  for  
miRNAs  that  are  upregulated  in  B  cells  that  lack  endogenous  miRNAs  upon  B  cell-­‐‑T  cell  
engagement.    
    
7.3 TCR-induced DNMT1 accumulation and its role in T helper 
cell differentiation 
As  mentioned  above,  it  has  been  well  recognized  that  iTreg  favors  low-­‐‑strength  
TCR  signals  for  optimal  differentiation.  However,  how  strong  TCR  signaling  inhibits  
iTreg  has  been  a  mystery.  Our  studies  in  chapter  4  of  this  dissertation  provided  a  
potential  molecular  mechanism  for  this  phenomenon.  We  found  that  TCR  stimulation  
with  high  affinity  or  longer  duration  significantly  induces  the  accumulation  of  DNMT1  
and  its  subsequent  enrichment  to  the  foxp3  locus,  which  enhances  DNA  methylation  that  
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negatively  controls  foxp3  transcription.  As  the  accumulation  of  DNMT1  protein  is  a  
general  phenomenon  upon  T  cell  activation  when  there  are  no  skewing  cytokines,  we  
are  curious  about  how  the  enhancement  of  DNMT1  level  may  influence  the  
differentiation  of  other  T  helper  subsets.    
Similar  to  iTregs,  Th17  cells  was  reported  to  also  favor  TCR  signals  with  low  
strength  for  optimal  differentiation13.  Interestingly,  in  that  study,  it  was  shown  that  
although  high-­‐‑strength  of  TCR  stimulation  induced  similar  level,  or  even  higher  NFAT  
activation  and  its  nuclear  translocation,  it  only  bound  to  the  il17  promoter  in  cells  that  
received  low-­‐‑strength  stimulation.  We  think  that  this  is  a  strong  indication  that,  like  
foxp3,  the  chromatin  accessibility  of  il17  locus  could  also  be  negatively  regulated  by  TCR  
signaling  strength.  It  is  worthwhile  to  further  examine  whether  the  DNA  methylation  
and  DNMT1  localization  in  the  il17  locus  could  be  affected  by  different  TCR  signaling  
strength.    
Another  interesting  observation  we  made  in  this  study  is  that  although  strong  
TCR  stimulation  led  to  overall  accumulation  of  DNMT1,  there  is  definitely  certain  
specificity  for  which  locus  it  will  enrich  to.  For  example,  under  strong  stimulation,  in  
contrast  to  foxp3  promoter,  the  ifng  locus  was  free  of  DNMT1  binding.  There  might  be  
two  potential  mechanisms  to  determine  this  specificity.  It  is  possible  that  strong  TCR  
activation  may  induce  the  activation  of  certain  pioneer  factor  that  specifically  binds  to  
foxp3  promoter,  which  subsequently  recruits  DNMT1  to  complete  silencing.  Equally  
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likely,  some  transcription  factor  induced  by  strong  TCR  activation  may  specifically  
localize  to  the  ifng  locus  to  exclude  DNMT1  from  binding.  In  either  case,  it  would  be  
extremely  interesting  to  further  identify  such  pioneer  factors  that  recruit  or  exclude  
DNMT1  from  binding.    
  
7.4 MeCP2: a general guardian for lineage stability? 
In  Chapter  5,  we  identified  MeCP2  as  an  important  safeguard  to  govern  Treg  
lineage  stability  during  inflammation.  This  raises  the  question  of  whether  it  also  has  any  
function  to  control  the  stability  or  plasticity  of  other  T  helper  cells.  The  function  of  
MeCP2  in  Tregs  lies  in  its  ability  to  bind  to  foxp3  locus  and  promote  local  histone  
acetylation  to  sustain  foxp3  transcription.  However,  MeCP2  has  been  shown  to  serve  
multifunctional  roles,  both  as  a  transcription  activator  or  repressor,  presumably  
dependent  upon  the  genomic  context  in  which  it  operates.  How  then  do  cues  in  the  
genomic  milieu  control  this  functional  switch?  Genome  wide  analyses  have  suggested  
that  for  MeCP2-­‐‑targeted  genes,  the  loci  activated  by  MeCP2  are  largely  unmethylated  or  
only  partially  methylated,  whereas  repressed  loci  are  enriched  in  fully  methylated  
elements169,172.  This  suggests  that  the  pivotal  factor  dictating  MeCP2  function  may  lie  in  
the  status  of  local  DNA  methylation.  Our  data  is  consistent  with  this  notion.  CNS2,  the  
primary  region  controlling  the  stability  of  Foxp3  expression75,  is  completely  
unmethylated  in  naïve  nTregs  and  becomes  partially  methylated  upon  inflammatory  
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stimulation.  Under  these  conditions,  MeCP2  functions  as  a  coactivator.  In  contrast,  the  
CNS2  region  is  fully  methylated  in  naïve  Tcon  cells,  a  situation  in  which  MeCP2  plays  
no  role  during  iTreg  induction.  We  speculate  that,  in  addition  to  Tregs,  MeCP2  may  
exert  a  much  broader  impact  on  the  lineage  specificity  and  plasticity  of  other  CD4+  T  cell  
subsets.  Following  lineage  commitment,  MeCP2  can  simultaneously  serve  as  a  
transcription  repressor  at  “closed”  loci  to  enforce  the  silencing  of  rival  cytokines,  as  well  
as  an  activator  at  fully-­‐‑  and/or  partially-­‐‑  “opened”  loci  to  support  the  expression  of  
master  transcription  factors  and  signature  cytokines.  Using  an  inducible  knockout  
system  (MeCP2f/y  ER-­‐‑Cre  mice),  we  are  now  actively  testing  whether  deletion  of  MeCP2  
after  the  commitment  of  Th1,  Th2,  or  Th17  cells  would  affect  their  potential  to  “re-­‐‑
differentiate”  into  opposing  lineages  under  skewing  conditions.  
  
7.5 MeCP2 and STAT3 signaling: implications for the 
pathogenesis of Rett Syndrome 
Since  its  identification  as  the  causal  factor  of  RTT,  MeCP2  has  been  extensively  
studied  in  the  nervous  system.  However  the  molecular  pathology  stemming  from  this  
protein  remains  largely  elusive.  Therefore  there  is  neither  cure  nor  treatment  for  this  
disease.  In  Chapter  6,  we  dissected  the  function  of  MeCP2  in  CD4+  T  cells  and  
determined  that  MeCP2  plays  a  critical  role  in  multiple  cytokine  signaling  pathways  by  
supporting  miR-­‐‑124  transcription  and  STAT3  activation.  Interestingly,  we  identified  that  
a  similar  mechanism  operates  during  CNTF  signaling  in  primary  neuronal  and  glia  cells  
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(data  not  shown).  STAT3  is  a  necessary  inflammatory  signal  for  driving  CD4+  T  cells  
differentiation  into  the  Th17  lineage.  But  in  the  central  nervous  system,  it  is  a  vital  
neurotrophic  transcription  factor  for  neuronal  survival  and  regeneration.    STAT3  
mutations  are  known  to  cause  a  severe  immunodeficiency  disease,  the  Job/Buckley  
syndrome,  one  symptoms  of  which  is  scoliosis246.    Perhaps  intriguingly,  RTT  patients  are  
also  prone  to  the  development  of  scoliosis  as  a  comorbidity247;  coincidentally,  mice  with  
osteoblast-­‐‑  and  osteocyte-­‐‑  specific  stat3  ablation  develop  a  severe  spinal  deformity  at  3-­‐‑4  
weeks  of  age248.  In  addition,  miR-­‐‑124,  the  direct  target  of  MeCP2  in  CD4+  T  cells,  is  also  
highly  expressed  in  the  central  nervous  system.  If  this  miR-­‐‑124-­‐‑STAT3  signaling  axis  
could  be  validated  in  the  nervous  systems  of  RTT  patients,  then  it  would  provide  a  new  
molecular  target  for  the  development  of  therapies,  or  guidance  for  current  growth-­‐‑
factor-­‐‑based  clinical  trials.  
  
7.6 Conclusions 
In  this  dissertation,  we  described  the  function  and  molecular  mechanism  of  a  
miRNA  cluster  (miR-­‐‑17-­‐‑92)  and  two  epigenetic  modulators  (DNMT1  and  MeCP2)  in  
controlling  T  cell-­‐‑mediated  immune  response.  Importantly,  we  demonstrated  how  these  
miRNAs  and  epigenetic  regulators  could  sense  alterations  from  the  environment  and  
translate  them  into  changes  of  downstream  gene  expression  to  ensure  functional  
differentiation  and  stabilization.  Further  identification  of  such  nodes  could  not  only  
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improve  our  understanding  of  the  biology  underlying  T  cell  response  but  also  
potentially  benefit  the  development  of  novel  treatments  for  patients  suffering  from  
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